

The burden of skin disease and eye disease due to onchocerciasis in Africa for 1990, 2020, and 2030

Text S4:

Detailed country-level results

Natalie V.S. Vinkeles Melchers¹, Wilma A. Stolk¹, Welmoed van Loon^{1,2}, Belén Pedrique³, Roel Bakker¹, Michele E. Murdoch⁴, Sake J. de Vlas¹, Luc E. Coffeng¹

1. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
2. Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
3. Drugs for Neglected Diseases initiative (DND*i*), Geneva, Switzerland
4. Department of Dermatology, Watford General Hospital, Watford, Hertfordshire, UK

* Correspondence to:

Luc E. Coffeng, Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O. box 2040, 3000 CA Rotterdam, The Netherlands; l.coffeng@erasmusmc.nl

Alternative:


Natalie VS Vinkeles Melchers, Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O. box 2040, 3000 CA Rotterdam, The Netherlands; n.vinkelesmelchers@erasmusmc.nl, Natalie.melchers@gmail.com; +31 614217276

| Country: Angola | | | | | | | | | |
|-----------------------------------|--|-----------------|-----------|----------------|-----------------|----------|----------------|-----------------|----------------|
| Projects: | Bengo, Benguela, Cuanza Norte, Huila, Kuando Kubango, Lunda Norte, Lunda sul, Moxico 1, Namibe, NY Benguela, NY Cuanza Norte, NY Huila, NY Lunda Norte, NY Moxico 1, P5Angola, Uige, Zaire | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,326 | 100 | — | 2,992 | 100 | — | 3,925 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 333 | 25.1 | — | 309 | 10.3 | — | 101 | 2.6 | — |
| Mf-positive (age 5+) | 332 | 25.1 | — | 309 | 10.3 | — | 101 | 2.6 | — |
| Worm infected | 442 | 33.3 | — | 589 | 19.7 | — | 285 | 7.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 55 | 4.2 | 1 | 50 | 1.7 | 1 | 15 | 0.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 43 | 3.2 | 8 | 34 | 1.1 | 6 | 8 | 0.2 | 1 |
| Reactive skin disease | 29 | 2.2 | 1 | 18 | 0.6 | 1 | 2 | <0.05 | <0.5 |
| Reversible skin disease | 72 | 5.4 | 9 | 51 | 1.7 | 7 | 10 | 0.2 | 2 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 11 | 0.8 | <0.5 | 17 | 0.6 | <0.5 | 14 | 0.4 | <0.5 |
| Severe depigmentation | 10 | 0.7 | 1 | 14 | 0.5 | 1 | 11 | 0.3 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 21 | 1.6 | 1 | 32 | 1.1 | 1 | 25 | 0.6 | 1 |
| Total skin disease (OSD) | 148 | 11.2 | 10 | 133 | 4.5 | 9 | 49 | 1.3 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 148 | 11.2 | 11 | 134 | 4.5 | 9 | 50 | 1.3 | 3 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Angola, by APOC project




- Projects:
- Bengo
 - Kuando Kubango
 - Namibe
 - NY Lunda Norte
 - Zaire
 - Benguela
 - Lunda Norte
 - NY Benguela
 - NY Moxico 1
 - Cuanza Norte
 - Lunda sul
 - NY Cuanza Norte
 - P5Angola
 - Huila
 - Moxico 1
 - NY Huila
 - Uige

| Country: Burundi | | | | | | | | | |
|-----------------------------------|---|-----------------|-----------|----------------|-----------------|----------|----------------|-----------------|----------------|
| Projects: | Bururi, Cibitoke-Bubanza, P5Burundi, Rutana | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,333 | 100 | — | 3,007 | 100 | — | 3,944 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 359 | 26.9 | — | 220 | 7.3 | — | 163 | 4.1 | — |
| Mf-positive (age 5+) | 358 | 26.9 | — | 220 | 7.3 | — | 163 | 4.1 | — |
| Worm infected | 472 | 35.4 | — | 432 | 14.4 | — | 300 | 7.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 68 | 5.1 | 1 | 33 | 1.1 | <0.5 | 25 | 0.6 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 46 | 3.5 | 8 | 27 | 0.9 | 5 | 14 | 0.4 | 3 |
| Reactive skin disease | 32 | 2.4 | 1 | 17 | 0.6 | 1 | 4 | 0.1 | <0.5 |
| Reversible skin disease | 78 | 5.9 | 10 | 44 | 1.5 | 6 | 17 | 0.4 | 3 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 12 | 0.9 | <0.5 | 16 | 0.5 | <0.5 | 13 | 0.3 | <0.5 |
| Severe depigmentation | 11 | 0.8 | 1 | 14 | 0.5 | 1 | 11 | 0.3 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 23 | 1.7 | 1 | 30 | 1.0 | 1 | 24 | 0.6 | 1 |
| Total skin disease (OSD) | 168 | 12.6 | 11 | 107 | 3.6 | 7 | 67 | 1.7 | 4 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 169 | 12.7 | 12 | 108 | 3.6 | 8 | 67 | 1.7 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Burundi, by APOC project




| Country: Cameroon | | | | | | | | | |
|-----------------------------------|---|-------------|------------|------------|------------|-----------|------------|------------|-----------|
| Projects: | Adamaoua 1, Adamaoua 2, Centre 1, Centre 2, Centre 3, East, Far North, Littoral 1, Littoral 2, Northern, Northwest, P20Cameroon, P5Cameroon, South, South West 1, South West 2, Western | | | | | | | | |
| Bioclimate: | Savannah, Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 5,121 | 100 | — | 11,555 | 100 | — | 15,156 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 2,241 | 43.8 | — | 829 | 7.2 | — | 426 | 2.8 | — |
| Mf-positive (age 5+) | 2,235 | 43.6 | — | 829 | 7.2 | — | 426 | 2.8 | — |
| Worm infected | 2,671 | 52.2 | — | 1,969 | 17.0 | — | 945 | 6.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 934 | 18.2 | 10 | 208 | 1.8 | 2 | 76 | 0.5 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 435 | 8.5 | 79 | 90 | 0.8 | 16 | 36 | 0.2 | 7 |
| Reactive skin disease | 352 | 6.9 | 16 | 45 | 0.4 | 2 | 10 | 0.1 | <0.5 |
| Reversible skin disease | 787 | 15.4 | 95 | 135 | 1.2 | 18 | 46 | 0.3 | 7 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 90 | 1.8 | 1 | 99 | 0.9 | 1 | 75 | 0.5 | 1 |
| Severe depigmentation | 123 | 2.4 | 8 | 120 | 1.0 | 8 | 84 | 0.6 | 5 |
| Atrophy | 3 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 5 | 0.1 | 2 | 3 | <0.05 | 1 | 2 | <0.05 | 1 |
| Irreversible skin disease | 220 | 4.3 | 11 | 222 | 1.9 | 10 | 161 | 1.1 | 7 |
| Total skin disease (OSD) | 1,942 | 37.9 | 116 | 565 | 4.9 | 31 | 283 | 1.9 | 15 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 32 | 0.6 | 1 | 28 | 0.2 | 1 | 18 | 0.1 | 1 |
| Blindness | 22 | 0.4 | 160 | 9 | 0.1 | 66 | 4 | <0.05 | 27 |
| Eye disease (OED) | 54 | 1.0 | 161 | 37 | 0.3 | 67 | 21 | 0.1 | 28 |
| Total all manifestations | 1,995 | 39.0 | 277 | 601 | 5.2 | 98 | 304 | 2.0 | 42 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Cameroon, by APOC project




- Projects:
- Adamaoua 1
 - Centre 3
 - Littoral 2
 - P5Cameroon
 - Western
 - Adamaoua 2
 - East
 - Northern
 - South
 - Centre 1
 - Far North
 - Northwest
 - South West 1
 - Centre 2
 - Littoral 1
 - P20Cameroon
 - South West 2

| Country: CAR | | | | | | | | | |
|-----------------------------------|---|-------------|------------|------------|------------|-----------|-----------|------------|-----------|
| Projects: | CAR region 3, CAR region 4, CAR region 5, CAR region 6, P20CAR, P5CAR | | | | | | | | |
| Bioclimate: | Savannah, Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,316 | 100 | — | 2,970 | 100 | — | 3,896 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 549 | 41.7 | — | 126 | 4.3 | — | 62 | 1.6 | — |
| Mf-positive (age 5+) | 548 | 41.7 | — | 126 | 4.3 | — | 62 | 1.6 | — |
| Worm infected | 671 | 51.0 | — | 284 | 9.6 | — | 148 | 3.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 195 | 14.8 | 2 | 31 | 1.0 | <0.5 | 15 | 0.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 91 | 6.9 | 16 | 13 | 0.4 | 2 | 5 | 0.1 | 1 |
| Reactive skin disease | 69 | 5.2 | 3 | 8 | 0.3 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease | 160 | 12.1 | 20 | 21 | 0.7 | 3 | 7 | 0.2 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 20 | 1.5 | <0.5 | 17 | 0.6 | <0.5 | 12 | 0.3 | <0.5 |
| Severe depigmentation | 22 | 1.7 | 1 | 16 | 0.6 | 1 | 11 | 0.3 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 43 | 3.2 | 2 | 34 | 1.1 | 1 | 23 | 0.6 | 1 |
| Total skin disease (OSD) | 398 | 30.2 | 24 | 86 | 2.9 | 4 | 45 | 1.1 | 2 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 37 | 2.8 | 1 | 27 | 0.9 | 1 | 17 | 0.4 | 1 |
| Blindness | 18 | 1.4 | 139 | 6 | 0.2 | 47 | 2 | 0.1 | 19 |
| Eye disease (OED) | 55 | 4.1 | 140 | 33 | 1.1 | 48 | 20 | 0.5 | 20 |
| Total all manifestations | 452 | 34.4 | 164 | 119 | 4.0 | 52 | 64 | 1.7 | 22 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in CAR, by APOC project




Projects: CAR region 3 CAR region 5 P20CAR
 CAR region 4 CAR region 6 P5CAR

| Country: Chad | | | | | | | | | |
|-----------------------------------|------------------------------|-------------|-----------|-----------|------------|-----------|-----------|------------|----------------|
| Projects: | Chad, P5Chad, P5Chad propext | | | | | | | | |
| Bioclimate: | Savannah | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,277 | 100 | — | 2,882 | 100 | — | 3,780 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 379 | 29.7 | — | 109 | 3.8 | — | 85 | 2.3 | — |
| Mf-positive (age 5+) | 379 | 29.7 | — | 109 | 3.8 | — | 85 | 2.3 | — |
| Worm infected | 499 | 39.0 | — | 181 | 6.3 | — | 160 | 4.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 85 | 6.7 | 1 | 21 | 0.7 | <0.5 | 18 | 0.5 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 49 | 3.8 | 9 | 13 | 0.5 | 2 | 7 | 0.2 | 1 |
| Reactive skin disease | 34 | 2.6 | 2 | 9 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Reversible skin disease | 83 | 6.5 | 10 | 22 | 0.8 | 3 | 9 | 0.2 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 12 | 0.9 | <0.5 | 11 | 0.4 | <0.5 | 9 | 0.2 | <0.5 |
| Severe depigmentation | 11 | 0.8 | 1 | 9 | 0.3 | 1 | 6 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 23 | 1.8 | 1 | 20 | 0.7 | 1 | 15 | 0.4 | <0.5 |
| Total skin disease (OSD) | 191 | 14.9 | 12 | 63 | 2.2 | 4 | 42 | 1.1 | 2 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 21 | 1.6 | 1 | 18 | 0.6 | 1 | 13 | 0.3 | <0.5 |
| Blindness | 7 | 0.6 | 52 | 4 | 0.1 | 26 | 2 | 0.1 | 17 |
| Eye disease (OED) | 28 | 2.2 | 53 | 21 | 0.7 | 27 | 15 | 0.4 | 17 |
| Total all manifestations | 219 | 17.1 | 65 | 84 | 2.9 | 31 | 58 | 1.5 | 19 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Chad, by APOC project




| Country: Congo | | | | | | | | | |
|-----------------------------------|----------------------------|-----------------|----------|----------------|-----------------|----------|----------------|-----------------|----------|
| Projects: | Congo 1, P20Congo, P5Congo | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 794 | 100 | — | 1,791 | 100 | — | 2,350 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 220 | 27.8 | — | 186 | 10.4 | — | 144 | 6.1 | — |
| Mf-positive (age 5+) | 220 | 27.7 | — | 186 | 10.4 | — | 144 | 6.1 | — |
| Worm infected | 287 | 36.1 | — | 281 | 15.7 | — | 248 | 10.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 46 | 5.8 | <0.5 | 40 | 2.2 | <0.5 | 29 | 1.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 30 | 3.8 | 6 | 26 | 1.4 | 5 | 14 | 0.6 | 3 |
| Reactive skin disease | 21 | 2.7 | 1 | 17 | 0.9 | 1 | 4 | 0.2 | <0.5 |
| Reversible skin disease | 51 | 6.5 | 6 | 43 | 2.4 | 5 | 18 | 0.8 | 3 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 0.9 | <0.5 | 11 | 0.6 | <0.5 | 10 | 0.4 | <0.5 |
| Severe depigmentation | 7 | 0.9 | <0.5 | 10 | 0.6 | 1 | 9 | 0.4 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 15 | 1.8 | 1 | 21 | 1.2 | 1 | 18 | 0.8 | 1 |
| Total skin disease (OSD) | 112 | 14.1 | 8 | 104 | 5.8 | 7 | 66 | 2.8 | 4 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 |
| Total all manifestations | 112 | 14.1 | 9 | 104 | 5.8 | 8 | 66 | 2.8 | 5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Congo, by APOC project




| Country: DRC | | | | | | | | | |
|-----------------------------------|---|-------------|------------|--------------|------------|------------|--------------|------------|------------|
| Projects: | Bandundu, Bas-Congo Kinshasa, Butembo-Beni, Equateur-Kiri, Ituri-Nord, Ituri-Sud, Kasai, Kasongo, Katanga-Nord, Katanga-Sud, Lualaba, Lubutu, Masisi-Walikale, Mongala, NY Katanga-Nord, NY Lualaba, NY Masisi-Walikale, NY Rutshuru-Ngoma, NY Sankuru, NY Ueles, P20DRC, P5DRC, Rutshuru-Ngoma, Sankuru, Tshopo, Tshuapa, Ubangi-Nord, Ubangi-Sud, Ueles | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 23,006 | 100 | — | 51,916 | 100 | — | 68,096 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 9,075 | 39.4 | — | 7,182 | 13.8 | — | 3,094 | 4.5 | — |
| Mf-positive (age 5+) | 9,053 | 39.4 | — | 7,177 | 13.8 | — | 3,094 | 4.5 | — |
| Worm infected | 11,032 | 48.0 | — | 13,608 | 26.2 | — | 7,390 | 10.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3,366 | 14.6 | 36 | 2,464 | 4.7 | 26 | 795 | 1.2 | 8 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1,654 | 7.2 | 300 | 858 | 1.7 | 156 | 241 | 0.4 | 44 |
| Reactive skin disease | 1,308 | 5.7 | 61 | 386 | 0.7 | 18 | 55 | 0.1 | 3 |
| Reversible skin disease | 2,963 | 12.9 | 361 | 1,244 | 2.4 | 174 | 296 | 0.4 | 46 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 351 | 1.5 | 4 | 496 | 1.0 | 5 | 399 | 0.6 | 4 |
| Severe depigmentation | 461 | 2.0 | 30 | 603 | 1.2 | 39 | 449 | 0.7 | 29 |
| Atrophy | 10 | <0.05 | <0.5 | 2 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 21 | 0.1 | 8 | 20 | <0.05 | 8 | 12 | <0.05 | 5 |
| Irreversible skin disease | 843 | 3.7 | 42 | 1,121 | 2.2 | 52 | 860 | 1.3 | 38 |
| Total skin disease (OSD) | 7,172 | 31.2 | 439 | 4,829 | 9.3 | 252 | 1,951 | 2.9 | 92 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 30 | 0.1 | 1 | 34 | 0.1 | 1 | 22 | <0.05 | 1 |
| Blindness | 41 | 0.2 | 286 | 30 | 0.1 | 214 | 13 | <0.05 | 93 |
| Eye disease (OED) | 70 | 0.3 | 287 | 64 | 0.1 | 215 | 35 | 0.1 | 94 |
| Total all manifestations | 7,242 | 31.5 | 726 | 4,893 | 9.4 | 467 | 1,986 | 2.9 | 186 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in DRC, by APOC project




| Country: Equatorial Guinea | | | | | | | | | |
|-----------------------------------|-------------------|-------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Projects: | Bioko, P5EqGuinea | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 199 | 100 | — | 448 | 100 | — | 588 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 76 | 38.2 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 75 | 37.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 89 | 44.8 | — | 1 | 0.2 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 35 | 17.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 19 | 9.3 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 17 | 8.3 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 35 | 17.7 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.7 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 6 | 3.2 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Atrophy | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 11 | 5.6 | 1 | 5 | 1.1 | <0.5 | 3 | 0.5 | <0.5 |
| Total skin disease (OSD) | 81 | 41.0 | 5 | 5 | 1.1 | <0.5 | 3 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.3 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 1 | 0.7 | 11 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 2 | 1.1 | 11 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 83 | 42.0 | 16 | 5 | 1.2 | 1 | 3 | 0.6 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Equatorial Guinea, by APOC project




Note: We assume that most MDA interventions on the mainland of Equatorial Guinea would continue until at least 2030. We assume no ivermectic MDA for Bioko since 2018 as the island is currently under post-treatment surveillance [1-3]‡.

| Country: Ethiopia | | | | | | | | | |
|-----------------------------------|---|-------------|-----------|------------|-----------------|-----------|------------|-----------------|-----------|
| Projects: | Assosa, Bench-Maji, East Wellega, Gambella, Horo Guduru, Illubabor, Jimma, Kaffa-Sheka, Kamashi, Metekel, North Gondar, NY East Wellega, NY West Wellega, P20Ethiopia, P5Ethiopia, West Shewa, West Wellega | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 6,727 | 100 | — | 15,180 | 100 | — | 19,911 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 2,206 | 32.8 | — | 1,614 | 10.6 | — | 681 | 3.4 | — |
| Mf-positive (age 5+) | 2,204 | 32.8 | — | 1,613 | 10.6 | — | 681 | 3.4 | — |
| Worm infected | 2,816 | 41.9 | — | 2,969 | 19.6 | — | 1,697 | 8.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 581 | 8.6 | 6 | 381 | 2.5 | 4 | 126 | 0.6 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 317 | 4.7 | 58 | 215 | 1.4 | 39 | 54 | 0.3 | 10 |
| Reactive skin disease | 225 | 3.3 | 10 | 123 | 0.8 | 6 | 10 | <0.05 | <0.5 |
| Reversible skin disease | 542 | 8.1 | 68 | 338 | 2.2 | 45 | 64 | 0.3 | 10 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 75 | 1.1 | 1 | 108 | 0.7 | 1 | 88 | 0.4 | 1 |
| Severe depigmentation | 75 | 1.1 | 5 | 99 | 0.6 | 6 | 74 | 0.4 | 5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 152 | 2.3 | 6 | 207 | 1.4 | 8 | 163 | 0.8 | 6 |
| Total skin disease (OSD) | 1,275 | 19.0 | 80 | 925 | 6.1 | 56 | 353 | 1.8 | 18 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | <0.05 | <0.5 | 3 | <0.05 | <0.5 | 1 | <0.05 | <0.5 |
| Blindness | 2 | <0.05 | 12 | 2 | <0.05 | 9 | 1 | <0.05 | 4 |
| Eye disease (OED) | 4 | 0.1 | 12 | 4 | <0.05 | 9 | 2 | <0.05 | 4 |
| Total all manifestations | 1,279 | 19.0 | 92 | 930 | 6.1 | 66 | 355 | 1.8 | 21 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ethiopia, by APOC project




| Country: Gabon | | | | | | | | | |
|-----------------------------------|----------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Projects: | P5Gabon | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 49 | 100 | — | 112 | 100 | — | 146 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 11 | 21.6 | — | 22 | 20.0 | — | 17 | 11.9 | — |
| Mf-positive (age 5+) | 11 | 21.6 | — | 22 | 20.0 | — | 17 | 11.9 | — |
| Worm infected | 15 | 29.3 | — | 31 | 27.6 | — | 32 | 22.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 2.5 | <0.5 | 3 | 2.3 | <0.5 | 2 | 1.5 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 2.6 | <0.5 | 3 | 2.3 | <0.5 | 1 | 0.9 | <0.5 |
| Reactive skin disease | 1 | 1.7 | <0.5 | 2 | 1.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reversible skin disease | 2 | 4.3 | <0.5 | 4 | 3.8 | 1 | 2 | 1.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | 1 | 0.7 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 1.3 | <0.5 | 1 | 1.2 | <0.5 | 1 | 0.9 | <0.5 |
| Total skin disease (OSD) | 4 | 8.1 | <0.5 | 8 | 7.3 | 1 | 5 | 3.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 4 | 8.1 | <0.5 | 8 | 7.3 | 1 | 5 | 3.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Gabon, by APOC project




| Country: Liberia | | | | | | | | | |
|-----------------------------------|----------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Projects: | All_Liberia | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 881 | 100 | — | 1,987 | 100 | — | 2,606 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 343 | 39.0 | — | 5 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 343 | 38.9 | — | 5 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 455 | 51.7 | — | 54 | 2.7 | — | 2 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 100 | 11.3 | 1 | 2 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 43 | 4.9 | 8 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 29 | 3.3 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 72 | 8.2 | 9 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 10 | 1.1 | <0.5 | 7 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Severe depigmentation | 9 | 1.0 | 1 | 6 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 19 | 2.1 | 1 | 13 | 0.7 | <0.5 | 8 | 0.3 | <0.5 |
| Total skin disease (OSD) | 191 | 21.7 | 11 | 15 | 0.8 | 1 | 8 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 191 | 21.7 | 11 | 15 | 0.8 | 1 | 8 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Liberia, by APOC project




| Country: | Malawi | | | | | | | | |
|-----------------------------------|---------------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Projects: | Malawi Extension, Thyolo Mwanza | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,172 | 100 | — | 2,645 | 100 | — | 3,469 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 273 | 23.3 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 273 | 23.3 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 374 | 31.9 | — | 41 | 1.5 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 41 | 3.5 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 32 | 2.8 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 22 | 1.8 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 54 | 4.6 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 0.7 | <0.5 | 7 | 0.3 | <0.5 | 5 | 0.1 | <0.5 |
| Severe depigmentation | 8 | 0.6 | <0.5 | 5 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 16 | 1.4 | 1 | 12 | 0.5 | <0.5 | 8 | 0.2 | <0.5 |
| Total skin disease (OSD) | 111 | 9.5 | 8 | 13 | 0.5 | <0.5 | 8 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 111 | 9.5 | 8 | 13 | 0.5 | 1 | 8 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Malawi, by APOC project




| Country: Mozambique | | | | | | | | | |
|-----------------------------------|-----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Projects: | P20Mozambique, P5Mozambique | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 36 | 100 | — | 82 | 100 | — | 107 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 7 | 20.0 | — | 14 | 17.2 | — | 6 | 5.7 | — |
| Mf-positive (age 5+) | 7 | 20.0 | — | 14 | 17.2 | — | 6 | 5.7 | — |
| Worm infected | 10 | 27.6 | — | 20 | 24.9 | — | 16 | 15.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 2.0 | <0.5 | 1 | 1.7 | <0.5 | 1 | 0.6 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 2.3 | <0.5 | 2 | 1.9 | <0.5 | <0.5 | 0.4 | <0.5 |
| Reactive skin disease | 1 | 1.6 | <0.5 | 1 | 1.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 1 | 3.9 | <0.5 | 3 | 3.1 | <0.5 | 1 | 0.5 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.4 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.2 | <0.5 | 1 | 1.0 | <0.5 | 1 | 0.7 | <0.5 |
| Total skin disease (OSD) | 3 | 7.1 | <0.5 | 5 | 5.9 | <0.5 | 2 | 1.8 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 3 | 7.2 | <0.5 | 5 | 5.9 | <0.5 | 2 | 1.8 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Mozambique, by APOC project




| Country: Nigeria | | | | | | | | | |
|-----------------------------------|---|-------------|------------|--------------|------------|------------|------------|------------|------------|
| Projects: | Adamawa, Akwa Ibom, Bauchi, Benue, Borno, Cross River, Edo Delta, Ekiti, Enugu Anambra Ebony, FCT, Gombe, Imo Abia, Jigawa, Kaduna, Kano, Kebbi, Kogi, Kwara, Niger, Ogun, Ondo, Osun, Oyo, P20Nigeria, P5Nigeria, Plateau Nassarawa, Plateau Nassarawa LF, Taraba, Yobe, Zamfara | | | | | | | | |
| Bioclimate: | Savannah, Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 28,322 | 100 | — | 63,911 | 100 | — | 83,829 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 7,352 | 26.0 | — | 2,084 | 3.3 | — | 1,475 | 1.8 | — |
| Mf-positive (age 5+) | 7,346 | 25.9 | — | 2,083 | 3.3 | — | 1,475 | 1.8 | — |
| Worm infected | 9,741 | 34.4 | — | 3,854 | 6.0 | — | 2,911 | 3.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1,430 | 5.0 | 15 | 278 | 0.4 | 3 | 187 | 0.2 | 2 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 970 | 3.4 | 176 | 241 | 0.4 | 44 | 119 | 0.1 | 22 |
| Reactive skin disease | 669 | 2.4 | 31 | 149 | 0.2 | 7 | 30 | <0.05 | 1 |
| Reversible skin disease | 1,638 | 5.8 | 207 | 390 | 0.6 | 51 | 149 | 0.2 | 23 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 245 | 0.9 | 3 | 223 | 0.3 | 2 | 168 | 0.2 | 2 |
| Severe depigmentation | 220 | 0.8 | 14 | 184 | 0.3 | 12 | 129 | 0.2 | 8 |
| Atrophy | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 2 | <0.05 | 1 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 468 | 1.7 | 17 | 408 | 0.6 | 15 | 298 | 0.4 | 10 |
| Total skin disease (OSD) | 3,536 | 12.5 | 240 | 1,076 | 1.7 | 68 | 634 | 0.8 | 35 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 224 | 0.8 | 7 | 217 | 0.3 | 7 | 169 | 0.2 | 5 |
| Blindness | 72 | 0.3 | 498 | 45 | 0.1 | 310 | 29 | <0.05 | 202 |
| Eye disease (OED) | 296 | 1.0 | 505 | 261 | 0.4 | 316 | 198 | 0.2 | 207 |
| Total all manifestations | 3,832 | 13.5 | 744 | 1,338 | 2.1 | 385 | 832 | 1.0 | 242 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Nigeria, by APOC project



- Projects:
- | | | | | |
|-------------|---------------------|--------|------------|----------------------|
| Adamawa | Edo Delta | Jigawa | Niger | P5Nigeria |
| Akwa Ibom | Ekiti | Kaduna | Ogun | Plateau Nassarawa |
| Bauchi | Enugu Anambra Ebony | Kano | Ondo | Plateau Nassarawa LF |
| Benue | FCT | Kebbi | Osun | Taraba |
| Borno | Gombe | Kogi | Oyo | Yobe |
| Cross River | Imo Abia | Kwara | P20Nigeria | Zamfara |


Note: We assume that most MDA interventions would continue until at least 2030 (even though some foci are considered for post-treatment surveillance). We assume no ivermectin MDA for Plateau and Nassarawa since 2018 as onchocerciasis transmission has been interrupted.[4]‡, page 354.

| Country: South Sudan | | | | | | | | | |
|-----------------------------------|---|-------------|------------|------------|------------|------------|------------|------------|------------|
| Projects: | East Bahr El Ghazal, East Equatoria, P20SouthSudan, P5SouthSudan, Upper Nile, West Bahr El Ghazal, West Equatoria | | | | | | | | |
| Bioclimate: | Savannah | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 3,849 | 100 | — | 8,686 | 100 | — | 11,393 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 1,122 | 29.1 | — | 979 | 11.3 | — | 323 | 2.8 | — |
| Mf-positive (age 5+) | 1,120 | 29.1 | — | 978 | 11.3 | — | 323 | 2.8 | — |
| Worm infected | 1,478 | 38.4 | — | 1,897 | 21.8 | — | 943 | 8.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 270 | 7.0 | 3 | 212 | 2.4 | 2 | 81 | 0.7 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 154 | 4.0 | 28 | 88 | 1.0 | 16 | 22 | 0.2 | 4 |
| Reactive skin disease | 109 | 2.8 | 5 | 40 | 0.5 | 2 | 6 | 0.1 | <0.5 |
| Reversible skin disease | 262 | 6.8 | 33 | 128 | 1.5 | 18 | 28 | 0.2 | 4 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 37 | 1.0 | <0.5 | 52 | 0.6 | 1 | 41 | 0.4 | <0.5 |
| Severe depigmentation | 35 | 0.9 | 2 | 46 | 0.5 | 3 | 33 | 0.3 | 2 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 73 | 1.9 | 3 | 98 | 1.1 | 4 | 74 | 0.7 | 3 |
| Total skin disease (OSD) | 605 | 15.7 | 39 | 438 | 5.0 | 24 | 184 | 1.6 | 8 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 66 | 1.7 | 2 | 90 | 1.0 | 3 | 68 | 0.6 | 2 |
| Blindness | 26 | 0.7 | 200 | 27 | 0.3 | 208 | 15 | 0.1 | 116 |
| Eye disease (OED) | 93 | 2.4 | 202 | 117 | 1.3 | 211 | 83 | 0.7 | 118 |
| Total all manifestations | 698 | 18.1 | 241 | 555 | 6.4 | 235 | 267 | 2.3 | 126 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in South Sudan, by APOC project




- Projects:
- East Bahr El Ghazal
 - P20SouthSudan
 - Upper Nile
 - West Equatoria
 - East Equatoria
 - P5SouthSudan
 - West Bahr El Ghazal

| Country: Sudan | | | | | | | | | |
|-----------------------------------|---------------------------------|------------|----------------|-----------|------------|----------------|-----------|------------|----------------|
| Projects: | P5Sudan, Sudan, Sudan Abu Hamed | | | | | | | | |
| Bioclimate: | Savannah | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 366 | 100 | — | 826 | 100 | — | 1,083 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 79 | 21.6 | — | 64 | 7.8 | — | 48 | 4.5 | — |
| Mf-positive (age 5+) | 79 | 21.6 | — | 64 | 7.8 | — | 48 | 4.5 | — |
| Worm infected | 107 | 29.1 | — | 117 | 14.2 | — | 89 | 8.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 9 | 2.4 | <0.5 | 8 | 1.0 | <0.5 | 7 | 0.6 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 10 | 2.6 | 2 | 8 | 1.0 | 1 | 4 | 0.4 | 1 |
| Reactive skin disease | 6 | 1.7 | <0.5 | 5 | 0.6 | <0.5 | 1 | 0.1 | <0.5 |
| Reversible skin disease | 16 | 4.3 | 2 | 13 | 1.6 | 2 | 5 | 0.5 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 0.7 | <0.5 | 4 | 0.5 | <0.5 | 3 | 0.3 | <0.5 |
| Severe depigmentation | 2 | 0.6 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 1.3 | <0.5 | 7 | 0.8 | <0.5 | 6 | 0.5 | <0.5 |
| Total skin disease (OSD) | 29 | 8.0 | 2 | 28 | 3.4 | 2 | 18 | 1.6 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 4 | 1.2 | <0.5 | 6 | 0.8 | <0.5 | 5 | 0.5 | <0.5 |
| Blindness | 1 | 0.4 | 9 | 2 | 0.2 | 11 | 1 | 0.1 | 8 |
| Eye disease (OED) | 6 | 1.6 | 9 | 8 | 1.0 | 11 | 7 | 0.6 | 8 |
| Total all manifestations | 35 | 9.6 | 12 | 36 | 4.4 | 13 | 24 | 2.2 | 9 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Sudan, by APOC project




| Country: Tanzania | | | | | | | | | |
|-----------------------------------|---|-------------|-----------|------------|-----------------|-----------|-----------|-----------------|----------|
| Projects: | Kilosa, Mahenge, Morogoro, P5Tanzania, Ruvuma, Tanga, Tukuyu, Tunduru | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,839 | 100 | — | 4,151 | 100 | — | 5,444 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 631 | 34.3 | — | 338 | 8.1 | — | 186 | 3.4 | — |
| Mf-positive (age 5+) | 630 | 34.3 | — | 338 | 8.1 | — | 186 | 3.4 | — |
| Worm infected | 787 | 42.8 | — | 594 | 14.3 | — | 403 | 7.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 189 | 10.3 | 2 | 68 | 1.6 | 1 | 35 | 0.6 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 103 | 5.6 | 19 | 42 | 1.0 | 8 | 16 | 0.3 | 3 |
| Reactive skin disease | 77 | 4.2 | 4 | 27 | 0.6 | 1 | 3 | 0.1 | <0.5 |
| Reversible skin disease | 180 | 9.8 | 22 | 69 | 1.7 | 9 | 19 | 0.3 | 3 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 23 | 1.3 | <0.5 | 27 | 0.6 | <0.5 | 21 | 0.4 | <0.5 |
| Severe depigmentation | 27 | 1.4 | 2 | 27 | 0.7 | 2 | 20 | 0.4 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 51 | 2.8 | 2 | 55 | 1.3 | 2 | 42 | 0.8 | 2 |
| Total skin disease (OSD) | 420 | 22.8 | 26 | 192 | 4.6 | 12 | 96 | 1.8 | 5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 |
| Blindness | 2 | 0.1 | 11 | 1 | <0.05 | 4 | <0.5 | <0.05 | 2 |
| Eye disease (OED) | 3 | 0.2 | 11 | 2 | <0.05 | 4 | 1 | <0.05 | 2 |
| Total all manifestations | 423 | 23.0 | 38 | 194 | 4.7 | 16 | 97 | 1.8 | 7 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Tanzania, by APOC project




Projects: Kilosa, Mahenge, Morogoro, P5Tanzania, Ruvuma, Tanga, Tukuyu, Tunduru

| Country: Uganda | | | | | | | | | |
|-----------------------------------|---|-------------|-----------|-----------|-----------------|----------------|----------------|-----------------|----------------|
| Projects: | P5Uganda, Phase 1, Phase 2, Phase 3, Phase 4, Phase 5 | | | | | | | | |
| Bioclimate: | Forest | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 2,155 | 100 | — | 4,863 | 100 | — | 6,379 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 708 | 32.9 | — | 7 | 0.2 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 707 | 32.8 | — | 7 | 0.2 | — | <0.5 | <0.05 | — |
| Worm infected | 881 | 40.9 | — | 150 | 3.1 | — | 4 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 209 | 9.7 | 2 | 10 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 117 | 5.5 | 21 | 3 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 90 | 4.2 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 207 | 9.6 | 25 | 3 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 27 | 1.2 | <0.5 | 20 | 0.4 | <0.5 | 13 | 0.2 | <0.5 |
| Severe depigmentation | 31 | 1.5 | 2 | 21 | 0.4 | 1 | 13 | 0.2 | 1 |
| Atrophy | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 60 | 2.8 | 3 | 42 | 0.9 | 2 | 27 | 0.4 | 1 |
| Total skin disease (OSD) | 476 | 22.1 | 30 | 54 | 1.1 | 2 | 27 | 0.4 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 0.1 | <0.5 | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 |
| Blindness | 2 | 0.1 | 15 | 1 | <0.05 | 4 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 4 | 0.2 | 15 | 2 | <0.05 | 4 | 1 | <0.05 | 1 |
| Total all manifestations | 480 | 22.3 | 45 | 56 | 1.1 | 6 | 27 | 0.4 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Uganda, by APOC project




Note: We assume no ivermectin MDA for Phase 2 and Phase 4 as the foci in these APOC-projects are currently under post-treatment surveillance (PTS), or completed the PTS successfully [5-10][‡], page 354. For the other APOC-projects in Uganda, we assume that most MDA interventions would continue until at least 2030 (even though some foci are also considered for PTS).

| Project, country: | | Bengo, Angola | | | | | | | |
|-----------------------------------|----------------|----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2010 | | | | | | | |
| Mean MDA coverage per year: | | 70.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 13 | 100 | — | 30 | 100 | — | 39 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 3 | 23.9 | — | 1 | 3.4 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 3 | 23.8 | — | 1 | 3.4 | — | <0.5 | <0.05 | — |
| Worm infected | 4 | 32.0 | — | 4 | 13.9 | — | <0.5 | 1.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | <0.5 | 3.5 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 2.9 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | <0.5 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 1 | 4.9 | <0.5 | <0.5 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.8 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Severe depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.4 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.4 | <0.5 | <0.5 | 0.9 | <0.5 | <0.5 | 0.5 | <0.5 |
| Total skin disease (OSD) | 1 | 9.8 | <0.5 | 1 | 1.8 | <0.5 | <0.5 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 1 | 9.8 | <0.5 | 1 | 1.8 | <0.5 | <0.5 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bengo, Angola




| Project, country: | | Benguela, Angola | | | | | | | |
|-----------------------------------|----------------|-------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2012 | | | | | | | |
| Mean MDA coverage per year: | | 59.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 25 | 100 | — | 57 | 100 | — | 75 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 6 | 23.6 | — | 4 | 7.6 | — | <0.5 | 0.3 | — |
| Mf-positive (age 5+) | 6 | 23.6 | — | 4 | 7.6 | — | <0.5 | 0.3 | — |
| Worm infected | 8 | 32.2 | — | 11 | 19.2 | — | 2 | 3.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 3.6 | <0.5 | 1 | 1.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 2.8 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | <0.5 | 1.9 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 1 | 4.8 | <0.5 | <0.5 | 0.7 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.8 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | <0.5 | 0.4 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.4 | <0.5 | 1 | 0.9 | <0.5 | <0.5 | 0.5 | <0.5 |
| Total skin disease (OSD) | 2 | 9.7 | <0.5 | 2 | 2.9 | <0.5 | <0.5 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 2 | 9.8 | <0.5 | 2 | 2.9 | <0.5 | <0.5 | 0.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Benguela, Angola




| Project, country: | | Cuanza Norte, Angola | | | | | | | | |
|-----------------------------------|--|-----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | | |
| MDA start year: | | 2011 | | | | | | | | |
| Mean MDA coverage per year: | | 71.2 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 13 | 100 | — | 29 | 100 | — | 38 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 3 | 22.6 | — | 1 | 4.0 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | | 3 | 22.6 | — | 1 | 4.0 | — | <0.5 | <0.05 | — |
| Worm infected | | 4 | 31.0 | — | 4 | 14.6 | — | <0.5 | 1.2 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | <0.5 | 3.1 | <0.5 | <0.5 | 0.7 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | <0.5 | 2.7 | <0.5 | <0.5 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | | <0.5 | 1.8 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 1 | 4.5 | <0.5 | <0.5 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | <0.5 | 0.7 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.2 | <0.5 |
| Severe depigmentation | | <0.5 | 0.6 | <0.5 | <0.5 | 0.3 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | <0.5 | 1.3 | <0.5 | <0.5 | 0.8 | <0.5 | <0.5 | 0.4 | <0.5 |
| Total skin disease (OSD) | | 1 | 8.9 | <0.5 | 1 | 1.8 | <0.5 | <0.5 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | | 1 | 8.9 | <0.5 | 1 | 1.8 | <0.5 | <0.5 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Cuanza Norte, Angola




| Project, country: | | Huila, Angola | | | | | | | |
|-----------------------------------|----------------|----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2007 | | | | | | | |
| Mean MDA coverage per year: | | 59.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 119 | 100 | — | 268 | 100 | — | 352 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 39 | 33.2 | — | 19 | 7.1 | — | 1 | 0.3 | — |
| Mf-positive (age 5+) | 39 | 33.2 | — | 19 | 7.1 | — | 1 | 0.3 | — |
| Worm infected | 50 | 42.0 | — | 56 | 20.9 | — | 10 | 2.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 11 | 8.8 | <0.5 | 6 | 2.1 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 6 | 4.9 | 1 | 2 | 0.6 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 3.5 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 10 | 8.4 | 1 | 2 | 0.7 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.2 | <0.5 | 2 | 0.7 | <0.5 | 1 | 0.4 | <0.5 |
| Severe depigmentation | 1 | 1.2 | <0.5 | 2 | 0.7 | <0.5 | 1 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 2.4 | <0.5 | 4 | 1.4 | <0.5 | 3 | 0.8 | <0.5 |
| Total skin disease (OSD) | 23 | 19.7 | 1 | 11 | 4.1 | <0.5 | 3 | 0.9 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 23 | 19.7 | 2 | 11 | 4.2 | 1 | 3 | 0.9 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Huila, Angola




| Project, country: | | Kuando Kubango, Angola | | | | | | | |
|-----------------------------------|----------------|-------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2007 | | | | | | | |
| Mean MDA coverage per year: | | 68.9 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 205 | 100 | — | 463 | 100 | — | 607 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 47 | 22.7 | — | 6 | 1.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 47 | 22.7 | — | 6 | 1.3 | — | <0.5 | <0.05 | — |
| Worm infected | 63 | 30.9 | — | 40 | 8.6 | — | 2 | 0.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 6 | 3.0 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 6 | 2.7 | 1 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 9 | 4.6 | 1 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.7 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.3 | <0.5 | 3 | 0.7 | <0.5 | 2 | 0.3 | <0.5 |
| Total skin disease (OSD) | 18 | 9.0 | 1 | 5 | 1.0 | <0.5 | 2 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 18 | 9.0 | 1 | 5 | 1.0 | <0.5 | 2 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kuando Kubango, Angola




| Project, country: | | Lunda Norte, Angola | | | | | | | |
|-----------------------------------|----------------|----------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 59.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 153 | 100 | — | 346 | 100 | — | 453 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 42 | 27.4 | — | 9 | 2.6 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 42 | 27.4 | — | 9 | 2.6 | — | <0.5 | <0.05 | — |
| Worm infected | 56 | 36.3 | — | 42 | 12.3 | — | 4 | 0.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 8 | 5.2 | <0.5 | 2 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 5 | 3.6 | 1 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 2.3 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 9 | 5.9 | 1 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.9 | <0.5 | 2 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Severe depigmentation | 1 | 0.8 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.7 | <0.5 | 3 | 0.9 | <0.5 | 2 | 0.5 | <0.5 |
| Total skin disease (OSD) | 20 | 12.8 | 1 | 6 | 1.7 | <0.5 | 2 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 20 | 12.8 | 1 | 6 | 1.7 | <0.5 | 2 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Lunda Norte, Angola




| Project, country: | | Lunda sul, Angola | | | | | | | |
|-----------------------------------|----------------|--------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 60.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 129 | 100 | — | 291 | 100 | — | 382 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 37 | 28.5 | — | 8 | 2.6 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 37 | 28.5 | — | 8 | 2.6 | — | <0.5 | <0.05 | — |
| Worm infected | 48 | 36.9 | — | 35 | 12.1 | — | 3 | 0.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 7 | 5.5 | <0.5 | 1 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 5 | 3.9 | 1 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 2.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 8 | 6.5 | 1 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.0 | <0.5 | 2 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Severe depigmentation | 1 | 0.9 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.8 | <0.5 | 3 | 1.0 | <0.5 | 2 | 0.5 | <0.5 |
| Total skin disease (OSD) | 18 | 13.8 | 1 | 5 | 1.7 | <0.5 | 2 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 18 | 13.8 | 1 | 5 | 1.7 | <0.5 | 2 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Lunda sul, Angola




| Project, country: | | Moxico 1, Angola | | | | | | | |
|-----------------------------------|----------------|-------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2007 | | | | | | | |
| Mean MDA coverage per year: | | 58.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 135 | 100 | — | 304 | 100 | — | 399 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 31 | 23.0 | — | 11 | 3.7 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 31 | 23.0 | — | 11 | 3.7 | — | <0.5 | <0.05 | — |
| Worm infected | 42 | 30.9 | — | 41 | 13.5 | — | 5 | 1.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 3.1 | <0.5 | 2 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.9 | 1 | 1 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 6 | 4.7 | 1 | 1 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.8 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.4 | <0.5 | 2 | 0.8 | <0.5 | 2 | 0.4 | <0.5 |
| Total skin disease (OSD) | 12 | 9.3 | 1 | 5 | 1.7 | <0.5 | 2 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 13 | 9.3 | 1 | 5 | 1.7 | <0.5 | 2 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Moxico 1, Angola




| Project, country: | | Namibe, Angola | | | | | | | |
|-----------------------------------|----------------|-----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2019 | | | | | | | |
| Mean MDA coverage per year: | | 61.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 18 | 100 | — | 40 | 100 | — | 53 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 5 | 26.1 | — | 10 | 23.9 | — | 3 | 5.3 | — |
| Mf-positive (age 5+) | 5 | 26.1 | — | 10 | 23.9 | — | 3 | 5.3 | — |
| Worm infected | 6 | 34.2 | — | 13 | 33.3 | — | 9 | 16.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 4.3 | <0.5 | 2 | 4.2 | <0.5 | <0.5 | 0.9 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 3.4 | <0.5 | 1 | 2.8 | <0.5 | <0.5 | 0.4 | <0.5 |
| Reactive skin disease | <0.5 | 2.3 | <0.5 | 1 | 1.6 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 1 | 5.7 | <0.5 | 2 | 4.5 | <0.5 | <0.5 | 0.4 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.9 | <0.5 | <0.5 | 0.8 | <0.5 | <0.5 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.8 | <0.5 | <0.5 | 0.7 | <0.5 | <0.5 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.7 | <0.5 | 1 | 1.6 | <0.5 | 1 | 1.0 | <0.5 |
| Total skin disease (OSD) | 2 | 11.7 | <0.5 | 4 | 10.2 | <0.5 | 1 | 2.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 2 | 11.7 | <0.5 | 4 | 10.2 | <0.5 | 1 | 2.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Namibe, Angola




| | | | | | | | | | |
|-----------------------------------|----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Benguela, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 57 | 100 | — | 128 | 100 | — | 168 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 15 | 27.2 | — | 32 | 24.8 | — | 9 | 5.6 | — |
| Mf-positive (age 5+) | 15 | 27.2 | — | 32 | 24.8 | — | 9 | 5.6 | — |
| Worm infected | 20 | 35.7 | — | 44 | 34.6 | — | 29 | 17.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3 | 5.1 | <0.5 | 6 | 4.9 | <0.5 | 2 | 1.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 2 | 3.6 | <0.5 | 4 | 3.0 | 1 | 1 | 0.4 | <0.5 |
| Reactive skin disease | 1 | 2.4 | <0.5 | 2 | 1.7 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 3 | 6.1 | <0.5 | 6 | 4.7 | 1 | 1 | 0.5 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.9 | <0.5 | 1 | 0.8 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.9 | <0.5 | 1 | 0.7 | <0.5 | 1 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 1.8 | <0.5 | 2 | 1.6 | <0.5 | 2 | 1.0 | <0.5 |
| Total skin disease (OSD) | 7 | 12.9 | 1 | 14 | 11.2 | 1 | 4 | 2.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 7 | 13.0 | 1 | 14 | 11.2 | 1 | 4 | 2.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Benguela, Angola




| | | | | | | | | | |
|-----------------------------------|--------------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Cuanza Norte, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 9 | 100 | — | 21 | 100 | — | 27 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 2 | 22.6 | — | 4 | 20.4 | — | 1 | 4.3 | — |
| Mf-positive (age 5+) | 2 | 22.6 | — | 4 | 20.4 | — | 1 | 4.3 | — |
| Worm infected | 3 | 29.8 | — | 6 | 28.9 | — | 4 | 14.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | <0.5 | 2.4 | <0.5 | <0.5 | 2.3 | <0.5 | <0.5 | 0.5 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 2.9 | <0.5 | 1 | 2.4 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reactive skin disease | <0.5 | 1.9 | <0.5 | <0.5 | 1.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | <0.5 | 4.8 | <0.5 | 1 | 3.7 | <0.5 | <0.5 | 0.4 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.8 | <0.5 | <0.5 | 0.7 | <0.5 | <0.5 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.5 | <0.5 | <0.5 | 1.4 | <0.5 | <0.5 | 0.9 | <0.5 |
| Total skin disease (OSD) | 1 | 8.7 | <0.5 | 2 | 7.4 | <0.5 | <0.5 | 1.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 1 | 8.7 | <0.5 | 2 | 7.4 | <0.5 | <0.5 | 1.7 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Cuanza Norte, Angola




| | | | | | | | | | |
|-----------------------------------|-------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Huila, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 11 | 100 | — | 26 | 100 | — | 34 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 3 | 26.5 | — | 6 | 24.4 | — | 2 | 5.6 | — |
| Mf-positive (age 5+) | 3 | 26.5 | — | 6 | 24.4 | — | 2 | 5.6 | — |
| Worm infected | 4 | 34.3 | — | 9 | 33.5 | — | 6 | 17.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 4.5 | <0.5 | 1 | 4.3 | <0.5 | <0.5 | 1.0 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 3.6 | <0.5 | 1 | 3.0 | <0.5 | <0.5 | 0.4 | <0.5 |
| Reactive skin disease | <0.5 | 2.5 | <0.5 | <0.5 | 1.7 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 1 | 6.0 | <0.5 | 1 | 4.7 | <0.5 | <0.5 | 0.5 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.9 | <0.5 | <0.5 | 0.9 | <0.5 | <0.5 | 0.6 | <0.5 |
| Severe depigmentation | <0.5 | 0.9 | <0.5 | <0.5 | 0.8 | <0.5 | <0.5 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.8 | <0.5 | <0.5 | 1.7 | <0.5 | <0.5 | 1.0 | <0.5 |
| Total skin disease (OSD) | 1 | 12.3 | <0.5 | 3 | 10.6 | <0.5 | 1 | 2.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 1 | 12.4 | <0.5 | 3 | 10.7 | <0.5 | 1 | 2.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Huila, Angola




| | | | | | | | | | |
|-----------------------------------|-------------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Lunda Norte, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 33 | 100 | — | 75 | 100 | — | 99 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 9 | 25.8 | — | 18 | 23.8 | — | 5 | 5.4 | — |
| Mf-positive (age 5+) | 9 | 25.8 | — | 18 | 23.8 | — | 5 | 5.4 | — |
| Worm infected | 11 | 33.9 | — | 25 | 33.0 | — | 16 | 16.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 4.1 | <0.5 | 3 | 4.0 | <0.5 | 1 | 0.9 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 3.3 | <0.5 | 2 | 2.9 | <0.5 | <0.5 | 0.4 | <0.5 |
| Reactive skin disease | 1 | 2.3 | <0.5 | 1 | 1.6 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 2 | 5.6 | <0.5 | 3 | 4.5 | <0.5 | <0.5 | 0.4 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.9 | <0.5 | 1 | 0.8 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.8 | <0.5 | 1 | 0.7 | <0.5 | <0.5 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 1.7 | <0.5 | 1 | 1.5 | <0.5 | 1 | 1.0 | <0.5 |
| Total skin disease (OSD) | 4 | 11.3 | <0.5 | 8 | 10.1 | 1 | 2 | 2.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 4 | 11.3 | <0.5 | 8 | 10.1 | 1 | 2 | 2.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Lunda Norte, Angola




| | | | | | | | | | |
|-----------------------------------|----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Moxico 1, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 172 | 100 | — | 388 | 100 | — | 510 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 34 | 19.9 | — | 62 | 16.1 | — | 14 | 2.8 | — |
| Mf-positive (age 5+) | 34 | 19.8 | — | 62 | 16.1 | — | 14 | 2.8 | — |
| Worm infected | 48 | 27.8 | — | 96 | 24.6 | — | 55 | 10.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 2.1 | <0.5 | 7 | 1.7 | <0.5 | 2 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.3 | 1 | 7 | 1.7 | 1 | 1 | 0.2 | <0.5 |
| Reactive skin disease | 3 | 1.5 | <0.5 | 4 | 0.9 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 6 | 3.8 | 1 | 10 | 2.6 | 1 | 1 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.7 | <0.5 | 2 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.2 | <0.5 | 4 | 1.0 | <0.5 | 3 | 0.6 | <0.5 |
| Total skin disease (OSD) | 12 | 7.0 | 1 | 21 | 5.3 | 2 | 6 | 1.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 12 | 7.0 | 1 | 21 | 5.4 | 2 | 6 | 1.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Moxico 1, Angola




| | | | | | | | | | |
|-----------------------------------|-------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | P5Angola, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 131 | 100 | — | 296 | 100 | — | 388 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 29 | 22.4 | — | 63 | 21.2 | — | 50 | 12.8 | — |
| Mf-positive (age 5+) | 29 | 22.4 | — | 63 | 21.2 | — | 50 | 12.8 | — |
| Worm infected | 39 | 30.0 | — | 85 | 28.7 | — | 90 | 23.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3 | 2.6 | <0.5 | 7 | 2.4 | <0.5 | 6 | 1.6 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.8 | 1 | 8 | 2.6 | 1 | 4 | 1.1 | 1 |
| Reactive skin disease | 2 | 1.8 | <0.5 | 5 | 1.7 | <0.5 | 1 | 0.3 | <0.5 |
| Reversible skin disease | 6 | 4.6 | 1 | 13 | 4.3 | 2 | 5 | 1.4 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.8 | <0.5 | 2 | 0.7 | <0.5 | 2 | 0.6 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 2 | 0.6 | <0.5 | 2 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.4 | <0.5 | 4 | 1.3 | <0.5 | 4 | 1.0 | <0.5 |
| Total skin disease (OSD) | 11 | 8.6 | 1 | 24 | 8.0 | 2 | 15 | 4.0 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 11 | 8.6 | 1 | 24 | 8.0 | 2 | 16 | 4.0 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Angola, Angola




| | | | | | | | | | |
|-----------------------------------|---------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Uige, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 95 | 100 | — | 214 | 100 | — | 280 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 26 | 27.3 | — | 52 | 24.4 | — | 15 | 5.2 | — |
| Mf-positive (age 5+) | 26 | 27.3 | — | 52 | 24.3 | — | 15 | 5.2 | — |
| Worm infected | 34 | 36.1 | — | 74 | 34.5 | — | 47 | 16.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 5 | 5.2 | <0.5 | 10 | 4.8 | <0.5 | 3 | 1.0 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 3 | 3.5 | 1 | 6 | 2.9 | 1 | 1 | 0.4 | <0.5 |
| Reactive skin disease | 2 | 2.3 | <0.5 | 3 | 1.6 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 6 | 5.9 | 1 | 10 | 4.5 | 1 | 1 | 0.4 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.9 | <0.5 | 2 | 0.8 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | 1 | 0.8 | <0.5 | 2 | 0.7 | <0.5 | 1 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.7 | <0.5 | 3 | 1.5 | <0.5 | 3 | 0.9 | <0.5 |
| Total skin disease (OSD) | 12 | 12.7 | 1 | 23 | 10.9 | 2 | 7 | 2.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 12 | 12.7 | 1 | 23 | 10.9 | 2 | 7 | 2.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Uige, Angola




| | | | | | | | | | |
|-----------------------------------|----------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Zaire, Angola | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 61.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 7 | 100 | — | 16 | 100 | — | 21 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 1 | 20.3 | — | 3 | 16.7 | — | 1 | 2.9 | — |
| Mf-positive (age 5+) | 1 | 20.3 | — | 3 | 16.7 | — | 1 | 2.9 | — |
| Worm infected | 2 | 28.0 | — | 4 | 25.3 | — | 2 | 11.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | <0.5 | 2.1 | <0.5 | <0.5 | 1.8 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 2.4 | <0.5 | <0.5 | 1.7 | <0.5 | <0.5 | 0.2 | <0.5 |
| Reactive skin disease | <0.5 | 1.6 | <0.5 | <0.5 | 1.0 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | <0.5 | 4.0 | <0.5 | <0.5 | 2.7 | <0.5 | <0.5 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.3 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.3 | <0.5 | <0.5 | 1.1 | <0.5 | <0.5 | 0.6 | <0.5 |
| Total skin disease (OSD) | 1 | 7.3 | <0.5 | 1 | 5.6 | <0.5 | <0.5 | 1.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 1 | 7.4 | <0.5 | 1 | 5.6 | <0.5 | <0.5 | 1.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Zaire, Angola




| Project, country: | | Bururi, Burundi | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 69.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 220 | 100 | — | 497 | 100 | — | 652 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 53 | 23.9 | — | 4 | 0.9 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 53 | 23.9 | — | 4 | 0.9 | — | <0.5 | <0.05 | — |
| Worm infected | 71 | 32.2 | — | 35 | 7.1 | — | 2 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 8 | 3.5 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 6 | 2.9 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 11 | 4.8 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.8 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.4 | <0.5 | 3 | 0.7 | <0.5 | 2 | 0.3 | <0.5 |
| Total skin disease (OSD) | 22 | 9.8 | 2 | 5 | 0.9 | <0.5 | 2 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 22 | 9.8 | 2 | 5 | 0.9 | <0.5 | 2 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bururi, Burundi




| Project, country: | | Cibitoke-Bubanza, Burundi | | | | | | | |
|-----------------------------------|----------------|----------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 72.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 526 | 100 | — | 1,187 | 100 | — | 1,557 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 173 | 32.9 | — | 11 | 0.9 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 173 | 32.9 | — | 11 | 0.9 | — | <0.5 | <0.05 | — |
| Worm infected | 222 | 42.2 | — | 99 | 8.3 | — | 4 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 43 | 8.1 | <0.5 | 4 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 24 | 4.5 | 4 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 17 | 3.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 40 | 7.7 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 1.1 | <0.5 | 6 | 0.5 | <0.5 | 4 | 0.3 | <0.5 |
| Severe depigmentation | 6 | 1.0 | <0.5 | 6 | 0.5 | <0.5 | 4 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 11 | 2.1 | <0.5 | 12 | 1.0 | <0.5 | 8 | 0.5 | <0.5 |
| Total skin disease (OSD) | 94 | 17.9 | 6 | 17 | 1.4 | 1 | 8 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 94 | 17.9 | 6 | 17 | 1.4 | 1 | 8 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Cibitoke–Bubanza, Burundi




| | | | | | | | | | |
|-----------------------------------|---------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | P5Burundi, Burundi | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 415 | 100 | — | 936 | 100 | — | 1,228 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 98 | 23.6 | — | 203 | 21.7 | — | 163 | 13.3 | — |
| Mf-positive (age 5+) | 98 | 23.6 | — | 203 | 21.7 | — | 163 | 13.3 | — |
| Worm infected | 131 | 31.5 | — | 278 | 29.7 | — | 294 | 24.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 14 | 3.3 | <0.5 | 28 | 3.0 | <0.5 | 25 | 2.0 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 12 | 3.0 | 2 | 25 | 2.7 | 5 | 14 | 1.1 | 3 |
| Reactive skin disease | 8 | 2.0 | <0.5 | 17 | 1.8 | 1 | 4 | 0.3 | <0.5 |
| Reversible skin disease | 20 | 4.9 | 3 | 42 | 4.5 | 5 | 17 | 1.4 | 3 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 0.8 | <0.5 | 7 | 0.7 | <0.5 | 7 | 0.6 | <0.5 |
| Severe depigmentation | 3 | 0.7 | <0.5 | 6 | 0.6 | <0.5 | 6 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 1.5 | <0.5 | 13 | 1.3 | <0.5 | 13 | 1.0 | <0.5 |
| Total skin disease (OSD) | 40 | 9.7 | 3 | 83 | 8.9 | 6 | 55 | 4.5 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 40 | 9.7 | 3 | 83 | 8.9 | 7 | 55 | 4.5 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Burundi, Burundi




| Project, country: | | Rutana, Burundi | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 71.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 171 | 100 | — | 387 | 100 | — | 508 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 35 | 20.4 | — | 2 | 0.5 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 35 | 20.4 | — | 2 | 0.5 | — | <0.5 | <0.05 | — |
| Worm infected | 48 | 28.1 | — | 20 | 5.2 | — | 1 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 2.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 1.5 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 7 | 3.9 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.7 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.3 | <0.5 | 2 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Total skin disease (OSD) | 12 | 7.3 | 1 | 3 | 0.7 | <0.5 | 1 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 13 | 7.3 | 1 | 3 | 0.7 | <0.5 | 1 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Rutana, Burundi




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-------------|----------------|-----------|------------|----------------|----------------|-----------------|----------------|
| Project, country: | Adamaoua 1, Cameroon | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2004 | | | | | | | | |
| Mean MDA coverage per year: | 67.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 287 | 100 | — | 648 | 100 | — | 850 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 88 | 30.6 | — | 9 | 1.4 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 88 | 30.5 | — | 9 | 1.4 | — | <0.5 | <0.05 | — |
| Worm infected | 113 | 39.3 | — | 53 | 8.1 | — | 5 | 0.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 22 | 7.8 | <0.5 | 3 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 13 | 4.4 | 2 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 9 | 3.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 22 | 7.5 | 3 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.0 | <0.5 | 3 | 0.5 | <0.5 | 2 | 0.2 | <0.5 |
| Severe depigmentation | 3 | 1.0 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 2.1 | <0.5 | 6 | 0.9 | <0.5 | 4 | 0.5 | <0.5 |
| Total skin disease (OSD) | 50 | 17.4 | 3 | 10 | 1.5 | <0.5 | 4 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 5 | 1.9 | <0.5 | 6 | 0.9 | <0.5 | 4 | 0.4 | <0.5 |
| Blindness | 2 | 0.8 | 17 | 1 | 0.2 | 10 | 1 | 0.1 | 4 |
| Eye disease (OED) | 8 | 2.7 | 17 | 7 | 1.1 | 10 | 4 | 0.5 | 4 |
| Total all manifestations | 58 | 20.1 | 20 | 17 | 2.6 | 10 | 8 | 1.0 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Adamaoua 1, Cameroon




| Project, country: | | Adamaoua 2, Cameroon | | | | | | | |
|-----------------------------------|-----------|-----------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 65.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 261 | 100 | — | 589 | 100 | — | 772 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 86 | 32.9 | — | 2 | 0.4 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 86 | 32.9 | — | 2 | 0.4 | — | <0.5 | <0.05 | — |
| Worm infected | 110 | 42.2 | — | 25 | 4.3 | — | 1 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 23 | 8.8 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 12 | 4.7 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 9 | 3.3 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 21 | 8.0 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.1 | <0.5 | 2 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Severe depigmentation | 3 | 1.0 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 2.1 | <0.5 | 5 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Total skin disease (OSD) | 49 | 19.0 | 3 | 6 | 1.0 | <0.5 | 3 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 5 | 2.0 | <0.5 | 4 | 0.7 | <0.5 | 3 | 0.4 | <0.5 |
| Blindness | 2 | 0.8 | 15 | 1 | 0.1 | 6 | <0.5 | <0.05 | 2 |
| Eye disease (OED) | 7 | 2.8 | 15 | 5 | 0.9 | 6 | 3 | 0.4 | 2 |
| Total all manifestations | 57 | 21.8 | 18 | 11 | 1.8 | 6 | 6 | 0.8 | 3 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Adamaoua 2, Cameroon




| Project, country: | | Centre 1, Cameroon | | | | | | | |
|-----------------------------------|------------|---------------------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2000 | | | | | | | |
| Mean MDA coverage per year: | | 69.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 265 | 100 | — | 598 | 100 | — | 785 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 136 | 51.2 | — | 14 | 2.4 | — | 1 | 0.1 | — |
| Mf-positive (age 5+) | 135 | 51.1 | — | 14 | 2.4 | — | 1 | 0.1 | — |
| Worm infected | 159 | 60.0 | — | 71 | 11.8 | — | 9 | 1.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 61 | 23.0 | 1 | 5 | 0.9 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 27 | 10.2 | 5 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 22 | 8.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 49 | 18.4 | 6 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 2.1 | <0.5 | 5 | 0.9 | <0.5 | 4 | 0.5 | <0.5 |
| Severe depigmentation | 8 | 2.9 | <0.5 | 6 | 1.1 | <0.5 | 4 | 0.5 | <0.5 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 13 | 5.1 | 1 | 12 | 2.0 | 1 | 8 | 1.0 | <0.5 |
| Total skin disease (OSD) | 123 | 46.4 | 7 | 18 | 3.0 | 1 | 8 | 1.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 1 | 0.2 | 4 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.4 | 4 | 1 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 124 | 46.8 | 11 | 19 | 3.1 | 2 | 8 | 1.1 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Centre 1, Cameroon




| Project, country: | | Centre 2, Cameroon | | | | | | | |
|-----------------------------------|----------------|---------------------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2000 | | | | | | | |
| Mean MDA coverage per year: | | 64.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 62 | 100 | — | 141 | 100 | — | 185 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 27 | 43.6 | — | 4 | 3.2 | — | 1 | 0.3 | — |
| Mf-positive (age 5+) | 27 | 43.5 | — | 4 | 3.2 | — | 1 | 0.3 | — |
| Worm infected | 33 | 52.2 | — | 18 | 12.7 | — | 3 | 1.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 11 | 17.2 | <0.5 | 2 | 1.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 5 | 8.1 | 1 | <0.5 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 6.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 9 | 14.4 | 1 | <0.5 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.7 | <0.5 | 1 | 0.8 | <0.5 | 1 | 0.4 | <0.5 |
| Severe depigmentation | 1 | 2.2 | <0.5 | 1 | 0.9 | <0.5 | 1 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 4.1 | <0.5 | 2 | 1.7 | <0.5 | 2 | 0.9 | <0.5 |
| Total skin disease (OSD) | 22 | 35.7 | 1 | 5 | 3.2 | <0.5 | 2 | 1.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.3 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 22 | 36.0 | 2 | 5 | 3.3 | 1 | 2 | 1.0 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Centre 2, Cameroon




| Project, country: | | Centre 3, Cameroon | | | | | | | |
|-----------------------------------|----------------|---------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 67.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 201 | 100 | — | 455 | 100 | — | 596 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 80 | 39.9 | — | 3 | 0.6 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 80 | 39.9 | — | 3 | 0.6 | — | <0.5 | <0.05 | — |
| Worm infected | 99 | 48.9 | — | 26 | 5.7 | — | 1 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 27 | 13.4 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 13 | 6.5 | 2 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 10 | 4.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 23 | 11.4 | 3 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.5 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Severe depigmentation | 3 | 1.6 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 3.1 | <0.5 | 5 | 1.1 | <0.5 | 3 | 0.6 | <0.5 |
| Total skin disease (OSD) | 56 | 27.9 | 3 | 6 | 1.4 | <0.5 | 3 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 56 | 28.0 | 4 | 7 | 1.5 | <0.5 | 3 | 0.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Centre 3, Cameroon




| | | | | | | | | | |
|-----------------------------------|-----------------------|-------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Project, country: | East, Cameroon | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2005 | | | | | | | | |
| Mean MDA coverage per year: | 74.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 74 | 100 | — | 166 | 100 | — | 218 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 29 | 39.7 | — | 6 | 3.4 | — | <0.5 | 0.2 | — |
| Mf-positive (age 5+) | 29 | 39.6 | — | 6 | 3.4 | — | <0.5 | 0.2 | — |
| Worm infected | 35 | 48.1 | — | 24 | 14.2 | — | 4 | 1.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 11 | 14.7 | <0.5 | 3 | 1.6 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 5 | 7.2 | 1 | 1 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 5.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 10 | 13.0 | 1 | 1 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.6 | <0.5 | 1 | 0.8 | <0.5 | 1 | 0.4 | <0.5 |
| Severe depigmentation | 1 | 2.0 | <0.5 | 2 | 1.0 | <0.5 | 1 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 3.6 | <0.5 | 3 | 1.8 | <0.5 | 2 | 0.9 | <0.5 |
| Total skin disease (OSD) | 23 | 31.3 | 1 | 6 | 3.8 | <0.5 | 2 | 1.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.3 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 23 | 31.6 | 2 | 6 | 3.9 | 1 | 2 | 1.1 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in East, Cameroon




| Project, country: | | Far North, Cameroon | | | | | | | |
|-----------------------------------|-----------|----------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 74.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 174 | 100 | — | 393 | 100 | — | 515 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 33 | 18.8 | — | 1 | 0.2 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 33 | 18.8 | — | 1 | 0.2 | — | <0.5 | <0.05 | — |
| Worm infected | 47 | 26.8 | — | 12 | 2.9 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3 | 1.8 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 2 | 1.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 6 | 3.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.6 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.5 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.0 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 11 | 6.4 | 1 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 1.0 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Blindness | <0.5 | 0.2 | 3 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 2 | 1.2 | 3 | 2 | 0.4 | 1 | 1 | 0.2 | 1 |
| Total all manifestations | 13 | 7.6 | 4 | 3 | 0.9 | 2 | 2 | 0.4 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Far North, Cameroon




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-------------|----------------|-----------|------------|----------------|----------------|------------|----------------|
| Project, country: | Littoral 1, Cameroon | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 63.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 174 | 100 | — | 393 | 100 | — | 515 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 92 | 52.6 | — | 49 | 12.5 | — | 8 | 1.5 | — |
| Mf-positive (age 5+) | 91 | 52.5 | — | 49 | 12.5 | — | 8 | 1.5 | — |
| Worm infected | 106 | 61.2 | — | 118 | 30.1 | — | 41 | 7.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 42 | 24.0 | <0.5 | 18 | 4.7 | <0.5 | 2 | 0.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 18 | 10.6 | 3 | 4 | 1.1 | 1 | <0.5 | 0.1 | <0.5 |
| Reactive skin disease | 15 | 8.6 | 1 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 33 | 19.2 | 4 | 5 | 1.3 | 1 | <0.5 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 2.1 | <0.5 | 5 | 1.2 | <0.5 | 4 | 0.7 | <0.5 |
| Severe depigmentation | 5 | 3.0 | <0.5 | 6 | 1.5 | <0.5 | 4 | 0.8 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 5.3 | <0.5 | 11 | 2.8 | <0.5 | 8 | 1.5 | <0.5 |
| Total skin disease (OSD) | 84 | 48.5 | 5 | 34 | 8.8 | 1 | 11 | 2.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.2 | 3 | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 1 | 0.4 | 3 | 1 | 0.1 | 2 | <0.5 | 0.1 | 1 |
| Total all manifestations | 85 | 48.9 | 8 | 35 | 8.9 | 3 | 11 | 2.1 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Littoral 1, Cameroon




| Project, country: | | Littoral 2, Cameroon | | | | | | | |
|-----------------------------------|-----------|-----------------------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 67.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 93 | 100 | — | 209 | 100 | — | 275 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 56 | 60.4 | — | 17 | 7.9 | — | 3 | 1.0 | — |
| Mf-positive (age 5+) | 56 | 60.1 | — | 17 | 7.9 | — | 3 | 1.0 | — |
| Worm infected | 63 | 68.0 | — | 47 | 22.6 | — | 16 | 6.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 31 | 33.3 | <0.5 | 7 | 3.2 | <0.5 | 1 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 14 | 14.6 | 2 | 1 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 12 | 12.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 25 | 27.3 | 3 | 1 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 2.7 | <0.5 | 2 | 1.2 | <0.5 | 2 | 0.7 | <0.5 |
| Severe depigmentation | 4 | 4.6 | <0.5 | 4 | 1.7 | <0.5 | 2 | 0.9 | <0.5 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.3 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 7 | 7.9 | <0.5 | 6 | 3.0 | <0.5 | 4 | 1.6 | <0.5 |
| Total skin disease (OSD) | 64 | 68.5 | 4 | 14 | 6.6 | 1 | 5 | 1.9 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.4 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 |
| Blindness | 1 | 0.6 | 4 | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 1 | 1.0 | 4 | <0.5 | 0.2 | 2 | <0.5 | 0.1 | 1 |
| Total all manifestations | 65 | 69.5 | 8 | 14 | 6.9 | 2 | 6 | 2.0 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Littoral 2, Cameroon




| | | | | | | | | | |
|-----------------------------------|---------------------------|-------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Project, country: | Northern, Cameroon | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 69.5 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 390 | 100 | — | 881 | 100 | — | 1,155 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 162 | 41.4 | — | 9 | 1.0 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 161 | 41.3 | — | 9 | 1.0 | — | <0.5 | <0.05 | — |
| Worm infected | 198 | 50.7 | — | 56 | 6.3 | — | 6 | 0.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 61 | 15.5 | 1 | 4 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 28 | 7.2 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 22 | 5.6 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 50 | 12.8 | 6 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 1.5 | <0.5 | 5 | 0.6 | <0.5 | 3 | 0.3 | <0.5 |
| Severe depigmentation | 7 | 1.8 | <0.5 | 5 | 0.6 | <0.5 | 3 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 13 | 3.4 | 1 | 10 | 1.2 | <0.5 | 7 | 0.6 | <0.5 |
| Total skin disease (OSD) | 124 | 31.7 | 7 | 15 | 1.7 | 1 | 7 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 12 | 3.1 | <0.5 | 10 | 1.1 | <0.5 | 7 | 0.6 | <0.5 |
| Blindness | 7 | 1.7 | 53 | 3 | 0.3 | 22 | 1 | 0.1 | 9 |
| Eye disease (OED) | 19 | 4.8 | 54 | 13 | 1.4 | 22 | 8 | 0.7 | 10 |
| Total all manifestations | 142 | 36.5 | 61 | 27 | 3.1 | 23 | 15 | 1.3 | 10 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Northern, Cameroon




| Project, country: | | Northwest, Cameroon | | | | | | | |
|-----------------------------------|------------|----------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2004 | | | | | | | |
| Mean MDA coverage per year: | | 72.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 507 | 100 | — | 1,144 | 100 | — | 1,501 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 223 | 44.1 | — | 18 | 1.6 | — | 1 | 0.1 | — |
| Mf-positive (age 5+) | 223 | 44.0 | — | 18 | 1.6 | — | 1 | 0.1 | — |
| Worm infected | 275 | 54.2 | — | 120 | 10.5 | — | 10 | 0.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 78 | 15.5 | 1 | 7 | 0.6 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 36 | 7.0 | 6 | 2 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 26 | 5.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 62 | 12.2 | 8 | 2 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 8 | 1.5 | <0.5 | 8 | 0.7 | <0.5 | 6 | 0.4 | <0.5 |
| Severe depigmentation | 8 | 1.7 | 1 | 8 | 0.7 | 1 | 5 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 17 | 3.3 | 1 | 17 | 1.4 | 1 | 11 | 0.7 | <0.5 |
| Total skin disease (OSD) | 157 | 30.9 | 9 | 26 | 2.2 | 1 | 11 | 0.8 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.1 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 157 | 31.1 | 12 | 26 | 2.3 | 2 | 12 | 0.8 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Northwest, Cameroon




| Project, country: | | P20Cameroon, Cameroon | | | | | | | |
|-----------------------------------|----------------|------------------------------|----------------|----------------|-------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2016 | | | | | | | |
| Mean MDA coverage per year: | | 73.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 93 | 100 | — | 211 | 100 | — | 276 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 40 | 43.3 | — | 64 | 30.5 | — | 8 | 2.9 | — |
| Mf-positive (age 5+) | 40 | 43.2 | — | 64 | 30.5 | — | 8 | 2.9 | — |
| Worm infected | 50 | 53.4 | — | 99 | 46.7 | — | 40 | 14.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 14 | 15.2 | <0.5 | 25 | 11.8 | <0.5 | 3 | 1.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 6 | 6.9 | 1 | 7 | 3.5 | 1 | 1 | 0.2 | <0.5 |
| Reactive skin disease | 5 | 5.1 | <0.5 | 2 | 1.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 11 | 12.0 | 1 | 10 | 4.5 | 1 | 1 | 0.3 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.5 | <0.5 | 3 | 1.3 | <0.5 | 2 | 0.8 | <0.5 |
| Severe depigmentation | 2 | 1.7 | <0.5 | 3 | 1.4 | <0.5 | 2 | 0.8 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 3.2 | <0.5 | 6 | 2.7 | <0.5 | 4 | 1.5 | <0.5 |
| Total skin disease (OSD) | 28 | 30.4 | 2 | 40 | 19.0 | 2 | 8 | 2.9 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 29 | 30.6 | 2 | 40 | 19.1 | 3 | 8 | 2.9 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20Cameroon, Cameroon




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-----------------|----------|----------------|-----------------|-----------|------------|-----------------|-----------|
| Project, country: | P5Cameroon, Cameroon | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 929 | 100 | — | 2,097 | 100 | — | 2,751 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 224 | 24.1 | — | 482 | 23.0 | — | 395 | 14.4 | — |
| Mf-positive (age 5+) | 224 | 24.1 | — | 482 | 23.0 | — | 395 | 14.4 | — |
| Worm infected | 298 | 32.1 | — | 648 | 30.9 | — | 702 | 25.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 34 | 3.6 | <0.5 | 72 | 3.4 | 1 | 64 | 2.3 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 29 | 3.1 | 5 | 61 | 2.9 | 11 | 34 | 1.3 | 6 |
| Reactive skin disease | 20 | 2.1 | 1 | 41 | 2.0 | 2 | 10 | 0.4 | <0.5 |
| Reversible skin disease | 48 | 5.2 | 6 | 102 | 4.9 | 13 | 45 | 1.6 | 7 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 8 | 0.9 | <0.5 | 16 | 0.8 | <0.5 | 17 | 0.6 | <0.5 |
| Severe depigmentation | 6 | 0.7 | <0.5 | 14 | 0.7 | 1 | 15 | 0.5 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 14 | 1.5 | 1 | 31 | 1.5 | 1 | 31 | 1.1 | 1 |
| Total skin disease (OSD) | 96 | 10.4 | 7 | 205 | 9.8 | 15 | 140 | 5.1 | 9 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | 1 | <0.05 | 1 |
| Total all manifestations | 97 | 10.4 | 8 | 205 | 9.8 | 16 | 141 | 5.1 | 10 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Cameroon, Cameroon




| Project, country: | | South, Cameroon | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 70.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 185 | 100 | — | 418 | 100 | — | 548 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 60 | 32.4 | — | 4 | 1.0 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 60 | 32.4 | — | 4 | 1.0 | — | <0.5 | <0.05 | — |
| Worm infected | 78 | 42.1 | — | 35 | 8.4 | — | 2 | 0.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 15 | 8.1 | <0.5 | 1 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 4.4 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 6 | 3.0 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 14 | 7.4 | 2 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.0 | <0.5 | 2 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Severe depigmentation | 2 | 1.0 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 2.0 | <0.5 | 4 | 0.9 | <0.5 | 2 | 0.5 | <0.5 |
| Total skin disease (OSD) | 33 | 17.6 | 2 | 6 | 1.4 | <0.5 | 3 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 33 | 17.6 | 2 | 6 | 1.4 | <0.5 | 3 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in South, Cameroon




| Project, country: | | South West 1, Cameroon | | | | | | | |
|-----------------------------------|------------|-------------------------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 68.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 243 | 100 | — | 548 | 100 | — | 719 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 143 | 59.0 | — | 16 | 3.0 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 143 | 58.9 | — | 16 | 3.0 | — | <0.5 | <0.05 | — |
| Worm infected | 163 | 66.9 | — | 88 | 16.1 | — | 8 | 1.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 72 | 29.6 | 1 | 7 | 1.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 31 | 12.7 | 6 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 26 | 10.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 56 | 23.2 | 7 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 2.6 | <0.5 | 6 | 1.0 | <0.5 | 4 | 0.6 | <0.5 |
| Severe depigmentation | 9 | 3.7 | 1 | 7 | 1.3 | <0.5 | 5 | 0.7 | <0.5 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 16 | 6.5 | 1 | 13 | 2.4 | 1 | 9 | 1.2 | <0.5 |
| Total skin disease (OSD) | 144 | 59.3 | 8 | 21 | 3.8 | 1 | 9 | 1.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 1 | 0.3 | 5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.5 | 5 | 1 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 145 | 59.8 | 13 | 22 | 3.9 | 2 | 9 | 1.3 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in South West 1, Cameroon




| Project, country: | | South West 2, Cameroon | | | | | | | |
|-----------------------------------|-----------|-------------------------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2001 | | | | | | | |
| Mean MDA coverage per year: | | 74.6 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 165 | 100 | — | 373 | 100 | — | 489 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 88 | 53.2 | — | 4 | 1.0 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 88 | 53.1 | — | 4 | 1.0 | — | <0.5 | <0.05 | — |
| Worm infected | 103 | 62.1 | — | 35 | 9.3 | — | 2 | 0.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 39 | 23.4 | <0.5 | 2 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 17 | 10.1 | 3 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 13 | 8.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 30 | 18.2 | 4 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 2.1 | <0.5 | 3 | 0.9 | <0.5 | 2 | 0.5 | <0.5 |
| Severe depigmentation | 5 | 2.8 | <0.5 | 4 | 1.1 | <0.5 | 2 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 8 | 5.0 | <0.5 | 7 | 2.0 | <0.5 | 5 | 1.0 | <0.5 |
| Total skin disease (OSD) | 77 | 46.6 | 4 | 10 | 2.6 | <0.5 | 5 | 1.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.2 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.3 | 2 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 78 | 46.9 | 6 | 10 | 2.6 | 1 | 5 | 1.0 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in South West 2, Cameroon




| | | | | | | | | | |
|-----------------------------------|--------------------------|-------------|-----------|------------|------------|-----------|----------------|-----------------|----------------|
| Project, country: | Western, Cameroon | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2001 | | | | | | | | |
| Mean MDA coverage per year: | 72.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,016 | 100 | — | 2,292 | 100 | — | 3,007 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 673 | 66.3 | — | 127 | 5.5 | — | 9 | 0.3 | — |
| Mf-positive (age 5+) | 670 | 65.9 | — | 127 | 5.5 | — | 9 | 0.3 | — |
| Worm infected | 743 | 73.2 | — | 497 | 21.7 | — | 95 | 3.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 391 | 38.5 | 4 | 50 | 2.2 | 1 | 3 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 170 | 16.7 | 31 | 9 | 0.4 | 2 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 149 | 14.6 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 318 | 31.3 | 38 | 10 | 0.4 | 2 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 31 | 3.1 | <0.5 | 31 | 1.4 | <0.5 | 23 | 0.8 | <0.5 |
| Severe depigmentation | 54 | 5.3 | 3 | 49 | 2.1 | 3 | 33 | 1.1 | 2 |
| Atrophy | 2 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 4 | 0.3 | 1 | 2 | 0.1 | 1 | 1 | <0.05 | <0.5 |
| Irreversible skin disease | 90 | 8.9 | 5 | 82 | 3.6 | 4 | 57 | 1.9 | 3 |
| Total skin disease (OSD) | 800 | 78.7 | 47 | 142 | 6.2 | 7 | 60 | 2.0 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 5 | 0.5 | <0.5 | 4 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Blindness | 7 | 0.7 | 48 | 2 | 0.1 | 17 | 1 | <0.05 | 7 |
| Eye disease (OED) | 11 | 1.1 | 48 | 6 | 0.3 | 17 | 3 | 0.1 | 7 |
| Total all manifestations | 811 | 79.9 | 95 | 148 | 6.5 | 24 | 63 | 2.1 | 9 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Western, Cameroon




| Project, country: | | CAR region 3, CAR | | | | | | | |
|-----------------------------------|------------|--------------------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 62.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 265 | 100 | — | 598 | 100 | — | 784 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 147 | 55.6 | — | 17 | 2.9 | — | 3 | 0.4 | — |
| Mf-positive (age 5+) | 147 | 55.5 | — | 17 | 2.9 | — | 3 | 0.4 | — |
| Worm infected | 172 | 64.8 | — | 67 | 11.2 | — | 17 | 2.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 66 | 24.8 | 1 | 5 | 0.8 | <0.5 | 1 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 28 | 10.5 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 22 | 8.3 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 50 | 18.9 | 6 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 2.2 | <0.5 | 5 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Severe depigmentation | 7 | 2.7 | <0.5 | 5 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 13 | 4.9 | 1 | 9 | 1.6 | <0.5 | 6 | 0.8 | <0.5 |
| Total skin disease (OSD) | 129 | 48.6 | 7 | 15 | 2.5 | 1 | 7 | 0.9 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 12 | 4.5 | <0.5 | 9 | 1.6 | <0.5 | 6 | 0.8 | <0.5 |
| Blindness | 7 | 2.5 | 53 | 2 | 0.4 | 19 | 1 | 0.1 | 8 |
| Eye disease (OED) | 19 | 7.0 | 53 | 12 | 2.0 | 19 | 7 | 0.9 | 8 |
| Total all manifestations | 147 | 55.6 | 61 | 26 | 4.4 | 20 | 14 | 1.8 | 9 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in CAR region 3, CAR




| Project, country: | | CAR region 4, CAR | | | | | | | | |
|-----------------------------------|--|--------------------------|-------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | | |
| MDA start year: | | 1999 | | | | | | | | |
| Mean MDA coverage per year: | | 61.5 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 276 | 100 | — | 623 | 100 | — | 817 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 102 | 36.8 | — | 5 | 0.8 | — | 1 | 0.1 | — |
| Mf-positive (age 5+) | | 101 | 36.7 | — | 5 | 0.8 | — | 1 | 0.1 | — |
| Worm infected | | 127 | 46.0 | — | 27 | 4.3 | — | 5 | 0.6 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | 31 | 11.4 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | 16 | 5.6 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | | 11 | 4.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 27 | 9.8 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | 4 | 1.3 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Severe depigmentation | | 4 | 1.3 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | 7 | 2.6 | <0.5 | 5 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Total skin disease (OSD) | | 66 | 23.8 | 4 | 6 | 1.0 | <0.5 | 3 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | 7 | 2.4 | <0.5 | 5 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Blindness | | 3 | 1.0 | 22 | 1 | 0.1 | 7 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | | 10 | 3.5 | 22 | 6 | 0.9 | 7 | 3 | 0.4 | 3 |
| Total all manifestations | | 75 | 27.3 | 26 | 12 | 2.0 | 7 | 7 | 0.8 | 3 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in CAR region 4, CAR




| | | | | | | | | | |
|-----------------------------------|--------------------------|-------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | CAR region 5, CAR | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 58.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 255 | 100 | — | 576 | 100 | — | 756 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 80 | 31.4 | — | 2 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 80 | 31.4 | — | 2 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 104 | 40.6 | — | 14 | 2.4 | — | 2 | 0.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 19 | 7.6 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 11 | 4.3 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 8 | 3.0 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 19 | 7.3 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.1 | <0.5 | 2 | 0.3 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 3 | 1.0 | <0.5 | 2 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 2.1 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Total skin disease (OSD) | 43 | 16.9 | 3 | 4 | 0.7 | <0.5 | 2 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 5 | 1.9 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Blindness | 2 | 0.7 | 12 | <0.5 | 0.1 | 3 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 6 | 2.5 | 12 | 4 | 0.7 | 4 | 2 | 0.3 | 1 |
| Total all manifestations | 50 | 19.4 | 15 | 8 | 1.3 | 4 | 4 | 0.6 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in CAR region 5, CAR




| | | | | | | | | | |
|-----------------------------------|--------------------------|-------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Project, country: | CAR region 6, CAR | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 60.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 393 | 100 | — | 887 | 100 | — | 1,163 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 181 | 46.0 | — | 18 | 2.0 | — | 3 | 0.2 | — |
| Mf-positive (age 5+) | 180 | 45.9 | — | 18 | 2.0 | — | 3 | 0.2 | — |
| Worm infected | 218 | 55.4 | — | 66 | 7.5 | — | 19 | 1.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 69 | 17.7 | 1 | 4 | 0.5 | <0.5 | 1 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 31 | 7.9 | 6 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 24 | 6.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 55 | 13.9 | 7 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 1.7 | <0.5 | 5 | 0.6 | <0.5 | 3 | 0.3 | <0.5 |
| Severe depigmentation | 8 | 1.9 | <0.5 | 5 | 0.6 | <0.5 | 3 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 14 | 3.7 | 1 | 10 | 1.2 | <0.5 | 7 | 0.6 | <0.5 |
| Total skin disease (OSD) | 139 | 35.2 | 8 | 15 | 1.7 | 1 | 7 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 13 | 3.4 | <0.5 | 10 | 1.1 | <0.5 | 6 | 0.5 | <0.5 |
| Blindness | 7 | 1.7 | 52 | 2 | 0.2 | 17 | 1 | 0.1 | 7 |
| Eye disease (OED) | 20 | 5.1 | 52 | 12 | 1.3 | 17 | 7 | 0.6 | 7 |
| Total all manifestations | 158 | 40.3 | 61 | 27 | 3.1 | 18 | 15 | 1.2 | 7 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in CAR region 6, CAR




| | | | | | | | | | |
|-----------------------------------|--------------------|-------------|----------------|----------------|-------------|----------------|----------------|-----------------|----------------|
| Project, country: | P20CAR, CAR | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 73.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 39 | 100 | — | 87 | 100 | — | 115 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 16 | 41.3 | — | 34 | 39.2 | — | 14 | 11.9 | — |
| Mf-positive (age 5+) | 16 | 41.2 | — | 34 | 39.2 | — | 14 | 11.9 | — |
| Worm infected | 20 | 51.3 | — | 44 | 50.9 | — | 33 | 29.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 5 | 13.5 | <0.5 | 12 | 13.4 | <0.5 | 4 | 3.8 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 2 | 6.3 | <0.5 | 5 | 5.5 | 1 | 1 | 1.0 | <0.5 |
| Reactive skin disease | 2 | 4.6 | <0.5 | 3 | 3.4 | <0.5 | <0.5 | 0.2 | <0.5 |
| Reversible skin disease | 4 | 10.9 | 1 | 8 | 8.9 | 1 | 1 | 1.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.4 | <0.5 | 1 | 1.4 | <0.5 | 1 | 0.9 | <0.5 |
| Severe depigmentation | 1 | 1.5 | <0.5 | 1 | 1.4 | <0.5 | 1 | 0.9 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 2.9 | <0.5 | 2 | 2.8 | <0.5 | 2 | 1.8 | <0.5 |
| Total skin disease (OSD) | 11 | 27.3 | 1 | 22 | 25.2 | 1 | 8 | 6.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 11 | 27.4 | 1 | 22 | 25.3 | 1 | 8 | 6.8 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20CAR, CAR




| | | | | | | | | | |
|-----------------------------------|-------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | P5CAR, CAR | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 88 | 100 | — | 198 | 100 | — | 260 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 23 | 26.3 | — | 50 | 25.3 | — | 42 | 16.1 | — |
| Mf-positive (age 5+) | 23 | 26.3 | — | 50 | 25.2 | — | 42 | 16.1 | — |
| Worm infected | 30 | 34.6 | — | 66 | 33.5 | — | 72 | 27.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 4.8 | <0.5 | 9 | 4.6 | <0.5 | 8 | 3.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 3 | 3.5 | 1 | 7 | 3.3 | 1 | 4 | 1.5 | 1 |
| Reactive skin disease | 2 | 2.4 | <0.5 | 4 | 2.3 | <0.5 | 1 | 0.4 | <0.5 |
| Reversible skin disease | 5 | 5.9 | 1 | 11 | 5.6 | 1 | 5 | 1.9 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.9 | <0.5 | 2 | 0.8 | <0.5 | 2 | 0.7 | <0.5 |
| Severe depigmentation | 1 | 0.8 | <0.5 | 2 | 0.8 | <0.5 | 2 | 0.6 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.7 | <0.5 | 3 | 1.6 | <0.5 | 3 | 1.3 | <0.5 |
| Total skin disease (OSD) | 11 | 12.4 | 1 | 23 | 11.8 | 2 | 17 | 6.5 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 11 | 12.5 | 1 | 24 | 11.9 | 2 | 17 | 6.5 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5CAR, CAR




| | | | | | | | | | |
|-----------------------------------|-------------------|-------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Chad, Chad | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1998 | | | | | | | | |
| Mean MDA coverage per year: | 72.2 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,068 | 100 | — | 2,409 | 100 | — | 3,160 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 326 | 30.5 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 325 | 30.5 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 425 | 39.8 | — | 29 | 1.2 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 75 | 7.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 42 | 4.0 | 8 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 29 | 2.8 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 72 | 6.7 | 9 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 10 | 1.0 | <0.5 | 8 | 0.3 | <0.5 | 5 | 0.2 | <0.5 |
| Severe depigmentation | 9 | 0.9 | 1 | 6 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 20 | 1.8 | 1 | 14 | 0.6 | <0.5 | 8 | 0.3 | <0.5 |
| Total skin disease (OSD) | 167 | 15.6 | 11 | 14 | 0.6 | <0.5 | 8 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 18 | 1.7 | 1 | 12 | 0.5 | <0.5 | 7 | 0.2 | <0.5 |
| Blindness | 6 | 0.6 | 46 | 2 | 0.1 | 14 | 1 | <0.05 | 5 |
| Eye disease (OED) | 25 | 2.3 | 47 | 14 | 0.6 | 14 | 8 | 0.3 | 6 |
| Total all manifestations | 192 | 17.9 | 57 | 28 | 1.2 | 15 | 16 | 0.5 | 6 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Chad, Chad




| | | | | | | | | | |
|-----------------------------------|---------------------|-------------|----------------|-----------|-------------|----------------|-----------|------------|----------------|
| Project, country: | P5Chad, Chad | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 133 | 100 | — | 300 | 100 | — | 393 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 36 | 27.3 | — | 74 | 24.7 | — | 59 | 15.0 | — |
| Mf-positive (age 5+) | 36 | 27.3 | — | 74 | 24.7 | — | 59 | 15.0 | — |
| Worm infected | 50 | 37.3 | — | 103 | 34.3 | — | 109 | 27.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 8 | 5.8 | <0.5 | 16 | 5.3 | <0.5 | 14 | 3.6 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 3.3 | 1 | 9 | 3.0 | 2 | 5 | 1.3 | 1 |
| Reactive skin disease | 3 | 2.3 | <0.5 | 6 | 2.0 | <0.5 | 1 | 0.4 | <0.5 |
| Reversible skin disease | 7 | 5.6 | 1 | 15 | 5.1 | 2 | 7 | 1.7 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.9 | <0.5 | 2 | 0.8 | <0.5 | 3 | 0.6 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | 2 | 0.6 | <0.5 | 2 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.5 | <0.5 | 4 | 1.4 | <0.5 | 4 | 1.1 | <0.5 |
| Total skin disease (OSD) | 17 | 13.0 | 1 | 35 | 11.8 | 2 | 25 | 6.4 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 1.4 | <0.5 | 4 | 1.3 | <0.5 | 4 | 1.0 | <0.5 |
| Blindness | 1 | 0.5 | 4 | 1 | 0.4 | 9 | 1 | 0.3 | 8 |
| Eye disease (OED) | 3 | 1.9 | 4 | 5 | 1.7 | 9 | 5 | 1.3 | 8 |
| Total all manifestations | 20 | 14.8 | 6 | 40 | 13.5 | 12 | 30 | 7.7 | 10 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Chad, Chad




| Project, country: | | P5Chad propext, Chad | | | | | | | |
|-----------------------------------|----------|-----------------------------|----------------|-----------|------------|----------------|-----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2025 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 76 | 100 | — | 172 | 100 | — | 226 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 17 | 22.3 | — | 34 | 20.0 | — | 27 | 11.7 | — |
| Mf-positive (age 5+) | 17 | 22.3 | — | 34 | 19.9 | — | 27 | 11.7 | — |
| Worm infected | 24 | 30.8 | — | 49 | 28.2 | — | 51 | 22.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 2 | 3.1 | <0.5 | 5 | 2.7 | <0.5 | 4 | 1.8 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 2 | 2.6 | <0.5 | 4 | 2.3 | 1 | 2 | 1.0 | <0.5 |
| Reactive skin disease | 1 | 1.7 | <0.5 | 3 | 1.5 | <0.5 | 1 | 0.2 | <0.5 |
| Reversible skin disease | 3 | 4.3 | <0.5 | 7 | 3.8 | 1 | 3 | 1.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.7 | <0.5 | 1 | 0.6 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.5 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 1.2 | <0.5 | 2 | 1.1 | <0.5 | 2 | 0.9 | <0.5 |
| Total skin disease (OSD) | 7 | 8.6 | <0.5 | 13 | 7.6 | 1 | 9 | 3.9 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 1.2 | <0.5 | 2 | 1.0 | <0.5 | 2 | 0.8 | <0.5 |
| Blindness | <0.5 | 0.3 | 2 | 1 | 0.3 | 3 | <0.5 | 0.2 | 3 |
| Eye disease (OED) | 1 | 1.5 | 2 | 2 | 1.3 | 4 | 2 | 1.0 | 3 |
| Total all manifestations | 8 | 10.0 | 2 | 15 | 8.9 | 5 | 11 | 4.9 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Chad propext, Chad




| Project, country: | | Congo 1, Congo | | | | | | | |
|-----------------------------------|----------------|-----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2001 | | | | | | | |
| Mean MDA coverage per year: | | 70.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 487 | 100 | — | 1,099 | 100 | — | 1,441 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 133 | 27.3 | — | 3 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 133 | 27.3 | — | 3 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 175 | 36.0 | — | 40 | 3.6 | — | 1 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 27 | 5.5 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 17 | 3.6 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 12 | 2.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 29 | 6.0 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 0.9 | <0.5 | 4 | 0.4 | <0.5 | 3 | 0.2 | <0.5 |
| Severe depigmentation | 4 | 0.8 | <0.5 | 3 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 8 | 1.7 | <0.5 | 7 | 0.7 | <0.5 | 5 | 0.3 | <0.5 |
| Total skin disease (OSD) | 64 | 13.2 | 4 | 9 | 0.8 | <0.5 | 5 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 65 | 13.3 | 5 | 9 | 0.8 | 1 | 5 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Congo 1, Congo




| Project, country: | | P20Congo, Congo | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-------------|----------------|----------------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2015 | | | | | | | |
| Mean MDA coverage per year: | | 76.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 21 | 100 | — | 48 | 100 | — | 63 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 12 | 56.7 | — | 18 | 37.4 | — | 2 | 2.7 | — |
| Mf-positive (age 5+) | 12 | 56.6 | — | 18 | 37.4 | — | 2 | 2.7 | — |
| Worm infected | 14 | 65.9 | — | 27 | 56.6 | — | 11 | 16.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 5 | 24.7 | <0.5 | 8 | 17.3 | <0.5 | 1 | 1.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 2 | 10.5 | <0.5 | 2 | 4.5 | <0.5 | <0.5 | 0.2 | <0.5 |
| Reactive skin disease | 2 | 8.2 | <0.5 | <0.5 | 1.0 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 4 | 18.7 | <0.5 | 3 | 5.5 | <0.5 | <0.5 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 2.2 | <0.5 | 1 | 1.8 | <0.5 | 1 | 1.0 | <0.5 |
| Severe depigmentation | 1 | 2.7 | <0.5 | 1 | 2.2 | <0.5 | 1 | 1.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 5.0 | <0.5 | 2 | 4.0 | <0.5 | 1 | 2.3 | <0.5 |
| Total skin disease (OSD) | 10 | 48.3 | 1 | 13 | 26.8 | 1 | 2 | 3.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.3 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Total all manifestations | 10 | 48.6 | 1 | 13 | 26.9 | 1 | 2 | 3.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20Congo, Congo




| Project, country: | | P5Congo, Congo | | | | | | | |
|-----------------------------------|----------------|-----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2025 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 286 | 100 | — | 645 | 100 | — | 846 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 75 | 26.4 | — | 166 | 25.7 | — | 142 | 16.8 | — |
| Mf-positive (age 5+) | 75 | 26.4 | — | 165 | 25.7 | — | 142 | 16.8 | — |
| Worm infected | 97 | 34.1 | — | 214 | 33.2 | — | 237 | 28.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 14 | 4.8 | <0.5 | 31 | 4.7 | <0.5 | 29 | 3.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 11 | 3.7 | 2 | 23 | 3.6 | 4 | 14 | 1.6 | 3 |
| Reactive skin disease | 7 | 2.6 | <0.5 | 16 | 2.5 | 1 | 4 | 0.5 | <0.5 |
| Reversible skin disease | 18 | 6.3 | 2 | 40 | 6.1 | 5 | 18 | 2.1 | 3 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 0.9 | <0.5 | 6 | 0.9 | <0.5 | 6 | 0.8 | <0.5 |
| Severe depigmentation | 3 | 0.9 | <0.5 | 6 | 0.9 | <0.5 | 6 | 0.7 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 1.8 | <0.5 | 12 | 1.8 | <0.5 | 12 | 1.5 | <0.5 |
| Total skin disease (OSD) | 37 | 13.0 | 3 | 82 | 12.7 | 6 | 59 | 7.0 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 |
| Total all manifestations | 37 | 13.0 | 3 | 82 | 12.7 | 6 | 59 | 7.0 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Congo, Congo




| | | | | | | | | | |
|-----------------------------------|----------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Bandundu, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2003 | | | | | | | | |
| Mean MDA coverage per year: | 70.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 3 | 100 | — | 8 | 100 | — | 10 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 1 | 27.1 | — | <0.5 | 0.5 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 1 | 27.1 | — | <0.5 | 0.5 | — | <0.5 | <0.05 | — |
| Worm infected | 1 | 34.8 | — | <0.5 | 5.6 | — | <0.5 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | <0.5 | 4.9 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 3.7 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | <0.5 | 2.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | <0.5 | 6.3 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 1.0 | <0.5 | <0.5 | 0.4 | <0.5 | <0.5 | 0.2 | <0.5 |
| Severe depigmentation | <0.5 | 0.9 | <0.5 | <0.5 | 0.4 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.9 | <0.5 | <0.5 | 0.8 | <0.5 | <0.5 | 0.4 | <0.5 |
| Total skin disease (OSD) | <0.5 | 13.1 | <0.5 | <0.5 | 1.0 | <0.5 | <0.5 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | <0.5 | 13.1 | <0.5 | <0.5 | 1.0 | <0.5 | <0.5 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bandundu, DRC




| Project, country: | | Bas-Congo Kinshasa, DRC | | | | | | | | |
|-----------------------------------|--|--------------------------------|-------------|-----------|----------------|-----------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | | |
| MDA start year: | | 2004 | | | | | | | | |
| Mean MDA coverage per year: | | 61.9 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 803 | 100 | — | 1,813 | 100 | — | 2,378 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 298 | 37.0 | — | 57 | 3.1 | — | 1 | 0.1 | — |
| Mf-positive (age 5+) | | 297 | 37.0 | — | 57 | 3.1 | — | 1 | 0.1 | — |
| Worm infected | | 373 | 46.4 | — | 251 | 13.8 | — | 29 | 1.2 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | 89 | 11.1 | 1 | 17 | 0.9 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | 45 | 5.6 | 8 | 4 | 0.2 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | | 32 | 4.0 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 77 | 9.6 | 10 | 5 | 0.3 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | 10 | 1.3 | <0.5 | 12 | 0.6 | <0.5 | 8 | 0.3 | <0.5 |
| Severe depigmentation | | 11 | 1.3 | 1 | 11 | 0.6 | 1 | 7 | 0.3 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | 21 | 2.6 | 1 | 23 | 1.2 | 1 | 15 | 0.6 | 1 |
| Total skin disease (OSD) | | 187 | 23.3 | 11 | 44 | 2.4 | 2 | 16 | 0.7 | 1 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | | 1 | 0.1 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | | 188 | 23.3 | 13 | 44 | 2.4 | 3 | 16 | 0.7 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bas-Congo Kinshasa, DRC




| Project, country: | | Butembo-Beni, DRC | | | | | | | | |
|-----------------------------------|--|--------------------------|-------------|-----------|-----------|------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | | |
| MDA start year: | | 2008 | | | | | | | | |
| Mean MDA coverage per year: | | 61.2 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 499 | 100 | — | 1,127 | 100 | — | 1,478 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 215 | 43.1 | — | 127 | 11.3 | — | 11 | 0.7 | — |
| Mf-positive (age 5+) | | 215 | 43.1 | — | 127 | 11.3 | — | 11 | 0.7 | — |
| Worm infected | | 266 | 53.3 | — | 326 | 29.0 | — | 77 | 5.2 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | 76 | 15.1 | 1 | 45 | 4.0 | <0.5 | 3 | 0.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | 34 | 6.8 | 6 | 11 | 1.0 | 2 | 1 | <0.05 | <0.5 |
| Reactive skin disease | | 26 | 5.1 | 1 | 2 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 60 | 12.0 | 7 | 13 | 1.2 | 2 | 1 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | 7 | 1.5 | <0.5 | 11 | 1.0 | <0.5 | 8 | 0.5 | <0.5 |
| Severe depigmentation | | 8 | 1.7 | 1 | 11 | 1.0 | 1 | 7 | 0.5 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | 16 | 3.2 | 1 | 22 | 2.0 | 1 | 15 | 1.0 | 1 |
| Total skin disease (OSD) | | 151 | 30.3 | 9 | 81 | 7.1 | 4 | 20 | 1.3 | 1 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | | 1 | 0.1 | 2 | 1 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | | 152 | 30.4 | 11 | 81 | 7.2 | 5 | 20 | 1.4 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Butembo–Beni, DRC




| Project, country: | | Equateur-Kiri, DRC | | | | | | | |
|-----------------------------------|------------|---------------------------|-----------|-----------|-----------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2006 | | | | | | | |
| Mean MDA coverage per year: | | 69.9 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 664 | 100 | — | 1,497 | 100 | — | 1,964 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 272 | 40.9 | — | 52 | 3.5 | — | 2 | 0.1 | — |
| Mf-positive (age 5+) | 271 | 40.9 | — | 52 | 3.5 | — | 2 | 0.1 | — |
| Worm infected | 339 | 51.1 | — | 253 | 16.9 | — | 23 | 1.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 89 | 13.4 | 1 | 21 | 1.4 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 42 | 6.3 | 8 | 5 | 0.4 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 30 | 4.6 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 72 | 10.9 | 9 | 6 | 0.4 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 1.4 | <0.5 | 12 | 0.8 | <0.5 | 8 | 0.4 | <0.5 |
| Severe depigmentation | 10 | 1.5 | 1 | 11 | 0.8 | 1 | 7 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 19 | 2.9 | 1 | 23 | 1.5 | 1 | 16 | 0.8 | 1 |
| Total skin disease (OSD) | 181 | 27.2 | 11 | 50 | 3.3 | 2 | 17 | 0.9 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.1 | 2 | 1 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 181 | 27.3 | 13 | 50 | 3.4 | 3 | 17 | 0.9 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Equateur–Kiri, DRC




| | | | | | | | | | |
|-----------------------------------|------------------------|-------------|-----------|------------|-------------|-----------|-----------|------------|----------------|
| Project, country: | Ituri-Nord, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2008 | | | | | | | | |
| Mean MDA coverage per year: | 75.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 671 | 100 | — | 1,515 | 100 | — | 1,987 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 423 | 63.0 | — | 306 | 20.2 | — | 57 | 2.9 | — |
| Mf-positive (age 5+) | 421 | 62.7 | — | 306 | 20.2 | — | 57 | 2.9 | — |
| Worm infected | 469 | 69.9 | — | 648 | 42.8 | — | 257 | 12.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 246 | 36.7 | 3 | 172 | 11.4 | 2 | 20 | 1.0 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 108 | 16.1 | 20 | 37 | 2.4 | 7 | 2 | 0.1 | <0.5 |
| Reactive skin disease | 96 | 14.3 | 4 | 3 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 205 | 30.5 | 24 | 39 | 2.6 | 7 | 2 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 20 | 3.0 | <0.5 | 28 | 1.8 | <0.5 | 22 | 1.1 | <0.5 |
| Severe depigmentation | 35 | 5.3 | 2 | 46 | 3.0 | 3 | 33 | 1.7 | 2 |
| Atrophy | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 3 | 0.4 | 1 | 3 | 0.2 | 1 | 2 | 0.1 | 1 |
| Irreversible skin disease | 59 | 8.8 | 4 | 77 | 5.1 | 4 | 57 | 2.9 | 3 |
| Total skin disease (OSD) | 510 | 76.0 | 30 | 289 | 19.1 | 13 | 79 | 4.0 | 4 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 3 | 0.5 | <0.5 | 4 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Blindness | 5 | 0.8 | 38 | 4 | 0.3 | 28 | 2 | 0.1 | 11 |
| Eye disease (OED) | 9 | 1.3 | 38 | 8 | 0.5 | 28 | 4 | 0.2 | 11 |
| Total all manifestations | 519 | 77.3 | 68 | 297 | 19.6 | 41 | 83 | 4.2 | 15 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ituri-Nord, DRC




| | | | | | | | | | |
|-----------------------------------|-----------------------|-------------|-----------|------------|-------------|-----------|------------|------------|-----------|
| Project, country: | Ituri-Sud, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2012 | | | | | | | | |
| Mean MDA coverage per year: | 68.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 614 | 100 | — | 1,385 | 100 | — | 1,816 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 354 | 57.7 | — | 462 | 33.4 | — | 177 | 9.7 | — |
| Mf-positive (age 5+) | 352 | 57.4 | — | 462 | 33.4 | — | 177 | 9.7 | — |
| Worm infected | 399 | 65.0 | — | 709 | 51.2 | — | 443 | 24.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 192 | 31.2 | 2 | 255 | 18.4 | 3 | 66 | 3.6 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 85 | 13.9 | 15 | 63 | 4.6 | 12 | 10 | 0.5 | 2 |
| Reactive skin disease | 74 | 12.0 | 3 | 15 | 1.1 | 1 | 2 | 0.1 | <0.5 |
| Reversible skin disease | 159 | 25.9 | 19 | 78 | 5.7 | 12 | 11 | 0.6 | 2 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 16 | 2.6 | <0.5 | 26 | 1.9 | <0.5 | 21 | 1.2 | <0.5 |
| Severe depigmentation | 27 | 4.4 | 2 | 42 | 3.1 | 3 | 32 | 1.8 | 2 |
| Atrophy | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 2 | 0.3 | 1 | 2 | 0.2 | 1 | 1 | 0.1 | 1 |
| Irreversible skin disease | 46 | 7.4 | 3 | 71 | 5.2 | 4 | 55 | 3.0 | 3 |
| Total skin disease (OSD) | 396 | 64.5 | 24 | 405 | 29.2 | 19 | 132 | 7.3 | 5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 0.4 | <0.5 | 4 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Blindness | 3 | 0.5 | 24 | 4 | 0.3 | 26 | 2 | 0.1 | 12 |
| Eye disease (OED) | 6 | 0.9 | 24 | 7 | 0.5 | 26 | 4 | 0.2 | 12 |
| Total all manifestations | 402 | 65.5 | 48 | 412 | 29.7 | 45 | 136 | 7.5 | 17 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ituri–Sud, DRC




| | | | | | | | | | |
|-----------------------------------|-------------------|-------------|------------|------------|------------|-----------|------------|-----------------|-----------|
| Project, country: | Kasai, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2001 | | | | | | | | |
| Mean MDA coverage per year: | 61.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 5,756 | 100 | — | 12,990 | 100 | — | 17,038 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 2,210 | 38.4 | — | 608 | 4.7 | — | 138 | 0.8 | — |
| Mf-positive (age 5+) | 2,205 | 38.3 | — | 607 | 4.7 | — | 138 | 0.8 | — |
| Worm infected | 2,690 | 46.7 | — | 1,912 | 14.7 | — | 542 | 3.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 801 | 13.9 | 9 | 260 | 2.0 | 3 | 46 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 403 | 7.0 | 73 | 49 | 0.4 | 9 | 4 | <0.05 | 1 |
| Reactive skin disease | 319 | 5.5 | 15 | 5 | <0.05 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease | 722 | 12.5 | 88 | 55 | 0.4 | 9 | 4 | <0.05 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 86 | 1.5 | 1 | 94 | 0.7 | 1 | 67 | 0.4 | 1 |
| Severe depigmentation | 113 | 2.0 | 7 | 114 | 0.9 | 7 | 78 | 0.5 | 5 |
| Atrophy | 2 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 5 | 0.1 | 2 | 4 | <0.05 | 2 | 2 | <0.05 | 1 |
| Irreversible skin disease | 207 | 3.6 | 10 | 212 | 1.6 | 10 | 146 | 0.9 | 7 |
| Total skin disease (OSD) | 1,730 | 30.1 | 107 | 526 | 4.1 | 22 | 196 | 1.2 | 8 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 7 | 0.1 | <0.5 | 6 | <0.05 | <0.5 | 4 | <0.05 | <0.5 |
| Blindness | 10 | 0.2 | 72 | 5 | <0.05 | 38 | 2 | <0.05 | 16 |
| Eye disease (OED) | 17 | 0.3 | 72 | 12 | 0.1 | 38 | 6 | <0.05 | 16 |
| Total all manifestations | 1,748 | 30.4 | 179 | 538 | 4.1 | 60 | 202 | 1.2 | 23 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kasai, DRC




| | | | | | | | | | |
|-----------------------------------|---------------------|-------------|-----------|-----------|-----------------|----------|----------------|-----------------|----------------|
| Project, country: | Kasongo, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2007 | | | | | | | | |
| Mean MDA coverage per year: | 63.6 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 721 | 100 | — | 1,627 | 100 | — | 2,134 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 228 | 31.6 | — | 81 | 5.0 | — | 8 | 0.4 | — |
| Mf-positive (age 5+) | 227 | 31.5 | — | 81 | 5.0 | — | 8 | 0.4 | — |
| Worm infected | 289 | 40.1 | — | 270 | 16.6 | — | 50 | 2.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 59 | 8.2 | 1 | 25 | 1.6 | <0.5 | 3 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 34 | 4.7 | 6 | 7 | 0.4 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 25 | 3.4 | 1 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 59 | 8.1 | 7 | 8 | 0.5 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 8 | 1.1 | <0.5 | 10 | 0.6 | <0.5 | 8 | 0.4 | <0.5 |
| Severe depigmentation | 8 | 1.2 | 1 | 10 | 0.6 | 1 | 7 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 17 | 2.3 | 1 | 21 | 1.3 | 1 | 15 | 0.7 | 1 |
| Total skin disease (OSD) | 134 | 18.6 | 9 | 54 | 3.3 | 2 | 18 | 0.8 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 1 | 0.1 | 2 | 1 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | 135 | 18.7 | 11 | 55 | 3.4 | 4 | 18 | 0.9 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kasongo, DRC




| Project, country: | | Katanga-Nord, DRC | | | | | | | |
|-----------------------------------|-----------|--------------------------|----------|-----------|------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2006 | | | | | | | |
| Mean MDA coverage per year: | | 71.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 335 | 100 | — | 756 | 100 | — | 992 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 126 | 37.6 | — | 37 | 4.9 | — | 3 | 0.3 | — |
| Mf-positive (age 5+) | 126 | 37.5 | — | 37 | 4.9 | — | 3 | 0.3 | — |
| Worm infected | 153 | 45.8 | — | 128 | 17.0 | — | 24 | 2.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 45 | 13.4 | <0.5 | 17 | 2.2 | <0.5 | 1 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 23 | 6.7 | 4 | 4 | 0.5 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 18 | 5.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 41 | 12.1 | 5 | 4 | 0.5 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 1.4 | <0.5 | 6 | 0.8 | <0.5 | 4 | 0.4 | <0.5 |
| Severe depigmentation | 6 | 1.9 | <0.5 | 7 | 1.0 | <0.5 | 5 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 11 | 3.4 | 1 | 13 | 1.8 | 1 | 9 | 0.9 | <0.5 |
| Total skin disease (OSD) | 97 | 28.9 | 6 | 34 | 4.5 | 2 | 11 | 1.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 3 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 1 | 0.3 | 3 | 1 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | 98 | 29.1 | 9 | 35 | 4.6 | 4 | 11 | 1.1 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Katanga–Nord, DRC




| | | | | | | | | | |
|-----------------------------------|-------------------------|-------------|-----------|-----------|------------|----------|----------------|-----------------|----------------|
| Project, country: | Katanga-Sud, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 68.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 371 | 100 | — | 837 | 100 | — | 1,098 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 141 | 38.0 | — | 52 | 6.2 | — | 9 | 0.8 | — |
| Mf-positive (age 5+) | 141 | 37.9 | — | 52 | 6.2 | — | 9 | 0.8 | — |
| Worm infected | 172 | 46.3 | — | 158 | 18.8 | — | 39 | 3.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 50 | 13.6 | 1 | 23 | 2.7 | <0.5 | 3 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 25 | 6.8 | 5 | 5 | 0.6 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 20 | 5.4 | 1 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 45 | 12.2 | 6 | 6 | 0.7 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 1.5 | <0.5 | 7 | 0.8 | <0.5 | 5 | 0.5 | <0.5 |
| Severe depigmentation | 7 | 1.9 | <0.5 | 9 | 1.0 | 1 | 6 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 13 | 3.5 | 1 | 16 | 1.9 | 1 | 11 | 1.0 | <0.5 |
| Total skin disease (OSD) | 109 | 29.3 | 7 | 44 | 5.2 | 2 | 14 | 1.3 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 1 | 0.2 | 4 | <0.5 | <0.05 | 3 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 1 | 0.3 | 4 | 1 | 0.1 | 3 | <0.5 | <0.05 | 1 |
| Total all manifestations | 110 | 29.6 | 11 | 45 | 5.3 | 5 | 15 | 1.3 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Katanga–Sud, DRC




| Project, country: | | Lualaba, DRC | | | | | | | |
|-----------------------------------|----------------|---------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2006 | | | | | | | |
| Mean MDA coverage per year: | | 74.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 120 | 100 | — | 272 | 100 | — | 356 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 48 | 39.7 | — | 7 | 2.5 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 48 | 39.7 | — | 7 | 2.5 | — | <0.5 | <0.05 | — |
| Worm infected | 59 | 49.1 | — | 37 | 13.6 | — | 3 | 0.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 16 | 13.2 | <0.5 | 3 | 1.0 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 6.4 | 1 | 1 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 6 | 4.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 13 | 11.1 | 2 | 1 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.4 | <0.5 | 2 | 0.7 | <0.5 | 1 | 0.4 | <0.5 |
| Severe depigmentation | 2 | 1.6 | <0.5 | 2 | 0.8 | <0.5 | 1 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 3.0 | <0.5 | 4 | 1.5 | <0.5 | 3 | 0.8 | <0.5 |
| Total skin disease (OSD) | 33 | 27.3 | 2 | 8 | 2.8 | <0.5 | 3 | 0.8 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 33 | 27.5 | 2 | 8 | 2.8 | 1 | 3 | 0.8 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Lualaba, DRC




| Project, country: | | Lubutu, DRC | | | | | | | |
|-----------------------------------|-----------|--------------------|----------------|-----------|-------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2008 | | | | | | | |
| Mean MDA coverage per year: | | 66.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 179 | 100 | — | 403 | 100 | — | 529 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 101 | 56.7 | — | 60 | 14.8 | — | 5 | 0.9 | — |
| Mf-positive (age 5+) | 101 | 56.6 | — | 60 | 14.8 | — | 5 | 0.9 | — |
| Worm infected | 118 | 66.0 | — | 149 | 36.8 | — | 36 | 6.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 45 | 25.2 | <0.5 | 24 | 6.1 | <0.5 | 2 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 19 | 10.8 | 4 | 6 | 1.4 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 15 | 8.4 | 1 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 34 | 19.2 | 4 | 6 | 1.6 | 1 | <0.5 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 2.2 | <0.5 | 6 | 1.4 | <0.5 | 4 | 0.8 | <0.5 |
| Severe depigmentation | 5 | 2.8 | <0.5 | 7 | 1.6 | <0.5 | 5 | 0.9 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 5.2 | <0.5 | 12 | 3.1 | 1 | 9 | 1.7 | <0.5 |
| Total skin disease (OSD) | 89 | 49.6 | 5 | 43 | 10.7 | 2 | 11 | 2.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.2 | 2 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.3 | 2 | 1 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 89 | 49.9 | 7 | 44 | 10.8 | 3 | 11 | 2.1 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Lubutu, DRC




| Project, country: | | Masisi-Walikale, DRC | | | | | | | |
|-----------------------------------|------------|-----------------------------|-----------|------------|-------------|-----------|-----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2009 | | | | | | | |
| Mean MDA coverage per year: | | 67.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 560 | 100 | — | 1,265 | 100 | — | 1,659 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 290 | 51.7 | — | 200 | 15.8 | — | 40 | 2.4 | — |
| Mf-positive (age 5+) | 289 | 51.5 | — | 200 | 15.8 | — | 40 | 2.4 | — |
| Worm infected | 341 | 60.8 | — | 449 | 35.5 | — | 149 | 9.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 128 | 22.8 | 1 | 91 | 7.2 | 1 | 14 | 0.9 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 56 | 10.0 | 10 | 21 | 1.7 | 4 | 2 | 0.1 | <0.5 |
| Reactive skin disease | 45 | 8.1 | 2 | 3 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 101 | 18.1 | 12 | 24 | 1.9 | 4 | 2 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 11 | 2.0 | <0.5 | 16 | 1.3 | <0.5 | 12 | 0.7 | <0.5 |
| Severe depigmentation | 16 | 2.8 | 1 | 21 | 1.7 | 1 | 15 | 0.9 | 1 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.1 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 28 | 5.0 | 1 | 39 | 3.0 | 2 | 28 | 1.7 | 1 |
| Total skin disease (OSD) | 257 | 45.9 | 15 | 154 | 12.1 | 7 | 44 | 2.7 | 2 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Blindness | 1 | 0.2 | 10 | 1 | 0.1 | 8 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | 2 | 0.4 | 10 | 2 | 0.2 | 8 | 1 | 0.1 | 3 |
| Total all manifestations | 260 | 46.3 | 25 | 156 | 12.3 | 15 | 46 | 2.8 | 5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Masisi–Walikale, DRC




| | | | | | | | | | |
|-----------------------------------|---------------------|-------------|-----------|-----------|-----------------|----------|----------------|-----------------|----------------|
| Project, country: | Mongala, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 68.8 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 779 | 100 | — | 1,758 | 100 | — | 2,306 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 286 | 36.7 | — | 59 | 3.4 | — | 2 | 0.1 | — |
| Mf-positive (age 5+) | 286 | 36.7 | — | 59 | 3.4 | — | 2 | 0.1 | — |
| Worm infected | 363 | 46.6 | — | 272 | 15.5 | — | 28 | 1.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 86 | 11.1 | 1 | 23 | 1.3 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 43 | 5.5 | 8 | 6 | 0.3 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 31 | 3.9 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 74 | 9.4 | 9 | 6 | 0.3 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 10 | 1.3 | <0.5 | 12 | 0.7 | <0.5 | 9 | 0.4 | <0.5 |
| Severe depigmentation | 10 | 1.3 | 1 | 12 | 0.7 | 1 | 8 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 21 | 2.6 | 1 | 24 | 1.3 | 1 | 16 | 0.7 | 1 |
| Total skin disease (OSD) | 181 | 23.2 | 11 | 53 | 3.0 | 2 | 17 | 0.8 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 3 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 1 | 0.1 | 3 | 1 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | 181 | 23.3 | 14 | 54 | 3.0 | 4 | 18 | 0.8 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Mongala, DRC




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Katanga-Nord, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2016 | | | | | | | | |
| Mean MDA coverage per year: | 66.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 243 | 100 | — | 549 | 100 | — | 720 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 60 | 24.5 | — | 91 | 16.5 | — | 10 | 1.4 | — |
| Mf-positive (age 5+) | 60 | 24.5 | — | 91 | 16.5 | — | 10 | 1.4 | — |
| Worm infected | 78 | 32.2 | — | 150 | 27.4 | — | 58 | 8.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 9 | 3.8 | <0.5 | 16 | 2.9 | <0.5 | 2 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 3.2 | 1 | 9 | 1.6 | 2 | 1 | 0.1 | <0.5 |
| Reactive skin disease | 5 | 2.2 | <0.5 | 3 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 13 | 5.4 | 2 | 11 | 2.0 | 2 | 1 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.8 | <0.5 | 4 | 0.7 | <0.5 | 3 | 0.4 | <0.5 |
| Severe depigmentation | 2 | 0.8 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 1.6 | <0.5 | 7 | 1.3 | <0.5 | 5 | 0.7 | <0.5 |
| Total skin disease (OSD) | 26 | 10.9 | 2 | 34 | 6.2 | 2 | 8 | 1.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 26 | 10.9 | 2 | 34 | 6.2 | 2 | 8 | 1.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Katanga–Nord, DRC




| | | | | | | | | | |
|-----------------------------------|------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Lualaba, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2016 | | | | | | | | |
| Mean MDA coverage per year: | 66.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 526 | 100 | — | 1,187 | 100 | — | 1,557 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 146 | 27.7 | — | 229 | 19.3 | — | 27 | 1.7 | — |
| Mf-positive (age 5+) | 146 | 27.7 | — | 229 | 19.3 | — | 27 | 1.7 | — |
| Worm infected | 188 | 35.8 | — | 368 | 31.0 | — | 148 | 9.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 27 | 5.1 | <0.5 | 46 | 3.9 | <0.5 | 5 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 20 | 3.7 | 4 | 22 | 1.8 | 4 | 2 | 0.1 | <0.5 |
| Reactive skin disease | 14 | 2.6 | 1 | 6 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 33 | 6.3 | 4 | 28 | 2.4 | 4 | 2 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 1.0 | <0.5 | 9 | 0.8 | <0.5 | 7 | 0.5 | <0.5 |
| Severe depigmentation | 5 | 0.9 | <0.5 | 8 | 0.7 | 1 | 6 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 10 | 1.8 | <0.5 | 18 | 1.5 | 1 | 13 | 0.9 | <0.5 |
| Total skin disease (OSD) | 70 | 13.3 | 5 | 92 | 7.8 | 5 | 21 | 1.3 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 70 | 13.3 | 5 | 93 | 7.8 | 6 | 21 | 1.3 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Lualaba, DRC




| | | | | | | | | | |
|-----------------------------------|--------------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Masisi-Walikale, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2016 | | | | | | | | |
| Mean MDA coverage per year: | 67.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 29 | 100 | — | 66 | 100 | — | 86 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 11 | 37.2 | — | 17 | 26.5 | — | 2 | 2.5 | — |
| Mf-positive (age 5+) | 11 | 37.2 | — | 17 | 26.5 | — | 2 | 2.5 | — |
| Worm infected | 14 | 47.0 | — | 27 | 41.4 | — | 11 | 13.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3 | 10.4 | <0.5 | 5 | 8.0 | <0.5 | 1 | 0.7 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 2 | 5.2 | <0.5 | 2 | 2.7 | <0.5 | <0.5 | 0.2 | <0.5 |
| Reactive skin disease | 1 | 3.7 | <0.5 | 1 | 0.8 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 3 | 9.0 | <0.5 | 2 | 3.5 | <0.5 | <0.5 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 1.2 | <0.5 | 1 | 1.1 | <0.5 | 1 | 0.6 | <0.5 |
| Severe depigmentation | <0.5 | 1.2 | <0.5 | 1 | 1.0 | <0.5 | <0.5 | 0.6 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 2.4 | <0.5 | 1 | 2.0 | <0.5 | 1 | 1.2 | <0.5 |
| Total skin disease (OSD) | 6 | 21.8 | <0.5 | 9 | 13.5 | <0.5 | 2 | 2.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 6 | 21.9 | <0.5 | 9 | 13.6 | 1 | 2 | 2.1 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Masisi–Walikale, DRC




| | | | | | | | | | |
|-----------------------------------|-------------------------------|-------------|----------------|----------------|-------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Rutshuru-Ngoma, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2013 | | | | | | | | |
| Mean MDA coverage per year: | 67.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 5 | 100 | — | 10 | 100 | — | 13 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 2 | 50.8 | — | 2 | 24.3 | — | <0.5 | 1.3 | — |
| Mf-positive (age 5+) | 2 | 50.8 | — | 2 | 24.3 | — | <0.5 | 1.3 | — |
| Worm infected | 3 | 61.4 | — | 5 | 46.0 | — | 1 | 10.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 18.8 | <0.5 | 1 | 9.4 | <0.5 | <0.5 | 0.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 8.1 | <0.5 | <0.5 | 2.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reactive skin disease | <0.5 | 5.7 | <0.5 | <0.5 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 1 | 13.8 | <0.5 | <0.5 | 2.7 | <0.5 | <0.5 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 1.8 | <0.5 | <0.5 | 1.3 | <0.5 | <0.5 | 0.8 | <0.5 |
| Severe depigmentation | <0.5 | 1.9 | <0.5 | <0.5 | 1.3 | <0.5 | <0.5 | 0.7 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 3.7 | <0.5 | <0.5 | 2.6 | <0.5 | <0.5 | 1.5 | <0.5 |
| Total skin disease (OSD) | 2 | 36.4 | <0.5 | 2 | 14.8 | <0.5 | <0.5 | 2.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 2 | 36.5 | <0.5 | 2 | 14.8 | <0.5 | <0.5 | 2.1 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Rutshuru–Ngoma, DRC




| | | | | | | | | | |
|-----------------------------------|------------------------|-------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY Sankuru, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2014 | | | | | | | | |
| Mean MDA coverage per year: | 66.8 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 251 | 100 | — | 566 | 100 | — | 743 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 70 | 27.9 | — | 83 | 14.6 | — | 10 | 1.3 | — |
| Mf-positive (age 5+) | 70 | 27.9 | — | 83 | 14.6 | — | 10 | 1.3 | — |
| Worm infected | 89 | 35.6 | — | 154 | 27.2 | — | 51 | 6.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 15 | 5.9 | <0.5 | 21 | 3.6 | <0.5 | 3 | 0.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 10 | 4.1 | 2 | 8 | 1.4 | 1 | 1 | 0.1 | <0.5 |
| Reactive skin disease | 7 | 2.9 | <0.5 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 18 | 7.1 | 2 | 10 | 1.7 | 2 | 1 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.0 | <0.5 | 4 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Severe depigmentation | 3 | 1.0 | <0.5 | 4 | 0.8 | <0.5 | 3 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 2.0 | <0.5 | 9 | 1.5 | <0.5 | 6 | 0.9 | <0.5 |
| Total skin disease (OSD) | 38 | 15.0 | 3 | 39 | 6.9 | 2 | 10 | 1.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 38 | 15.1 | 3 | 39 | 6.9 | 3 | 10 | 1.4 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Sankuru, DRC




| | | | | | | | | | |
|-----------------------------------|----------------------|-------------|----------------|-----------|-------------|----------|-----------|-------------|----------------|
| Project, country: | NY Ueles, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2014 | | | | | | | | |
| Mean MDA coverage per year: | 67.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 85 | 100 | — | 193 | 100 | — | 253 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 50 | 59.0 | — | 81 | 42.1 | — | 36 | 14.4 | — |
| Mf-positive (age 5+) | 50 | 58.7 | — | 81 | 42.1 | — | 36 | 14.3 | — |
| Worm infected | 57 | 66.4 | — | 110 | 57.3 | — | 79 | 31.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 28 | 32.7 | <0.5 | 47 | 24.3 | <0.5 | 15 | 5.9 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 12 | 14.4 | 2 | 13 | 6.7 | 2 | 2 | 1.0 | <0.5 |
| Reactive skin disease | 11 | 12.6 | <0.5 | 4 | 2.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 23 | 27.0 | 3 | 17 | 9.0 | 3 | 3 | 1.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 2.7 | <0.5 | 4 | 2.2 | <0.5 | 3 | 1.4 | <0.5 |
| Severe depigmentation | 4 | 4.6 | <0.5 | 7 | 3.6 | <0.5 | 5 | 2.1 | <0.5 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.3 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Irreversible skin disease | 7 | 7.8 | <0.5 | 12 | 6.0 | 1 | 9 | 3.6 | <0.5 |
| Total skin disease (OSD) | 58 | 67.5 | 3 | 76 | 39.2 | 4 | 27 | 10.6 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.4 | <0.5 | 1 | 0.3 | <0.5 | <0.5 | 0.2 | <0.5 |
| Blindness | 1 | 0.6 | 4 | 1 | 0.4 | 5 | <0.5 | 0.1 | 2 |
| Eye disease (OED) | 1 | 1.0 | 4 | 1 | 0.7 | 5 | 1 | 0.3 | 2 |
| Total all manifestations | 58 | 68.5 | 7 | 77 | 39.9 | 9 | 27 | 10.9 | 3 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY Ueles, DRC




| | | | | | | | | | |
|-----------------------------------|--------------------|-------------|-----------|--------------|-------------|-----------|------------|-------------|-----------|
| Project, country: | P20DRC, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 65.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,259 | 100 | — | 2,841 | 100 | — | 3,726 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 592 | 47.0 | — | 1,268 | 44.6 | — | 518 | 13.9 | — |
| Mf-positive (age 5+) | 591 | 46.9 | — | 1,266 | 44.6 | — | 518 | 13.9 | — |
| Worm infected | 712 | 56.5 | — | 1,591 | 56.0 | — | 1,201 | 32.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 238 | 18.9 | 3 | 532 | 18.7 | 6 | 219 | 5.9 | 2 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 107 | 8.5 | 19 | 210 | 7.4 | 38 | 50 | 1.3 | 9 |
| Reactive skin disease | 83 | 6.6 | 4 | 141 | 5.0 | 7 | 7 | 0.2 | <0.5 |
| Reversible skin disease | 190 | 15.1 | 23 | 352 | 12.4 | 45 | 57 | 1.5 | 9 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 22 | 1.8 | <0.5 | 48 | 1.7 | 1 | 41 | 1.1 | <0.5 |
| Severe depigmentation | 28 | 2.2 | 2 | 62 | 2.2 | 4 | 51 | 1.4 | 3 |
| Atrophy | <0.5 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.1 | <0.5 | 2 | 0.1 | 1 | 1 | <0.05 | 1 |
| Irreversible skin disease | 52 | 4.1 | 2 | 114 | 4.0 | 5 | 94 | 2.5 | 4 |
| Total skin disease (OSD) | 480 | 38.1 | 28 | 997 | 35.1 | 56 | 370 | 9.9 | 16 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 0.1 | <0.5 | 3 | 0.1 | <0.5 | 3 | 0.1 | <0.5 |
| Blindness | 2 | 0.2 | 14 | 4 | 0.1 | 28 | 2 | 0.1 | 15 |
| Eye disease (OED) | 4 | 0.3 | 14 | 8 | 0.3 | 28 | 5 | 0.1 | 15 |
| Total all manifestations | 484 | 38.4 | 42 | 1,005 | 35.4 | 84 | 375 | 10.1 | 31 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20DRC, DRC




| | | | | | | | | | |
|-----------------------------------|-------------------|-----------------|-----------|------------|-----------------|-----------|------------|-----------------|-----------|
| Project, country: | P5DRC, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 4,003 | 100 | — | 9,033 | 100 | — | 11,848 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 975 | 24.4 | — | 2,113 | 23.4 | — | 1,732 | 14.6 | — |
| Mf-positive (age 5+) | 974 | 24.3 | — | 2,111 | 23.4 | — | 1,732 | 14.6 | — |
| Worm infected | 1,294 | 32.3 | — | 2,820 | 31.2 | — | 3,069 | 25.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 148 | 3.7 | 2 | 321 | 3.6 | 3 | 287 | 2.4 | 3 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 125 | 3.1 | 23 | 268 | 3.0 | 49 | 154 | 1.3 | 28 |
| Reactive skin disease | 84 | 2.1 | 4 | 180 | 2.0 | 8 | 42 | 0.4 | 2 |
| Reversible skin disease | 209 | 5.2 | 27 | 448 | 5.0 | 57 | 196 | 1.7 | 30 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 32 | 0.8 | <0.5 | 72 | 0.8 | 1 | 79 | 0.7 | 1 |
| Severe depigmentation | 29 | 0.7 | 2 | 62 | 0.7 | 4 | 64 | 0.5 | 4 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 62 | 1.5 | 2 | 134 | 1.5 | 5 | 143 | 1.2 | 5 |
| Total skin disease (OSD) | 418 | 10.4 | 30 | 903 | 10.0 | 65 | 627 | 5.3 | 38 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 2 | 1 | <0.05 | 4 | <0.5 | <0.05 | 2 |
| Eye disease (OED) | 1 | <0.05 | 2 | 2 | <0.05 | 4 | 2 | <0.05 | 2 |
| Total all manifestations | 419 | 10.5 | 32 | 905 | 10.0 | 70 | 629 | 5.3 | 40 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5DRC, DRC




| | | | | | | | | | |
|-----------------------------------|----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Rutshuru-Ngoma, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 65.2 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 353 | 100 | — | 796 | 100 | — | 1,045 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 138 | 39.2 | — | 28 | 3.5 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 138 | 39.1 | — | 28 | 3.5 | — | <0.5 | <0.05 | — |
| Worm infected | 176 | 49.9 | — | 137 | 17.1 | — | 11 | 1.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 40 | 11.2 | <0.5 | 9 | 1.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 19 | 5.4 | 3 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 13 | 3.8 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 32 | 9.2 | 4 | 3 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 1.3 | <0.5 | 5 | 0.7 | <0.5 | 4 | 0.4 | <0.5 |
| Severe depigmentation | 4 | 1.2 | <0.5 | 5 | 0.6 | <0.5 | 3 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 2.5 | <0.5 | 10 | 1.3 | <0.5 | 7 | 0.6 | <0.5 |
| Total skin disease (OSD) | 81 | 22.9 | 5 | 21 | 2.7 | 1 | 7 | 0.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 81 | 22.9 | 5 | 21 | 2.7 | 1 | 7 | 0.7 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Rutshuru–Ngoma, DRC




| | | | | | | | | | |
|-----------------------------------|---------------------|-------------|-----------|-----------|------------|-----------|----------------|-----------------|----------------|
| Project, country: | Sankuru, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2003 | | | | | | | | |
| Mean MDA coverage per year: | 71.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 571 | 100 | — | 1,289 | 100 | — | 1,690 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 270 | 47.2 | — | 98 | 7.6 | — | 13 | 0.8 | — |
| Mf-positive (age 5+) | 268 | 47.0 | — | 98 | 7.6 | — | 13 | 0.8 | — |
| Worm infected | 312 | 54.6 | — | 271 | 21.1 | — | 83 | 4.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 133 | 23.2 | 1 | 48 | 3.7 | 1 | 5 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 62 | 10.9 | 11 | 9 | 0.7 | 2 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 54 | 9.4 | 2 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 116 | 20.3 | 14 | 9 | 0.7 | 2 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 12 | 2.1 | <0.5 | 13 | 1.0 | <0.5 | 10 | 0.6 | <0.5 |
| Severe depigmentation | 20 | 3.5 | 1 | 21 | 1.6 | 1 | 14 | 0.8 | 1 |
| Atrophy | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 2 | 0.3 | 1 | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 |
| Irreversible skin disease | 34 | 6.0 | 2 | 35 | 2.7 | 2 | 25 | 1.5 | 1 |
| Total skin disease (OSD) | 283 | 49.5 | 17 | 92 | 7.2 | 4 | 30 | 1.8 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 0.3 | <0.5 | 2 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Blindness | 3 | 0.5 | 20 | 1 | 0.1 | 11 | 1 | <0.05 | 4 |
| Eye disease (OED) | 5 | 0.8 | 20 | 3 | 0.2 | 11 | 2 | 0.1 | 4 |
| Total all manifestations | 287 | 50.3 | 37 | 96 | 7.4 | 15 | 32 | 1.9 | 6 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Sankuru, DRC




| Project, country: | | Tshopo, DRC | | | | | | | |
|-----------------------------------|------------|--------------------|-----------|------------|-------------|-----------|-----------|------------|----------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2003 | | | | | | | |
| Mean MDA coverage per year: | | 54.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 853 | 100 | — | 1,925 | 100 | — | 2,525 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 438 | 51.4 | — | 296 | 15.4 | — | 92 | 3.6 | — |
| Mf-positive (age 5+) | 437 | 51.2 | — | 296 | 15.4 | — | 92 | 3.6 | — |
| Worm infected | 512 | 60.1 | — | 630 | 32.7 | — | 279 | 11.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 200 | 23.4 | 2 | 124 | 6.4 | 1 | 31 | 1.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 89 | 10.4 | 16 | 27 | 1.4 | 5 | 4 | 0.1 | 1 |
| Reactive skin disease | 72 | 8.5 | 3 | 6 | 0.3 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease | 161 | 18.9 | 19 | 33 | 1.7 | 5 | 5 | 0.2 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 18 | 2.1 | <0.5 | 24 | 1.2 | <0.5 | 18 | 0.7 | <0.5 |
| Severe depigmentation | 26 | 3.0 | 2 | 31 | 1.6 | 2 | 22 | 0.9 | 1 |
| Atrophy | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.1 | <0.5 | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 |
| Irreversible skin disease | 45 | 5.3 | 2 | 56 | 2.9 | 3 | 40 | 1.6 | 2 |
| Total skin disease (OSD) | 406 | 47.6 | 24 | 214 | 11.1 | 9 | 76 | 3.0 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 0.2 | <0.5 | 2 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Blindness | 2 | 0.3 | 17 | 2 | 0.1 | 12 | 1 | <0.05 | 5 |
| Eye disease (OED) | 4 | 0.5 | 17 | 4 | 0.2 | 12 | 2 | 0.1 | 5 |
| Total all manifestations | 410 | 48.1 | 41 | 217 | 11.3 | 21 | 78 | 3.1 | 8 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Tshopo, DRC




| | | | | | | | | | |
|-----------------------------------|---------------------|-------------|-----------|------------|-------------|-----------|-----------|------------|----------|
| Project, country: | Tshuapa, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 57.2 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 760 | 100 | — | 1,715 | 100 | — | 2,249 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 381 | 50.2 | — | 264 | 15.4 | — | 67 | 3.0 | — |
| Mf-positive (age 5+) | 380 | 50.1 | — | 264 | 15.4 | — | 67 | 3.0 | — |
| Worm infected | 449 | 59.0 | — | 570 | 33.2 | — | 229 | 10.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 165 | 21.7 | 2 | 105 | 6.1 | 1 | 22 | 1.0 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 74 | 9.7 | 13 | 25 | 1.5 | 5 | 3 | 0.1 | 1 |
| Reactive skin disease | 59 | 7.8 | 3 | 5 | 0.3 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease | 133 | 17.5 | 16 | 30 | 1.8 | 5 | 4 | 0.2 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 15 | 2.0 | <0.5 | 21 | 1.2 | <0.5 | 16 | 0.7 | <0.5 |
| Severe depigmentation | 21 | 2.7 | 1 | 27 | 1.6 | 2 | 19 | 0.8 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 37 | 4.9 | 2 | 49 | 2.9 | 2 | 35 | 1.6 | 2 |
| Total skin disease (OSD) | 335 | 44.0 | 20 | 184 | 10.8 | 8 | 61 | 2.7 | 2 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 |
| Blindness | 2 | 0.2 | 11 | 1 | 0.1 | 9 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | 3 | 0.4 | 11 | 3 | 0.2 | 9 | 1 | 0.1 | 3 |
| Total all manifestations | 337 | 44.4 | 30 | 187 | 10.9 | 17 | 62 | 2.8 | 6 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Tshuapa, DRC




| Project, country: | | Ubangi-Nord, DRC | | | | | | | |
|-----------------------------------|------------|-------------------------|-----------|------------|-------------|-----------|-----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2006 | | | | | | | |
| Mean MDA coverage per year: | | 59.6 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 428 | 100 | — | 966 | 100 | — | 1,267 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 207 | 48.3 | — | 157 | 16.2 | — | 56 | 4.4 | — |
| Mf-positive (age 5+) | 206 | 48.1 | — | 156 | 16.2 | — | 56 | 4.4 | — |
| Worm infected | 244 | 57.1 | — | 316 | 32.7 | — | 152 | 12.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 94 | 21.9 | 1 | 71 | 7.4 | 1 | 19 | 1.5 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 42 | 9.9 | 8 | 16 | 1.6 | 3 | 2 | 0.2 | <0.5 |
| Reactive skin disease | 35 | 8.2 | 2 | 3 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 78 | 18.1 | 9 | 19 | 2.0 | 3 | 3 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 2.0 | <0.5 | 12 | 1.2 | <0.5 | 9 | 0.7 | <0.5 |
| Severe depigmentation | 12 | 2.9 | 1 | 16 | 1.7 | 1 | 11 | 0.9 | 1 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 22 | 5.1 | 1 | 28 | 2.9 | 1 | 21 | 1.6 | 1 |
| Total skin disease (OSD) | 193 | 45.2 | 12 | 119 | 12.3 | 5 | 43 | 3.4 | 2 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Blindness | 1 | 0.3 | 10 | 1 | 0.1 | 8 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | 2 | 0.5 | 10 | 2 | 0.2 | 8 | 1 | 0.1 | 3 |
| Total all manifestations | 196 | 45.7 | 21 | 121 | 12.5 | 13 | 44 | 3.5 | 5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ubangi–Nord, DRC




| Project, country: | | Ubangi-Sud, DRC | | | | | | | | |
|-----------------------------------|--|------------------------|-----------------|----------|----------------|-----------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | | |
| MDA start year: | | 2006 | | | | | | | | |
| Mean MDA coverage per year: | | 60.8 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 722 | 100 | — | 1,629 | 100 | — | 2,136 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 231 | 32.0 | — | 80 | 4.9 | — | 2 | 0.1 | — |
| Mf-positive (age 5+) | | 231 | 32.0 | — | 80 | 4.9 | — | 2 | 0.1 | — |
| Worm infected | | 297 | 41.2 | — | 289 | 17.7 | — | 36 | 1.7 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | 56 | 7.7 | 1 | 21 | 1.3 | <0.5 | 1 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | 32 | 4.4 | 6 | 7 | 0.4 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | | 22 | 3.0 | 1 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 54 | 7.5 | 7 | 7 | 0.4 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | 8 | 1.1 | <0.5 | 10 | 0.6 | <0.5 | 7 | 0.3 | <0.5 |
| Severe depigmentation | | 7 | 1.0 | <0.5 | 9 | 0.6 | 1 | 6 | 0.3 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | 15 | 2.1 | 1 | 19 | 1.2 | 1 | 13 | 0.6 | <0.5 |
| Total skin disease (OSD) | | 125 | 17.3 | 8 | 47 | 2.9 | 2 | 14 | 0.7 | 1 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | | 125 | 17.3 | 9 | 47 | 2.9 | 3 | 14 | 0.7 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ubangi–Sud, DRC




| | | | | | | | | | |
|-----------------------------------|-------------------|-------------|-----------|------------|-------------|-----------|-----------|------------|----------------|
| Project, country: | Ueles, DRC | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2002 | | | | | | | | |
| Mean MDA coverage per year: | 65.5 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 842 | 100 | — | 1,900 | 100 | — | 2,492 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 512 | 60.8 | — | 268 | 14.1 | — | 76 | 3.0 | — |
| Mf-positive (age 5+) | 509 | 60.5 | — | 268 | 14.1 | — | 76 | 3.0 | — |
| Worm infected | 574 | 68.2 | — | 607 | 32.0 | — | 282 | 11.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 288 | 34.3 | 3 | 122 | 6.4 | 1 | 24 | 1.0 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 127 | 15.1 | 23 | 20 | 1.1 | 4 | 2 | 0.1 | <0.5 |
| Reactive skin disease | 112 | 13.3 | 5 | 2 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 239 | 28.3 | 28 | 23 | 1.2 | 4 | 2 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 24 | 2.8 | <0.5 | 27 | 1.4 | <0.5 | 20 | 0.8 | <0.5 |
| Severe depigmentation | 41 | 4.9 | 3 | 42 | 2.2 | 3 | 29 | 1.2 | 2 |
| Atrophy | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 3 | 0.4 | 1 | 2 | 0.1 | 1 | 1 | 0.1 | 1 |
| Irreversible skin disease | 69 | 8.2 | 4 | 72 | 3.8 | 4 | 51 | 2.1 | 3 |
| Total skin disease (OSD) | 596 | 70.9 | 36 | 216 | 11.4 | 9 | 78 | 3.1 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 4 | 0.5 | <0.5 | 3 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Blindness | 6 | 0.7 | 44 | 3 | 0.2 | 22 | 1 | <0.05 | 9 |
| Eye disease (OED) | 10 | 1.2 | 44 | 6 | 0.3 | 22 | 3 | 0.1 | 9 |
| Total all manifestations | 606 | 72.0 | 79 | 222 | 11.7 | 31 | 81 | 3.2 | 12 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ueles, DRC




| Project, country: | | Bioko, Equatorial Guinea | | | | | | | |
|-----------------------------------|-----------|---------------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1990 | | | | | | | |
| Mean MDA coverage per year: | | 49.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 59 | 100 | — | 134 | 100 | — | 176 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 44 | 74.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 44 | 73.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 47 | 79.8 | — | <0.5 | 0.2 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 32 | 53.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 15 | 24.5 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 14 | 23.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 28 | 47.8 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 3.9 | <0.5 | 1 | 1.0 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | 5 | 9.2 | <0.5 | 2 | 1.8 | <0.5 | 1 | 0.8 | <0.5 |
| Atrophy | <0.5 | 0.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 1.5 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Irreversible skin disease | 9 | 15.3 | 1 | 4 | 2.9 | <0.5 | 2 | 1.4 | <0.5 |
| Total skin disease (OSD) | 69 | 116.5 | 4 | 4 | 2.9 | <0.5 | 2 | 1.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 1.1 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Blindness | 1 | 2.4 | 11 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 2 | 3.6 | 11 | <0.5 | 0.3 | 1 | <0.5 | 0.1 | <0.5 |
| Total all manifestations | 71 | 120.1 | 15 | 4 | 3.2 | 1 | 3 | 1.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bioko, Equatorial Guinea




Note: We assume no ivermectic MDA for Bioko since 2018 as the island is currently under post-treatment surveillance [1-3]‡, page 354.

| Project, country: | | P5EqGuinea, Equatorial Guinea | | | | | | | |
|-----------------------------------|----------------|--------------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2025 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 139 | 100 | — | 314 | 100 | — | 412 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 31 | 22.6 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 31 | 22.6 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 41 | 29.8 | — | <0.5 | 0.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3 | 2.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.9 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 7 | 4.8 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.8 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.5 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 12 | 8.7 | 1 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 12 | 8.7 | 1 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5EqGuinea, Equatorial Guinea




| | | | | | | | | | |
|-----------------------------------|-------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Assosa, Ethiopia | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2019 | | | | | | | | |
| Mean MDA coverage per year: | 72.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 317 | 100 | — | 716 | 100 | — | 939 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 84 | 26.5 | — | 123 | 17.2 | — | 1 | 0.1 | — |
| Mf-positive (age 5+) | 84 | 26.5 | — | 123 | 17.2 | — | 1 | 0.1 | — |
| Worm infected | 111 | 34.8 | — | 244 | 34.1 | — | 81 | 8.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 15 | 4.7 | <0.5 | 32 | 4.5 | <0.5 | 3 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 11 | 3.4 | 2 | 20 | 2.7 | 4 | 1 | 0.1 | <0.5 |
| Reactive skin disease | 7 | 2.3 | <0.5 | 10 | 1.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 18 | 5.7 | 2 | 30 | 4.2 | 4 | 1 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 0.9 | <0.5 | 6 | 0.8 | <0.5 | 5 | 0.5 | <0.5 |
| Severe depigmentation | 2 | 0.7 | <0.5 | 5 | 0.7 | <0.5 | 4 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 1.6 | <0.5 | 11 | 1.5 | <0.5 | 8 | 0.9 | <0.5 |
| Total skin disease (OSD) | 38 | 12.0 | 3 | 73 | 10.3 | 5 | 13 | 1.3 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 38 | 12.1 | 3 | 74 | 10.3 | 5 | 13 | 1.3 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Assosa, Ethiopia




| Project, country: | | Bench-Maji, Ethiopia | | | | | | | |
|-----------------------------------|----------------|-----------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2003 | | | | | | | |
| Mean MDA coverage per year: | | 70.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 420 | 100 | — | 947 | 100 | — | 1,242 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 162 | 38.7 | — | 6 | 0.6 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 162 | 38.6 | — | 6 | 0.6 | — | <0.5 | <0.05 | — |
| Worm infected | 206 | 49.0 | — | 66 | 6.9 | — | 2 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 49 | 11.6 | 1 | 2 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 23 | 5.5 | 4 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 16 | 3.9 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 40 | 9.5 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 1.3 | <0.5 | 5 | 0.6 | <0.5 | 4 | 0.3 | <0.5 |
| Severe depigmentation | 5 | 1.3 | <0.5 | 5 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 11 | 2.6 | <0.5 | 10 | 1.1 | <0.5 | 7 | 0.5 | <0.5 |
| Total skin disease (OSD) | 99 | 23.7 | 6 | 13 | 1.4 | 1 | 7 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 100 | 23.7 | 7 | 13 | 1.4 | 1 | 7 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bench–Maji, Ethiopia




| Project, country: | | East Wellega, Ethiopia | | | | | | | |
|-----------------------------------|----------------|-------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2004 | | | | | | | |
| Mean MDA coverage per year: | | 72.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 514 | 100 | — | 1,160 | 100 | — | 1,521 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 175 | 34.1 | — | 9 | 0.8 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 175 | 34.0 | — | 9 | 0.8 | — | <0.5 | <0.05 | — |
| Worm infected | 224 | 43.5 | — | 91 | 7.8 | — | 3 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 46 | 9.0 | <0.5 | 4 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 25 | 4.8 | 4 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 18 | 3.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 42 | 8.2 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 1.1 | <0.5 | 6 | 0.5 | <0.5 | 4 | 0.3 | <0.5 |
| Severe depigmentation | 6 | 1.1 | <0.5 | 6 | 0.5 | <0.5 | 4 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 12 | 2.3 | <0.5 | 12 | 1.0 | <0.5 | 8 | 0.5 | <0.5 |
| Total skin disease (OSD) | 100 | 19.5 | 6 | 17 | 1.4 | 1 | 8 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 101 | 19.6 | 7 | 17 | 1.5 | 1 | 8 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in East Wellega, Ethiopia




| Project, country: | | Gambella, Ethiopia | | | | | | | |
|-----------------------------------|----------------|---------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2004 | | | | | | | |
| Mean MDA coverage per year: | | 70.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 61 | 100 | — | 139 | 100 | — | 182 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 22 | 36.4 | — | 1 | 0.9 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 22 | 36.4 | — | 1 | 0.9 | — | <0.5 | <0.05 | — |
| Worm infected | 28 | 45.7 | — | 11 | 7.9 | — | <0.5 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 6 | 10.3 | <0.5 | <0.5 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 3 | 5.3 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 2 | 3.8 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 6 | 9.1 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.3 | <0.5 | 1 | 0.6 | <0.5 | 1 | 0.3 | <0.5 |
| Severe depigmentation | 1 | 1.2 | <0.5 | 1 | 0.5 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 2.5 | <0.5 | 2 | 1.1 | <0.5 | 1 | 0.5 | <0.5 |
| Total skin disease (OSD) | 13 | 21.9 | 1 | 2 | 1.5 | <0.5 | 1 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 13 | 22.0 | 1 | 2 | 1.5 | <0.5 | 1 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Gambella, Ethiopia




| Project, country: | | Horo Guduru, Ethiopia | | | | | | | |
|-----------------------------------|----------------|------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2019 | | | | | | | |
| Mean MDA coverage per year: | | 72.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 30 | 100 | — | 68 | 100 | — | 89 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 10 | 34.7 | — | 22 | 32.0 | — | 4 | 4.4 | — |
| Mf-positive (age 5+) | 10 | 34.6 | — | 22 | 32.0 | — | 4 | 4.4 | — |
| Worm infected | 13 | 44.8 | — | 30 | 44.3 | — | 17 | 19.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 3 | 9.0 | <0.5 | 6 | 8.7 | <0.5 | 1 | 1.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 4.6 | <0.5 | 3 | 3.9 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reactive skin disease | 1 | 3.2 | <0.5 | 1 | 2.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 2 | 7.8 | <0.5 | 4 | 6.0 | 1 | <0.5 | 0.3 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 1.1 | <0.5 | 1 | 1.0 | <0.5 | 1 | 0.7 | <0.5 |
| Severe depigmentation | <0.5 | 1.0 | <0.5 | 1 | 0.9 | <0.5 | <0.5 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 2.1 | <0.5 | 1 | 2.0 | <0.5 | 1 | 1.2 | <0.5 |
| Total skin disease (OSD) | 6 | 19.0 | <0.5 | 11 | 16.7 | 1 | 3 | 3.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 6 | 19.0 | <0.5 | 11 | 16.8 | 1 | 3 | 3.0 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Horo Guduru, Ethiopia




| Project, country: | | Illubabor, Ethiopia | | | | | | | |
|-----------------------------------|----------------|----------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2004 | | | | | | | |
| Mean MDA coverage per year: | | 76.9 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 435 | 100 | — | 981 | 100 | — | 1,287 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 169 | 38.9 | — | 6 | 0.6 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 169 | 38.9 | — | 6 | 0.6 | — | <0.5 | <0.05 | — |
| Worm infected | 214 | 49.3 | — | 63 | 6.4 | — | 3 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 54 | 12.3 | 1 | 3 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 25 | 5.8 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 18 | 4.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 44 | 10.0 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 1.3 | <0.5 | 6 | 0.6 | <0.5 | 4 | 0.3 | <0.5 |
| Severe depigmentation | 6 | 1.4 | <0.5 | 5 | 0.5 | <0.5 | 3 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 12 | 2.7 | <0.5 | 11 | 1.1 | <0.5 | 7 | 0.6 | <0.5 |
| Total skin disease (OSD) | 109 | 25.1 | 7 | 14 | 1.5 | 1 | 7 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 109 | 25.2 | 8 | 15 | 1.5 | 1 | 7 | 0.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Illubabor, Ethiopia




| Project, country: | | Jimma, Ethiopia | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2004 | | | | | | | |
| Mean MDA coverage per year: | | 78.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 513 | 100 | — | 1,158 | 100 | — | 1,519 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 145 | 28.2 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 145 | 28.2 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 191 | 37.1 | — | 35 | 3.0 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 29 | 5.6 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 19 | 3.7 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 13 | 2.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 31 | 6.1 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 0.9 | <0.5 | 4 | 0.4 | <0.5 | 3 | 0.2 | <0.5 |
| Severe depigmentation | 4 | 0.8 | <0.5 | 4 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 1.8 | <0.5 | 8 | 0.7 | <0.5 | 5 | 0.3 | <0.5 |
| Total skin disease (OSD) | 69 | 13.5 | 5 | 9 | 0.8 | <0.5 | 5 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 69 | 13.5 | 5 | 9 | 0.8 | <0.5 | 5 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Jimma, Ethiopia




| Project, country: | | Kaffa-Sheka, Ethiopia | | | | | | | |
|-----------------------------------|------------|------------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2001 | | | | | | | |
| Mean MDA coverage per year: | | 71.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 729 | 100 | — | 1,645 | 100 | — | 2,157 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 326 | 44.8 | — | 7 | 0.4 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 326 | 44.7 | — | 7 | 0.4 | — | <0.5 | <0.05 | — |
| Worm infected | 396 | 54.4 | — | 90 | 5.5 | — | 3 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 113 | 15.5 | 1 | 3 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 52 | 7.2 | 9 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 38 | 5.3 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 91 | 12.4 | 11 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 12 | 1.6 | <0.5 | 11 | 0.7 | <0.5 | 7 | 0.3 | <0.5 |
| Severe depigmentation | 12 | 1.7 | 1 | 10 | 0.6 | 1 | 6 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 24 | 3.4 | 1 | 21 | 1.3 | 1 | 14 | 0.6 | <0.5 |
| Total skin disease (OSD) | 228 | 31.3 | 13 | 25 | 1.5 | 1 | 14 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.1 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 229 | 31.5 | 16 | 25 | 1.5 | 2 | 14 | 0.6 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kaffa–Sheka, Ethiopia




| Project, country: | | Kamashi, Ethiopia | | | | | | | |
|-----------------------------------|----------------|--------------------------|----------------|-----------|-------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2016 | | | | | | | |
| Mean MDA coverage per year: | | 74.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 271 | 100 | — | 612 | 100 | — | 802 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 102 | 37.7 | — | 55 | 9.0 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 102 | 37.7 | — | 55 | 9.0 | — | <0.5 | <0.05 | — |
| Worm infected | 129 | 47.5 | — | 235 | 38.4 | — | 30 | 3.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 33 | 12.3 | <0.5 | 52 | 8.4 | 1 | 1 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 16 | 5.9 | 3 | 16 | 2.6 | 3 | 1 | 0.1 | <0.5 |
| Reactive skin disease | 12 | 4.4 | 1 | 3 | 0.6 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 28 | 10.2 | 3 | 20 | 3.2 | 3 | 1 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 1.3 | <0.5 | 6 | 1.1 | <0.5 | 5 | 0.6 | <0.5 |
| Severe depigmentation | 4 | 1.4 | <0.5 | 7 | 1.1 | <0.5 | 5 | 0.6 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 8 | 2.8 | <0.5 | 14 | 2.2 | 1 | 10 | 1.3 | <0.5 |
| Total skin disease (OSD) | 69 | 25.3 | 4 | 85 | 13.9 | 4 | 12 | 1.5 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 1 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | 1 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | 69 | 25.5 | 5 | 85 | 13.9 | 6 | 12 | 1.5 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kamashi, Ethiopia




| | | | | | | | | | |
|-----------------------------------|--------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Metekel, Ethiopia | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2004 | | | | | | | | |
| Mean MDA coverage per year: | 66.8 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 93 | 100 | — | 209 | 100 | — | 275 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 28 | 30.1 | — | 2 | 0.8 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 28 | 30.1 | — | 2 | 0.8 | — | <0.5 | <0.05 | — |
| Worm infected | 37 | 39.5 | — | 15 | 7.2 | — | 1 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 6 | 6.6 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 4.0 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 2.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 6 | 6.7 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.0 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 1 | 0.9 | <0.5 | 1 | 0.4 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.9 | <0.5 | 2 | 0.8 | <0.5 | 1 | 0.4 | <0.5 |
| Total skin disease (OSD) | 14 | 15.2 | 1 | 2 | 1.1 | <0.5 | 1 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 14 | 15.2 | 1 | 2 | 1.1 | <0.5 | 1 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Metekel, Ethiopia




| Project, country: | | North Gondar, Ethiopia | | | | | | | |
|-----------------------------------|----------------|-------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2003 | | | | | | | |
| Mean MDA coverage per year: | | 68.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 180 | 100 | — | 406 | 100 | — | 533 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 51 | 28.5 | — | 2 | 0.5 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 51 | 28.5 | — | 2 | 0.5 | — | <0.5 | <0.05 | — |
| Worm infected | 67 | 37.0 | — | 21 | 5.3 | — | 1 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 11 | 5.9 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 7 | 3.9 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 5 | 2.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 12 | 6.6 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.0 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 2 | 0.9 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.9 | <0.5 | 3 | 0.8 | <0.5 | 2 | 0.4 | <0.5 |
| Total skin disease (OSD) | 26 | 14.4 | 2 | 4 | 1.0 | <0.5 | 2 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 26 | 14.4 | 2 | 4 | 1.0 | <0.5 | 2 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in North Gondar, Ethiopia




| | | | | | | | | | |
|-----------------------------------|----------------------------------|-------------|----------------|----------------|-------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY East Wellega, Ethiopia | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2016 | | | | | | | | |
| Mean MDA coverage per year: | 74.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 165 | 100 | — | 371 | 100 | — | 487 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 63 | 38.5 | — | 96 | 25.8 | — | 8 | 1.7 | — |
| Mf-positive (age 5+) | 63 | 38.4 | — | 96 | 25.8 | — | 8 | 1.7 | — |
| Worm infected | 81 | 49.0 | — | 155 | 41.8 | — | 55 | 11.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 20 | 12.2 | <0.5 | 34 | 9.2 | <0.5 | 3 | 0.7 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 9 | 5.7 | 2 | 10 | 2.7 | 2 | 1 | 0.1 | <0.5 |
| Reactive skin disease | 7 | 4.1 | <0.5 | 3 | 0.7 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 16 | 9.8 | 2 | 13 | 3.4 | 2 | 1 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.3 | <0.5 | 4 | 1.1 | <0.5 | 3 | 0.6 | <0.5 |
| Severe depigmentation | 2 | 1.3 | <0.5 | 4 | 1.1 | <0.5 | 3 | 0.6 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 2.7 | <0.5 | 8 | 2.2 | <0.5 | 6 | 1.2 | <0.5 |
| Total skin disease (OSD) | 41 | 24.7 | 2 | 55 | 14.8 | 3 | 10 | 2.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 41 | 24.8 | 3 | 55 | 14.9 | 3 | 10 | 2.1 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY East Wellega, Ethiopia




| | | | | | | | | | |
|-----------------------------------|----------------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | NY West Wellega, Ethiopia | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2016 | | | | | | | | |
| Mean MDA coverage per year: | 73.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 167 | 100 | — | 377 | 100 | — | 495 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 41 | 24.8 | — | 18 | 4.8 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 41 | 24.8 | — | 18 | 4.8 | — | <0.5 | <0.05 | — |
| Worm infected | 56 | 33.7 | — | 96 | 25.4 | — | 9 | 1.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 7 | 4.2 | <0.5 | 9 | 2.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 5 | 3.0 | 1 | 4 | 1.1 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 2.0 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 8 | 5.0 | 1 | 5 | 1.3 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.8 | <0.5 | 2 | 0.6 | <0.5 | 2 | 0.4 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | 2 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.5 | <0.5 | 4 | 1.1 | <0.5 | 3 | 0.6 | <0.5 |
| Total skin disease (OSD) | 18 | 10.7 | 1 | 18 | 4.9 | 1 | 3 | 0.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 18 | 10.7 | 1 | 18 | 4.9 | 1 | 3 | 0.7 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in NY West Wellega, Ethiopia




| Project, country: | | P20Ethiopia, Ethiopia | | | | | | | |
|-----------------------------------|----------------|------------------------------|----------------|----------------|-------------|----------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2019 | | | | | | | |
| Mean MDA coverage per year: | | 73.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 191 | 100 | — | 431 | 100 | — | 566 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 81 | 42.1 | — | 168 | 39.0 | — | 39 | 6.9 | — |
| Mf-positive (age 5+) | 80 | 42.1 | — | 168 | 39.0 | — | 39 | 6.9 | — |
| Worm infected | 101 | 52.8 | — | 223 | 51.8 | — | 136 | 24.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 27 | 14.2 | <0.5 | 60 | 14.0 | 1 | 16 | 2.9 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 12 | 6.4 | 2 | 24 | 5.5 | 4 | 4 | 0.6 | 1 |
| Reactive skin disease | 9 | 4.7 | <0.5 | 14 | 3.3 | 1 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 21 | 11.2 | 3 | 38 | 8.8 | 5 | 4 | 0.7 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.5 | <0.5 | 6 | 1.3 | <0.5 | 5 | 0.9 | <0.5 |
| Severe depigmentation | 3 | 1.5 | <0.5 | 6 | 1.4 | <0.5 | 5 | 0.9 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 3.0 | <0.5 | 12 | 2.8 | 1 | 10 | 1.7 | <0.5 |
| Total skin disease (OSD) | 54 | 28.4 | 3 | 110 | 25.6 | 6 | 30 | 5.3 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 1 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | <0.5 | 0.1 | 1 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | 1 |
| Total all manifestations | 55 | 28.5 | 4 | 111 | 25.7 | 8 | 30 | 5.3 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20Ethiopia, Ethiopia




| Project, country: | | P5Ethiopia, Ethiopia | | | | | | | |
|-----------------------------------|----------------|-----------------------------|-----------|------------|-----------------|-----------|------------|-----------------|-----------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2023 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 2,018 | 100 | — | 4,553 | 100 | — | 5,972 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 494 | 24.5 | — | 1,059 | 23.3 | — | 619 | 10.4 | — |
| Mf-positive (age 5+) | 494 | 24.5 | — | 1,059 | 23.2 | — | 619 | 10.4 | — |
| Worm infected | 656 | 32.5 | — | 1,424 | 31.3 | — | 1,327 | 22.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 75 | 3.7 | 1 | 161 | 3.5 | 2 | 100 | 1.7 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 62 | 3.1 | 11 | 130 | 2.9 | 24 | 47 | 0.8 | 8 |
| Reactive skin disease | 41 | 2.0 | 2 | 89 | 2.0 | 4 | 10 | 0.2 | <0.5 |
| Reversible skin disease | 103 | 5.1 | 13 | 219 | 4.8 | 28 | 56 | 0.9 | 9 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 16 | 0.8 | <0.5 | 36 | 0.8 | <0.5 | 36 | 0.6 | <0.5 |
| Severe depigmentation | 14 | 0.7 | 1 | 30 | 0.7 | 2 | 28 | 0.5 | 2 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 30 | 1.5 | 1 | 66 | 1.5 | 2 | 64 | 1.1 | 2 |
| Total skin disease (OSD) | 209 | 10.3 | 15 | 447 | 9.8 | 32 | 220 | 3.7 | 12 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | 1 | <0.05 | 2 | 1 | <0.05 | 1 |
| Total all manifestations | 209 | 10.4 | 16 | 448 | 9.8 | 34 | 221 | 3.7 | 14 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Ethiopia, Ethiopia




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | West Shewa, Ethiopia | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2023 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 33 | 100 | — | 75 | 100 | — | 98 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 7 | 22.1 | — | 16 | 21.0 | — | 9 | 9.0 | — |
| Mf-positive (age 5+) | 7 | 22.1 | — | 16 | 21.0 | — | 9 | 9.0 | — |
| Worm infected | 10 | 30.0 | — | 22 | 28.7 | — | 20 | 20.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 2.7 | <0.5 | 2 | 2.6 | <0.5 | 1 | 1.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 2.7 | <0.5 | 2 | 2.5 | <0.5 | 1 | 0.7 | <0.5 |
| Reactive skin disease | 1 | 1.8 | <0.5 | 1 | 1.7 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 1 | 4.5 | <0.5 | 3 | 4.2 | <0.5 | 1 | 0.8 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | 1 | 0.7 | <0.5 | <0.5 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.3 | <0.5 | 1 | 1.3 | <0.5 | 1 | 0.9 | <0.5 |
| Total skin disease (OSD) | 3 | 8.5 | <0.5 | 6 | 8.1 | <0.5 | 3 | 2.9 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 3 | 8.5 | <0.5 | 6 | 8.1 | <0.5 | 3 | 2.9 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in West Shewa, Ethiopia




| Project, country: | | West Wellega, Ethiopia | | | | | | | |
|-----------------------------------|------------|-------------------------------|-----------|-----------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2004 | | | | | | | |
| Mean MDA coverage per year: | | 72.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 590 | 100 | — | 1,332 | 100 | — | 1,747 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 244 | 41.3 | — | 22 | 1.7 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 243 | 41.3 | — | 22 | 1.7 | — | <0.5 | <0.05 | — |
| Worm infected | 297 | 50.3 | — | 149 | 11.2 | — | 9 | 0.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 86 | 14.6 | 1 | 10 | 0.7 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 41 | 6.9 | 7 | 3 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 31 | 5.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 72 | 12.2 | 9 | 3 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 1.6 | <0.5 | 10 | 0.8 | <0.5 | 7 | 0.4 | <0.5 |
| Severe depigmentation | 11 | 1.8 | 1 | 11 | 0.8 | 1 | 7 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 20 | 3.4 | 1 | 21 | 1.6 | 1 | 14 | 0.8 | 1 |
| Total skin disease (OSD) | 178 | 30.2 | 11 | 33 | 2.5 | 1 | 15 | 0.8 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 3 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.2 | 3 | 1 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 179 | 30.3 | 14 | 34 | 2.5 | 3 | 15 | 0.9 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in West Wellega, Ethiopia




| Project, country: | | P5Gabon, Gabon | | | | | | | |
|-----------------------------------|----------------|-----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2025 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 49 | 100 | — | 112 | 100 | — | 146 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 11 | 21.6 | — | 22 | 20.0 | — | 17 | 11.9 | — |
| Mf-positive (age 5+) | 11 | 21.6 | — | 22 | 20.0 | — | 17 | 11.9 | — |
| Worm infected | 15 | 29.3 | — | 31 | 27.6 | — | 32 | 22.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 2.5 | <0.5 | 3 | 2.3 | <0.5 | 2 | 1.5 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 2.6 | <0.5 | 3 | 2.3 | <0.5 | 1 | 0.9 | <0.5 |
| Reactive skin disease | 1 | 1.7 | <0.5 | 2 | 1.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reversible skin disease | 2 | 4.3 | <0.5 | 4 | 3.8 | 1 | 2 | 1.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | 1 | 0.7 | <0.5 | 1 | 0.5 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 1.3 | <0.5 | 1 | 1.2 | <0.5 | 1 | 0.9 | <0.5 |
| Total skin disease (OSD) | 4 | 8.1 | <0.5 | 8 | 7.3 | 1 | 5 | 3.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 4 | 8.1 | <0.5 | 8 | 7.3 | 1 | 5 | 3.6 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Gabon, Gabon




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | All_Liberia, Liberia | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2004 | | | | | | | | |
| Mean MDA coverage per year: | 66.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 881 | 100 | — | 1,987 | 100 | — | 2,606 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 343 | 39.0 | — | 5 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 343 | 38.9 | — | 5 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 455 | 51.7 | — | 54 | 2.7 | — | 2 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 100 | 11.3 | 1 | 2 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 43 | 4.9 | 8 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 29 | 3.3 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 72 | 8.2 | 9 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 10 | 1.1 | <0.5 | 7 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Severe depigmentation | 9 | 1.0 | 1 | 6 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 19 | 2.1 | 1 | 13 | 0.7 | <0.5 | 8 | 0.3 | <0.5 |
| Total skin disease (OSD) | 191 | 21.7 | 11 | 15 | 0.8 | 1 | 8 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 191 | 21.7 | 11 | 15 | 0.8 | 1 | 8 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in All_Liberia, Liberia




| Project, country: | | Malawi Extension, Malawi | | | | | | | |
|-----------------------------------|----------------|---------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2000 | | | | | | | |
| Mean MDA coverage per year: | | 69.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 665 | 100 | — | 1,501 | 100 | — | 1,968 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 136 | 20.4 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 136 | 20.4 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 188 | 28.3 | — | 26 | 1.7 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 15 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 16 | 2.4 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 10 | 1.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 26 | 3.9 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 0.7 | <0.5 | 4 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 4 | 0.6 | <0.5 | 3 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 8 | 1.2 | <0.5 | 7 | 0.5 | <0.5 | 4 | 0.2 | <0.5 |
| Total skin disease (OSD) | 49 | 7.4 | 4 | 7 | 0.5 | <0.5 | 4 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 49 | 7.4 | 4 | 7 | 0.5 | <0.5 | 4 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Malawi Extension, Malawi




| Project, country: | | Thyolo Mwanza, Malawi | | | | | | | |
|-----------------------------------|----------------|------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1997 | | | | | | | |
| Mean MDA coverage per year: | | 69.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 507 | 100 | — | 1,145 | 100 | — | 1,501 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 137 | 27.0 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 137 | 27.0 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 185 | 36.6 | — | 15 | 1.3 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 26 | 5.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 17 | 3.3 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 11 | 2.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 28 | 5.5 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 0.8 | <0.5 | 3 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Severe depigmentation | 4 | 0.7 | <0.5 | 2 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 8 | 1.6 | <0.5 | 6 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |
| Total skin disease (OSD) | 62 | 12.3 | 4 | 6 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 62 | 12.3 | 4 | 6 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Thyolo Mwanza, Malawi




| Project, country: | | P20Mozambique, Mozambique | | | | | | | |
|-----------------------------------|----------------|----------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2019 | | | | | | | |
| Mean MDA coverage per year: | | 64.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 9 | 100 | — | 21 | 100 | — | 27 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 2 | 20.4 | — | 4 | 16.8 | — | 1 | 2.7 | — |
| Mf-positive (age 5+) | 2 | 20.3 | — | 4 | 16.8 | — | 1 | 2.7 | — |
| Worm infected | 3 | 28.2 | — | 5 | 25.7 | — | 3 | 10.6 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | <0.5 | 2.2 | <0.5 | <0.5 | 1.9 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 2.4 | <0.5 | <0.5 | 1.8 | <0.5 | <0.5 | 0.2 | <0.5 |
| Reactive skin disease | <0.5 | 1.6 | <0.5 | <0.5 | 1.0 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | <0.5 | 4.0 | <0.5 | 1 | 2.8 | <0.5 | <0.5 | 0.2 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.4 | <0.5 |
| Severe depigmentation | <0.5 | 0.5 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.2 | <0.5 | <0.5 | 1.0 | <0.5 | <0.5 | 0.6 | <0.5 |
| Total skin disease (OSD) | 1 | 7.4 | <0.5 | 1 | 5.7 | <0.5 | <0.5 | 1.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 1 | 7.4 | <0.5 | 1 | 5.7 | <0.5 | <0.5 | 1.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20Mozambique, Mozambique




| | | | | | | | | | |
|-----------------------------------|---------------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | P5Mozambique, Mozambique | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2023 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 27 | 100 | — | 61 | 100 | — | 80 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 5 | 19.9 | — | 11 | 17.3 | — | 5 | 6.8 | — |
| Mf-positive (age 5+) | 5 | 19.9 | — | 11 | 17.3 | — | 5 | 6.8 | — |
| Worm infected | 7 | 27.5 | — | 15 | 24.7 | — | 13 | 16.5 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 1 | 2.0 | <0.5 | 1 | 1.7 | <0.5 | 1 | 0.8 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 2.3 | <0.5 | 1 | 2.0 | <0.5 | <0.5 | 0.5 | <0.5 |
| Reactive skin disease | <0.5 | 1.5 | <0.5 | 1 | 1.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Reversible skin disease | 1 | 3.9 | <0.5 | 2 | 3.3 | <0.5 | <0.5 | 0.6 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.4 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | <0.5 | 0.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.2 | <0.5 | 1 | 1.0 | <0.5 | 1 | 0.7 | <0.5 |
| Total skin disease (OSD) | 2 | 7.1 | <0.5 | 4 | 6.0 | <0.5 | 2 | 2.0 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 2 | 7.1 | <0.5 | 4 | 6.0 | <0.5 | 2 | 2.1 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Mozambique, Mozambique




| Project, country: | | Adamawa, Nigeria | | | | | | | |
|-----------------------------------|------------|-------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 72.9 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,019 | 100 | — | 2,298 | 100 | — | 3,015 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 241 | 23.7 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 241 | 23.7 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 323 | 31.7 | — | 22 | 0.9 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 34 | 3.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 29 | 2.9 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 20 | 2.0 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 49 | 4.9 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 0.7 | <0.5 | 6 | 0.3 | <0.5 | 4 | 0.1 | <0.5 |
| Severe depigmentation | 7 | 0.7 | <0.5 | 4 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 14 | 1.4 | 1 | 11 | 0.5 | <0.5 | 6 | 0.2 | <0.5 |
| Total skin disease (OSD) | 98 | 9.6 | 7 | 11 | 0.5 | <0.5 | 6 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 13 | 1.3 | <0.5 | 9 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Blindness | 4 | 0.4 | 27 | 1 | 0.1 | 8 | 1 | <0.05 | 4 |
| Eye disease (OED) | 17 | 1.7 | 27 | 10 | 0.4 | 8 | 5 | 0.2 | 4 |
| Total all manifestations | 115 | 11.3 | 35 | 21 | 0.9 | 9 | 12 | 0.4 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Adamawa, Nigeria




| | | | | | | | | | |
|-----------------------------------|---------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Akwa Ibom, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2004 | | | | | | | | |
| Mean MDA coverage per year: | 74.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 17 | 100 | — | 39 | 100 | — | 52 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 4 | 21.6 | — | <0.5 | 0.2 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 4 | 21.6 | — | <0.5 | 0.2 | — | <0.5 | <0.05 | — |
| Worm infected | 5 | 29.3 | — | 2 | 4.1 | — | <0.5 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | <0.5 | 2.5 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | <0.5 | 2.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | <0.5 | 1.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 1 | 4.3 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 0.7 | <0.5 | <0.5 | 0.3 | <0.5 | <0.5 | 0.2 | <0.5 |
| Severe depigmentation | <0.5 | 0.6 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 1.3 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.3 | <0.5 |
| Total skin disease (OSD) | 1 | 8.1 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 1 | 8.1 | <0.5 | <0.5 | 0.6 | <0.5 | <0.5 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Akwa Ibom, Nigeria




| Project, country: | | Bauchi, Nigeria | | | | | | | |
|-----------------------------------|------------|------------------------|----------------|-----------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 63.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,044 | 100 | — | 2,355 | 100 | — | 3,089 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 225 | 21.5 | — | 5 | 0.2 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 225 | 21.5 | — | 5 | 0.2 | — | <0.5 | <0.05 | — |
| Worm infected | 307 | 29.4 | — | 75 | 3.2 | — | 2 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 26 | 2.5 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 27 | 2.6 | 5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 18 | 1.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 45 | 4.3 | 6 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 8 | 0.7 | <0.5 | 7 | 0.3 | <0.5 | 4 | 0.1 | <0.5 |
| Severe depigmentation | 6 | 0.6 | <0.5 | 5 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 14 | 1.3 | <0.5 | 11 | 0.5 | <0.5 | 7 | 0.2 | <0.5 |
| Total skin disease (OSD) | 85 | 8.1 | 7 | 13 | 0.6 | <0.5 | 7 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 12 | 1.2 | <0.5 | 10 | 0.4 | <0.5 | 6 | 0.2 | <0.5 |
| Blindness | 4 | 0.4 | 26 | 2 | 0.1 | 11 | 1 | <0.05 | 5 |
| Eye disease (OED) | 16 | 1.5 | 26 | 12 | 0.5 | 11 | 7 | 0.2 | 5 |
| Total all manifestations | 101 | 9.6 | 33 | 25 | 1.1 | 12 | 14 | 0.5 | 5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Bauchi, Nigeria




| | | | | | | | | | |
|-----------------------------------|-----------------------|-------------|-----------|-----------|-----------------|----------|----------------|-----------------|----------------|
| Project, country: | Benue, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 62.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 2,058 | 100 | — | 4,644 | 100 | — | 6,092 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 783 | 38.0 | — | 41 | 0.9 | — | 1 | <0.05 | — |
| Mf-positive (age 5+) | 782 | 38.0 | — | 41 | 0.9 | — | 1 | <0.05 | — |
| Worm infected | 984 | 47.8 | — | 340 | 7.3 | — | 20 | 0.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 239 | 11.6 | 3 | 16 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 118 | 5.7 | 21 | 4 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 85 | 4.1 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 203 | 9.9 | 25 | 4 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 27 | 1.3 | <0.5 | 26 | 0.6 | <0.5 | 18 | 0.3 | <0.5 |
| Severe depigmentation | 28 | 1.4 | 2 | 24 | 0.5 | 2 | 15 | 0.3 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 56 | 2.7 | 2 | 51 | 1.1 | 2 | 34 | 0.6 | 1 |
| Total skin disease (OSD) | 498 | 24.2 | 30 | 71 | 1.5 | 3 | 34 | 0.6 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 1 | <0.05 | 5 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 2 | 0.1 | 5 | 1 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | 500 | 24.3 | 36 | 72 | 1.5 | 5 | 34 | 0.6 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Benue, Nigeria




| Project, country: | | Borno, Nigeria | | | | | | | |
|-----------------------------------|-----------|-----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 72.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 820 | 100 | — | 1,851 | 100 | — | 2,428 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 160 | 19.5 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 160 | 19.5 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 229 | 27.9 | — | 17 | 0.9 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 18 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 18 | 2.2 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 11 | 1.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 29 | 3.5 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 0.6 | <0.5 | 3 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Severe depigmentation | 4 | 0.5 | <0.5 | 2 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 1.1 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Total skin disease (OSD) | 56 | 6.8 | 4 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 8 | 1.0 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Blindness | 2 | 0.3 | 15 | 1 | <0.05 | 4 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 10 | 1.3 | 16 | 6 | 0.3 | 4 | 3 | 0.1 | 1 |
| Total all manifestations | 66 | 8.1 | 20 | 11 | 0.6 | 4 | 6 | 0.3 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Borno, Nigeria




| Project, country: | | Cross River, Nigeria | | | | | | | |
|-----------------------------------|------------|-----------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1998 | | | | | | | |
| Mean MDA coverage per year: | | 75.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 744 | 100 | — | 1,679 | 100 | — | 2,202 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 222 | 29.8 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 221 | 29.8 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 285 | 38.4 | — | 17 | 1.0 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 55 | 7.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 32 | 4.3 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 23 | 3.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 55 | 7.4 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 8 | 1.0 | <0.5 | 5 | 0.3 | <0.5 | 4 | 0.2 | <0.5 |
| Severe depigmentation | 8 | 1.1 | 1 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 16 | 2.1 | 1 | 10 | 0.6 | <0.5 | 6 | 0.3 | <0.5 |
| Total skin disease (OSD) | 126 | 17.0 | 8 | 11 | 0.7 | <0.5 | 6 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.1 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 127 | 17.1 | 10 | 11 | 0.7 | 1 | 7 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Cross River, Nigeria




| | | | | | | | | | |
|-----------------------------------|---------------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Edo Delta, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 75.6 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 956 | 100 | — | 2,158 | 100 | — | 2,831 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 266 | 27.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 265 | 27.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 351 | 36.7 | — | 12 | 0.6 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 52 | 5.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 34 | 3.5 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 23 | 2.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 57 | 5.9 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 0.9 | <0.5 | 6 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 8 | 0.8 | <0.5 | 5 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 16 | 1.7 | 1 | 11 | 0.5 | <0.5 | 6 | 0.2 | <0.5 |
| Total skin disease (OSD) | 125 | 13.1 | 8 | 11 | 0.5 | <0.5 | 6 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 125 | 13.1 | 9 | 11 | 0.5 | <0.5 | 6 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Edo Delta, Nigeria




| | | | | | | | | | |
|-----------------------------------|-----------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Ekiti, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 68.7 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,291 | 100 | — | 2,913 | 100 | — | 3,821 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 265 | 20.5 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 264 | 20.5 | — | 1 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 363 | 28.1 | — | 32 | 1.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 28 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 31 | 2.4 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 21 | 1.6 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 52 | 4.0 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 8 | 0.7 | <0.5 | 7 | 0.2 | <0.5 | 4 | 0.1 | <0.5 |
| Severe depigmentation | 7 | 0.5 | <0.5 | 4 | 0.1 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 16 | 1.2 | 1 | 11 | 0.4 | <0.5 | 7 | 0.2 | <0.5 |
| Total skin disease (OSD) | 95 | 7.3 | 7 | 11 | 0.4 | <0.5 | 7 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 95 | 7.4 | 8 | 11 | 0.4 | <0.5 | 7 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ekiti, Nigeria




| Project, country: | | Enugu Anambra Ebony, Nigeria | | | | | | | |
|-----------------------------------|------------|-------------------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 76.6 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,421 | 100 | — | 3,207 | 100 | — | 4,206 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 691 | 48.6 | — | 5 | 0.2 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 690 | 48.6 | — | 5 | 0.2 | — | <0.5 | <0.05 | — |
| Worm infected | 831 | 58.5 | — | 76 | 2.4 | — | 4 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 273 | 19.2 | 3 | 3 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 119 | 8.4 | 22 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 92 | 6.5 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 211 | 14.9 | 26 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 25 | 1.8 | <0.5 | 19 | 0.6 | <0.5 | 13 | 0.3 | <0.5 |
| Severe depigmentation | 31 | 2.2 | 2 | 21 | 0.6 | 1 | 13 | 0.3 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 57 | 4.0 | 3 | 40 | 1.2 | 2 | 25 | 0.6 | 1 |
| Total skin disease (OSD) | 542 | 38.1 | 31 | 43 | 1.3 | 2 | 25 | 0.6 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.1 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 2 | 0.1 | 10 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 3 | 0.2 | 10 | 1 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Total all manifestations | 545 | 38.3 | 42 | 44 | 1.4 | 4 | 26 | 0.6 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Enugu Anambra Ebony, Nigeria




| Project, country: | | FCT, Nigeria | | | | | | | |
|-----------------------------------|----------------|---------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1998 | | | | | | | |
| Mean MDA coverage per year: | | 71.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 302 | 100 | — | 681 | 100 | — | 893 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 67 | 22.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 67 | 22.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 90 | 29.8 | — | 7 | 1.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 8 | 2.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 2.8 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 6 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 14 | 4.7 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.8 | <0.5 | 2 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 2 | 0.6 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 1.4 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Total skin disease (OSD) | 26 | 8.7 | 2 | 3 | 0.5 | <0.5 | 2 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 26 | 8.7 | 2 | 3 | 0.5 | <0.5 | 2 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in FCT, Nigeria




| Project, country: | | Gombe, Nigeria | | | | | | | |
|-----------------------------------|------------|-----------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 68.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,134 | 100 | — | 2,559 | 100 | — | 3,356 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 261 | 23.1 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 261 | 23.0 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 351 | 31.0 | — | 57 | 2.2 | — | 1 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 35 | 3.1 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 32 | 2.9 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 22 | 1.9 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 54 | 4.8 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 0.8 | <0.5 | 7 | 0.3 | <0.5 | 5 | 0.1 | <0.5 |
| Severe depigmentation | 7 | 0.6 | <0.5 | 5 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 16 | 1.4 | 1 | 12 | 0.5 | <0.5 | 8 | 0.2 | <0.5 |
| Total skin disease (OSD) | 106 | 9.3 | 8 | 14 | 0.5 | <0.5 | 8 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 15 | 1.3 | <0.5 | 11 | 0.4 | <0.5 | 7 | 0.2 | <0.5 |
| Blindness | 5 | 0.4 | 32 | 1 | 0.1 | 10 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | 20 | 1.7 | 33 | 13 | 0.5 | 10 | 7 | 0.2 | 3 |
| Total all manifestations | 125 | 11.0 | 41 | 26 | 1.0 | 11 | 15 | 0.4 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Gombe, Nigeria




| Project, country: | | Imo Abia, Nigeria | | | | | | | |
|-----------------------------------|----------------|--------------------------|----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 65.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 783 | 100 | — | 1,768 | 100 | — | 2,319 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 226 | 28.8 | — | 5 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 226 | 28.8 | — | 5 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 293 | 37.4 | — | 63 | 3.6 | — | 2 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 49 | 6.3 | 1 | 2 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 31 | 3.9 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 22 | 2.8 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 52 | 6.7 | 7 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 1.0 | <0.5 | 6 | 0.3 | <0.5 | 4 | 0.2 | <0.5 |
| Severe depigmentation | 7 | 0.9 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 15 | 1.9 | 1 | 11 | 0.6 | <0.5 | 6 | 0.3 | <0.5 |
| Total skin disease (OSD) | 116 | 14.8 | 8 | 13 | 0.7 | <0.5 | 6 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 117 | 14.9 | 8 | 13 | 0.7 | 1 | 6 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Imo Abia, Nigeria




| Project, country: | | Jigawa, Nigeria | | | | | | | |
|-----------------------------------|-----------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 63.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 212 | 100 | — | 479 | 100 | — | 629 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 45 | 21.1 | — | <0.5 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 45 | 21.1 | — | <0.5 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 61 | 28.6 | — | 10 | 2.0 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 5 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 5 | 2.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 1.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 9 | 4.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.7 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.2 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 16 | 7.6 | 1 | 2 | 0.5 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 1.2 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Blindness | 1 | 0.3 | 5 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 3 | 1.5 | 5 | 2 | 0.4 | 2 | 1 | 0.2 | 1 |
| Total all manifestations | 19 | 9.1 | 6 | 4 | 0.9 | 2 | 2 | 0.4 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Jigawa, Nigeria




| Project, country: | | Kaduna, Nigeria | | | | | | | |
|-----------------------------------|------------|------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1991 | | | | | | | |
| Mean MDA coverage per year: | | 77.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,650 | 100 | — | 3,723 | 100 | — | 4,884 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 393 | 23.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 392 | 23.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 522 | 31.6 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 57 | 3.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 50 | 3.0 | 9 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 34 | 2.1 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 84 | 5.1 | 11 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 13 | 0.8 | <0.5 | 5 | 0.1 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 11 | 0.7 | 1 | 3 | 0.1 | <0.5 | 2 | <0.05 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 24 | 1.5 | 1 | 9 | 0.2 | <0.5 | 4 | 0.1 | <0.5 |
| Total skin disease (OSD) | 164 | 10.0 | 12 | 9 | 0.2 | <0.5 | 4 | 0.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 22 | 1.3 | 1 | 8 | 0.2 | <0.5 | 4 | 0.1 | <0.5 |
| Blindness | 7 | 0.4 | 49 | 1 | <0.05 | 5 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 29 | 1.8 | 50 | 9 | 0.2 | 5 | 4 | 0.1 | 1 |
| Total all manifestations | 194 | 11.7 | 62 | 17 | 0.5 | 6 | 8 | 0.2 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kaduna, Nigeria




| Project, country: | | Kano, Nigeria | | | | | | | |
|-----------------------------------|-----------|----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 76.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 589 | 100 | — | 1,329 | 100 | — | 1,743 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 121 | 20.5 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 121 | 20.5 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 167 | 28.3 | — | 5 | 0.4 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 13 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 14 | 2.4 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 9 | 1.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 23 | 4.0 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 0.7 | <0.5 | 3 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 3 | 0.5 | <0.5 | 2 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 7 | 1.2 | <0.5 | 4 | 0.3 | <0.5 | 3 | 0.2 | <0.5 |
| Total skin disease (OSD) | 43 | 7.4 | 3 | 4 | 0.3 | <0.5 | 3 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 7 | 1.1 | <0.5 | 4 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Blindness | 2 | 0.3 | 13 | 1 | <0.05 | 4 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 8 | 1.4 | 13 | 5 | 0.3 | 4 | 2 | 0.1 | 1 |
| Total all manifestations | 52 | 8.8 | 17 | 9 | 0.7 | 4 | 5 | 0.3 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kano, Nigeria




| | | | | | | | | | |
|-----------------------------------|-----------------------|------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Kebbi, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 66.8 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 124 | 100 | — | 279 | 100 | — | 366 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 24 | 19.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 24 | 19.2 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 34 | 27.1 | — | 3 | 1.2 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 2 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 3 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 2 | 1.5 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 5 | 3.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.6 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.4 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 1 | 1.1 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 8 | 6.7 | 1 | 1 | 0.3 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 1.0 | <0.5 | 1 | 0.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Blindness | <0.5 | 0.3 | 2 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 2 | 1.3 | 3 | 1 | 0.3 | 1 | 1 | 0.1 | <0.5 |
| Total all manifestations | 10 | 8.0 | 3 | 2 | 0.7 | 1 | 1 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kebbi, Nigeria




| | | | | | | | | | |
|-----------------------------------|----------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Kogi, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1998 | | | | | | | | |
| Mean MDA coverage per year: | 75.8 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,063 | 100 | — | 2,399 | 100 | — | 3,146 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 275 | 25.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 275 | 25.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 364 | 34.3 | — | 9 | 0.4 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 48 | 4.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 35 | 3.3 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 24 | 2.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 58 | 5.5 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 0.8 | <0.5 | 6 | 0.2 | <0.5 | 4 | 0.1 | <0.5 |
| Severe depigmentation | 8 | 0.7 | 1 | 5 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 17 | 1.6 | 1 | 10 | 0.4 | <0.5 | 6 | 0.2 | <0.5 |
| Total skin disease (OSD) | 123 | 11.6 | 9 | 11 | 0.4 | <0.5 | 6 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 124 | 11.6 | 9 | 11 | 0.4 | <0.5 | 6 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kogi, Nigeria




| Project, country: | | Kwara, Nigeria | | | | | | | |
|-----------------------------------|------------|-----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 73.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 898 | 100 | — | 2,027 | 100 | — | 2,659 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 223 | 24.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 223 | 24.8 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 301 | 33.5 | — | 20 | 1.0 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 37 | 4.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 26 | 2.9 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 18 | 2.0 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 45 | 5.0 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 0.8 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 6 | 0.6 | <0.5 | 4 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 13 | 1.4 | <0.5 | 9 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Total skin disease (OSD) | 94 | 10.5 | 6 | 9 | 0.5 | <0.5 | 5 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 12 | 1.3 | <0.5 | 8 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Blindness | 4 | 0.4 | 25 | 1 | 0.1 | 8 | <0.5 | <0.05 | 2 |
| Eye disease (OED) | 16 | 1.7 | 26 | 9 | 0.5 | 9 | 5 | 0.2 | 2 |
| Total all manifestations | 110 | 12.2 | 32 | 19 | 0.9 | 9 | 10 | 0.4 | 3 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kwara, Nigeria




| Project, country: | | Niger, Nigeria | | | | | | | |
|-----------------------------------|------------|-----------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 66.6 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,579 | 100 | — | 3,564 | 100 | — | 4,675 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 332 | 21.0 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 332 | 21.0 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 458 | 29.0 | — | 63 | 1.8 | — | 1 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 39 | 2.5 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 39 | 2.5 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 26 | 1.6 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 65 | 4.1 | 8 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 10 | 0.7 | <0.5 | 8 | 0.2 | <0.5 | 5 | 0.1 | <0.5 |
| Severe depigmentation | 8 | 0.5 | 1 | 6 | 0.2 | <0.5 | 4 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 19 | 1.2 | 1 | 15 | 0.4 | 1 | 9 | 0.2 | <0.5 |
| Total skin disease (OSD) | 123 | 7.8 | 9 | 16 | 0.4 | 1 | 9 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 18 | 1.1 | 1 | 13 | 0.4 | <0.5 | 8 | 0.2 | <0.5 |
| Blindness | 5 | 0.3 | 34 | 2 | <0.05 | 11 | 1 | <0.05 | 4 |
| Eye disease (OED) | 23 | 1.4 | 35 | 15 | 0.4 | 11 | 8 | 0.2 | 4 |
| Total all manifestations | 145 | 9.2 | 44 | 30 | 0.8 | 12 | 17 | 0.4 | 5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Niger, Nigeria




| Project, country: | | Ogun, Nigeria | | | | | | | |
|-----------------------------------|----------------|----------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2002 | | | | | | | | |
| Mean MDA coverage per year: | 77.2 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 205 | 100 | — | 462 | 100 | — | 606 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 57 | 27.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 57 | 27.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 76 | 37.0 | — | 8 | 1.7 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 11 | 5.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 7 | 3.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 5 | 2.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 12 | 5.9 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.9 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 2 | 0.8 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.7 | <0.5 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Total skin disease (OSD) | 27 | 13.0 | 2 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 27 | 13.0 | 2 | 3 | 0.6 | <0.5 | 2 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ogun, Nigeria




| | | | | | | | | | |
|-----------------------------------|----------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Ondo, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 75.9 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 814 | 100 | — | 1,837 | 100 | — | 2,409 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 206 | 25.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 206 | 25.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 279 | 34.3 | — | 8 | 0.5 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 35 | 4.3 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 26 | 3.1 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 17 | 2.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 42 | 5.2 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 0.8 | <0.5 | 5 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 6 | 0.7 | <0.5 | 3 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 12 | 1.5 | <0.5 | 8 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Total skin disease (OSD) | 90 | 11.0 | 6 | 8 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 90 | 11.0 | 7 | 8 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ondo, Nigeria




| | | | | | | | | | |
|-----------------------------------|----------------------|-----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Osun, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 1998 | | | | | | | | |
| Mean MDA coverage per year: | 63.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 960 | 100 | — | 2,167 | 100 | — | 2,842 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 211 | 22.0 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 211 | 22.0 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 292 | 30.5 | — | 48 | 2.2 | — | 1 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 29 | 3.0 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 25 | 2.6 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 16 | 1.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 41 | 4.3 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 0.7 | <0.5 | 5 | 0.2 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 5 | 0.6 | <0.5 | 4 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 12 | 1.3 | <0.5 | 9 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Total skin disease (OSD) | 82 | 8.5 | 6 | 10 | 0.5 | <0.5 | 5 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 82 | 8.6 | 6 | 10 | 0.5 | <0.5 | 5 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Osun, Nigeria




| | | | | | | | | | |
|-----------------------------------|---------------------|-------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Oyo, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 65.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total population at risk | 655 | 100 | — | 1,478 | 100 | — | 1,938 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 149 | 22.8 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 149 | 22.8 | — | 2 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 208 | 31.8 | — | 32 | 2.1 | — | 1 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 23 | 3.5 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 17 | 2.6 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 11 | 1.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 28 | 4.3 | 4 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 0.7 | <0.5 | 3 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Severe depigmentation | 4 | 0.5 | <0.5 | 2 | 0.1 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 8 | 1.3 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.2 | <0.5 |
| Total skin disease (OSD) | 59 | 9.1 | 4 | 6 | 0.4 | <0.5 | 3 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 8 | 1.1 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Blindness | 2 | 0.3 | 15 | 1 | <0.05 | 5 | <0.5 | <0.05 | 2 |
| Eye disease (OED) | 10 | 1.5 | 15 | 6 | 0.4 | 5 | 3 | 0.2 | 2 |
| Total all manifestations | 69 | 10.5 | 19 | 11 | 0.8 | 5 | 6 | 0.3 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Oyo, Nigeria




| Project, country: | | P20Nigeria, Nigeria | | | | | | | |
|-----------------------------------|----------------|----------------------------|----------------|----------------|-------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2019 | | | | | | | |
| Mean MDA coverage per year: | | 73.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 132 | 100 | — | 298 | 100 | — | 391 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 54 | 41.0 | — | 115 | 38.5 | — | 23 | 6.0 | — |
| Mf-positive (age 5+) | 54 | 41.0 | — | 115 | 38.5 | — | 23 | 6.0 | — |
| Worm infected | 68 | 51.4 | — | 153 | 51.1 | — | 91 | 23.3 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 17 | 12.9 | <0.5 | 38 | 12.8 | <0.5 | 9 | 2.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 6.0 | 1 | 15 | 5.1 | 3 | 2 | 0.5 | <0.5 |
| Reactive skin disease | 6 | 4.3 | <0.5 | 9 | 3.0 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 14 | 10.3 | 2 | 24 | 8.1 | 3 | 2 | 0.5 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.4 | <0.5 | 4 | 1.3 | <0.5 | 3 | 0.8 | <0.5 |
| Severe depigmentation | 2 | 1.3 | <0.5 | 4 | 1.3 | <0.5 | 3 | 0.7 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 2.7 | <0.5 | 8 | 2.6 | <0.5 | 6 | 1.6 | <0.5 |
| Total skin disease (OSD) | 34 | 25.9 | 2 | 70 | 23.5 | 4 | 17 | 4.3 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 34 | 26.0 | 2 | 70 | 23.6 | 4 | 17 | 4.3 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20Nigeria, Nigeria




| | | | | | | | | | |
|-----------------------------------|---------------------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Project, country: | P5Nigeria, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2025 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 4,491 | 100 | — | 10,135 | 100 | — | 13,294 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 930 | 20.7 | — | 1,892 | 18.7 | — | 1,450 | 10.9 | — |
| Mf-positive (age 5+) | 929 | 20.7 | — | 1,891 | 18.7 | — | 1,450 | 10.9 | — |
| Worm infected | 1,288 | 28.7 | — | 2,665 | 26.3 | — | 2,781 | 20.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 105 | 2.3 | 1 | 210 | 2.1 | 2 | 178 | 1.3 | 2 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 111 | 2.5 | 20 | 218 | 2.2 | 40 | 117 | 0.9 | 21 |
| Reactive skin disease | 72 | 1.6 | 3 | 140 | 1.4 | 6 | 30 | 0.2 | 1 |
| Reversible skin disease | 183 | 4.1 | 23 | 358 | 3.5 | 46 | 147 | 1.1 | 23 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 30 | 0.7 | <0.5 | 60 | 0.6 | 1 | 62 | 0.5 | 1 |
| Severe depigmentation | 23 | 0.5 | 1 | 49 | 0.5 | 3 | 49 | 0.4 | 3 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 54 | 1.2 | 2 | 109 | 1.1 | 4 | 112 | 0.8 | 4 |
| Total skin disease (OSD) | 341 | 7.6 | 26 | 677 | 6.7 | 52 | 436 | 3.3 | 28 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 49 | 1.1 | 2 | 103 | 1.0 | 3 | 103 | 0.8 | 3 |
| Blindness | 14 | 0.3 | 94 | 28 | 0.3 | 194 | 23 | 0.2 | 161 |
| Eye disease (OED) | 62 | 1.4 | 95 | 131 | 1.3 | 197 | 126 | 1.0 | 164 |
| Total all manifestations | 404 | 9.0 | 122 | 808 | 8.0 | 249 | 563 | 4.2 | 192 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Nigeria, Nigeria




| Project, country: | | Plateau Nassarawa, Nigeria | | | | | | | |
|-----------------------------------|------------|-----------------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 1998 | | | | | | | |
| Mean MDA coverage per year: | | 72.7 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 911 | 100 | — | 2,055 | 100 | — | 2,695 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 227 | 24.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 227 | 24.9 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 301 | 33.0 | — | 13 | 0.6 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 35 | 3.8 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 29 | 3.2 | 5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 19 | 2.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 48 | 5.3 | 6 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 7 | 0.8 | <0.5 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Severe depigmentation | 6 | 0.7 | <0.5 | 4 | 0.2 | <0.5 | 2 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 13 | 1.5 | <0.5 | 9 | 0.4 | <0.5 | 6 | 0.2 | <0.5 |
| Total skin disease (OSD) | 96 | 10.5 | 7 | 9 | 0.4 | <0.5 | 6 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 13 | 1.4 | <0.5 | 8 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Blindness | 4 | 0.4 | 28 | 1 | <0.05 | 7 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | 17 | 1.9 | 28 | 9 | 0.4 | 7 | 5 | 0.2 | 3 |
| Total all manifestations | 113 | 12.4 | 35 | 18 | 0.9 | 7 | 11 | 0.4 | 3 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Plateau Nassarawa, Nigeria




Note: We assume no ivermectin MDA for Plateau and Nassarawa since 2018 as onchocerciasis transmission has been interrupted.[4][†], page 354.

| Project, country: | | Plateau Nassarawa LF, Nigeria | | | | | | | |
|-----------------------------------|------------|--------------------------------------|-----------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2000 | | | | | | | |
| Mean MDA coverage per year: | | 81.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 922 | 100 | — | 2,080 | 100 | — | 2,729 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 279 | 30.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 279 | 30.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 367 | 39.8 | — | 14 | 0.7 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 66 | 7.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 37 | 4.0 | 7 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 25 | 2.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 62 | 6.8 | 8 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 9 | 1.0 | <0.5 | 7 | 0.3 | <0.5 | 4 | 0.1 | <0.5 |
| Severe depigmentation | 8 | 0.9 | 1 | 5 | 0.3 | <0.5 | 3 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 17 | 1.9 | 1 | 12 | 0.6 | <0.5 | 7 | 0.2 | <0.5 |
| Total skin disease (OSD) | 145 | 15.8 | 9 | 12 | 0.6 | <0.5 | 7 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 16 | 1.7 | <0.5 | 11 | 0.5 | <0.5 | 6 | 0.2 | <0.5 |
| Blindness | 5 | 0.6 | 39 | 2 | 0.1 | 12 | <0.5 | <0.05 | 3 |
| Eye disease (OED) | 22 | 2.3 | 40 | 12 | 0.6 | 12 | 7 | 0.2 | 4 |
| Total all manifestations | 167 | 18.1 | 49 | 24 | 1.2 | 13 | 13 | 0.5 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Plateau Nassarawa LF, Nigeria




Note: We assume no ivermectin MDA for Plateau and Nassarawa since 2018 as onchocerciasis transmission has been interrupted.^{[4]†, page 354.}

| | | | | | | | | | |
|-----------------------------------|------------------------|-------------|-----------|-----------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Taraba, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 1998 | | | | | | | | |
| Mean MDA coverage per year: | 69.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 991 | 100 | — | 2,236 | 100 | — | 2,932 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 310 | 31.2 | — | 9 | 0.4 | — | 1 | <0.05 | — |
| Mf-positive (age 5+) | 309 | 31.2 | — | 9 | 0.4 | — | 1 | <0.05 | — |
| Worm infected | 397 | 40.1 | — | 75 | 3.4 | — | 6 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 80 | 8.0 | 1 | 4 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 45 | 4.5 | 8 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 32 | 3.3 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 77 | 7.8 | 10 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 11 | 1.1 | <0.5 | 8 | 0.4 | <0.5 | 5 | 0.2 | <0.5 |
| Severe depigmentation | 10 | 1.1 | 1 | 7 | 0.3 | <0.5 | 4 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 22 | 2.2 | 1 | 15 | 0.7 | 1 | 9 | 0.3 | <0.5 |
| Total skin disease (OSD) | 178 | 18.0 | 11 | 20 | 0.9 | 1 | 10 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 19 | 2.0 | 1 | 14 | 0.6 | <0.5 | 9 | 0.3 | <0.5 |
| Blindness | 8 | 0.8 | 61 | 3 | 0.1 | 21 | 1 | <0.05 | 8 |
| Eye disease (OED) | 28 | 2.8 | 62 | 17 | 0.8 | 21 | 10 | 0.3 | 9 |
| Total all manifestations | 206 | 20.8 | 73 | 37 | 1.6 | 22 | 20 | 0.7 | 9 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Taraba, Nigeria




| | | | | | | | | | |
|-----------------------------------|----------------------|------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Yobe, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 71.4 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 366 | 100 | — | 827 | 100 | — | 1,085 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 70 | 19.1 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 70 | 19.1 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 99 | 27.0 | — | 5 | 0.6 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 7 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 2.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 5 | 1.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 13 | 3.6 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.6 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 2 | 0.5 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 1.0 | <0.5 | 2 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Total skin disease (OSD) | 24 | 6.5 | 2 | 2 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 4 | 1.0 | <0.5 | 2 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Blindness | 1 | 0.3 | 7 | <0.5 | <0.05 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 5 | 1.2 | 7 | 2 | 0.3 | 2 | 1 | 0.1 | 1 |
| Total all manifestations | 28 | 7.7 | 9 | 5 | 0.6 | 2 | 3 | 0.2 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Yobe, Nigeria




| | | | | | | | | | |
|-----------------------------------|-------------------------|------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Project, country: | Zamfara, Nigeria | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 1999 | | | | | | | | |
| Mean MDA coverage per year: | 73.8 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 170 | 100 | — | 384 | 100 | — | 503 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 36 | 21.1 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 36 | 21.1 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 49 | 28.6 | — | 2 | 0.5 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 2.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 1.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 7 | 4.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.7 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.2 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 13 | 7.6 | 1 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 1.2 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Blindness | 1 | 0.3 | 4 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 3 | 1.5 | 4 | 1 | 0.4 | 1 | 1 | 0.1 | <0.5 |
| Total all manifestations | 15 | 9.1 | 5 | 3 | 0.7 | 1 | 2 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Zamfara, Nigeria




| Project, country: | | East Bahr El Ghazal, South Sudan | | | | | | | |
|-----------------------------------|-----------|---|----------------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 51.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 326 | 100 | — | 736 | 100 | — | 966 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 105 | 32.1 | — | 46 | 6.2 | — | 4 | 0.4 | — |
| Mf-positive (age 5+) | 105 | 32.1 | — | 46 | 6.2 | — | 4 | 0.4 | — |
| Worm infected | 138 | 42.3 | — | 125 | 17.0 | — | 30 | 3.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 27 | 8.3 | <0.5 | 10 | 1.3 | <0.5 | 1 | 0.1 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 14 | 4.3 | 3 | 3 | 0.4 | 1 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 10 | 2.9 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 24 | 7.2 | 3 | 4 | 0.5 | 1 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.0 | <0.5 | 4 | 0.5 | <0.5 | 3 | 0.3 | <0.5 |
| Severe depigmentation | 3 | 0.9 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 2.0 | <0.5 | 7 | 0.9 | <0.5 | 5 | 0.5 | <0.5 |
| Total skin disease (OSD) | 57 | 17.5 | 4 | 20 | 2.8 | 1 | 6 | 0.6 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 6 | 1.8 | <0.5 | 7 | 0.9 | <0.5 | 4 | 0.5 | <0.5 |
| Blindness | 2 | 0.6 | 15 | 2 | 0.2 | 11 | 1 | 0.1 | 5 |
| Eye disease (OED) | 8 | 2.4 | 15 | 8 | 1.1 | 11 | 5 | 0.5 | 5 |
| Total all manifestations | 65 | 19.9 | 19 | 29 | 3.9 | 12 | 11 | 1.2 | 5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in East Bahr El Ghazal, South Sudan




| | | | | | | | | | |
|-----------------------------------|------------------------------------|-------------|----------------|-----------|------------|----------------|-----------|------------|----------------|
| Project, country: | East Equatoria, South Sudan | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hyperendemic | | | | | | | | |
| MDA start year: | 2006 | | | | | | | | |
| Mean MDA coverage per year: | 41.3 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 580 | 100 | — | 1,309 | 100 | — | 1,716 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 180 | 31.0 | — | 143 | 10.9 | — | 26 | 1.5 | — |
| Mf-positive (age 5+) | 180 | 31.0 | — | 143 | 10.9 | — | 26 | 1.5 | — |
| Worm infected | 236 | 40.8 | — | 275 | 21.0 | — | 133 | 7.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 44 | 7.6 | <0.5 | 24 | 1.8 | <0.5 | 7 | 0.4 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 24 | 4.1 | 4 | 10 | 0.8 | 2 | 1 | 0.1 | <0.5 |
| Reactive skin disease | 16 | 2.8 | 1 | 5 | 0.4 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 40 | 6.9 | 5 | 15 | 1.2 | 2 | 1 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 1.0 | <0.5 | 8 | 0.6 | <0.5 | 6 | 0.3 | <0.5 |
| Severe depigmentation | 5 | 0.9 | <0.5 | 6 | 0.5 | <0.5 | 4 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 11 | 1.9 | <0.5 | 14 | 1.1 | <0.5 | 10 | 0.6 | <0.5 |
| Total skin disease (OSD) | 95 | 16.4 | 6 | 53 | 4.0 | 3 | 18 | 1.1 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 10 | 1.8 | <0.5 | 13 | 1.0 | <0.5 | 9 | 0.5 | <0.5 |
| Blindness | 4 | 0.6 | 26 | 3 | 0.2 | 23 | 1 | 0.1 | 10 |
| Eye disease (OED) | 14 | 2.4 | 26 | 16 | 1.2 | 23 | 11 | 0.6 | 11 |
| Total all manifestations | 109 | 18.8 | 32 | 69 | 5.2 | 26 | 29 | 1.7 | 11 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in East Equatoria, South Sudan




| Project, country: | | P20SouthSudan, South Sudan | | | | | | | |
|-----------------------------------|----------------|-----------------------------------|----------------|----------|-------------|----------------|----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2020 | | | | | | | |
| Mean MDA coverage per year: | | 54.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 16 | 100 | — | 37 | 100 | — | 48 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 6 | 37.7 | — | 13 | 36.5 | — | 7 | 13.6 | — |
| Mf-positive (age 5+) | 6 | 37.6 | — | 13 | 36.5 | — | 7 | 13.6 | — |
| Worm infected | 8 | 48.1 | — | 17 | 46.9 | — | 15 | 30.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 2 | 10.8 | <0.5 | 4 | 10.6 | <0.5 | 2 | 3.9 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 1 | 5.2 | <0.5 | 2 | 5.0 | <0.5 | 1 | 1.1 | <0.5 |
| Reactive skin disease | 1 | 3.6 | <0.5 | 1 | 3.5 | <0.5 | <0.5 | 0.3 | <0.5 |
| Reversible skin disease | 1 | 8.8 | <0.5 | 3 | 8.5 | <0.5 | 1 | 1.3 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | <0.5 | 1.2 | <0.5 | <0.5 | 1.2 | <0.5 | <0.5 | 0.8 | <0.5 |
| Severe depigmentation | <0.5 | 1.1 | <0.5 | <0.5 | 1.1 | <0.5 | <0.5 | 0.7 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | <0.5 | 2.3 | <0.5 | 1 | 2.2 | <0.5 | 1 | 1.5 | <0.5 |
| Total skin disease (OSD) | 4 | 22.0 | <0.5 | 8 | 21.3 | <0.5 | 3 | 6.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 2.2 | <0.5 | 1 | 2.1 | <0.5 | 1 | 1.4 | <0.5 |
| Blindness | <0.5 | 0.8 | 1 | <0.5 | 0.8 | 2 | <0.5 | 0.4 | 1 |
| Eye disease (OED) | <0.5 | 3.0 | 1 | 1 | 2.9 | 2 | 1 | 1.8 | 1 |
| Total all manifestations | 4 | 25.0 | 1 | 9 | 24.2 | 3 | 4 | 8.5 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P20SouthSudan, South Sudan




| Project, country: | | P5SouthSudan, South Sudan | | | | | | | |
|-----------------------------------|-----------|----------------------------------|----------------|-----------|------------|----------------|-----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2025 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 450 | 100 | — | 1,015 | 100 | — | 1,331 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 91 | 20.2 | — | 183 | 18.0 | — | 141 | 10.6 | — |
| Mf-positive (age 5+) | 91 | 20.2 | — | 182 | 18.0 | — | 141 | 10.6 | — |
| Worm infected | 127 | 28.2 | — | 262 | 25.8 | — | 272 | 20.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 10 | 2.2 | <0.5 | 20 | 1.9 | <0.5 | 17 | 1.3 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 11 | 2.4 | 2 | 21 | 2.1 | 4 | 11 | 0.8 | 2 |
| Reactive skin disease | 7 | 1.5 | <0.5 | 13 | 1.3 | 1 | 3 | 0.2 | <0.5 |
| Reversible skin disease | 17 | 3.9 | 2 | 34 | 3.4 | 4 | 14 | 1.1 | 2 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 0.6 | <0.5 | 6 | 0.6 | <0.5 | 6 | 0.5 | <0.5 |
| Severe depigmentation | 2 | 0.5 | <0.5 | 5 | 0.5 | <0.5 | 5 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 1.1 | <0.5 | 11 | 1.1 | <0.5 | 11 | 0.8 | <0.5 |
| Total skin disease (OSD) | 33 | 7.3 | 3 | 65 | 6.4 | 5 | 42 | 3.1 | 3 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 5 | 1.1 | <0.5 | 10 | 0.9 | <0.5 | 9 | 0.7 | <0.5 |
| Blindness | 1 | 0.3 | 9 | 3 | 0.3 | 19 | 2 | 0.2 | 16 |
| Eye disease (OED) | 6 | 1.4 | 9 | 12 | 1.2 | 19 | 12 | 0.9 | 16 |
| Total all manifestations | 39 | 8.7 | 11 | 77 | 7.6 | 24 | 54 | 4.0 | 19 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5SouthSudan, South Sudan




| Project, country: | | Upper Nile, South Sudan | | | | | | | |
|-----------------------------------|-----------|--------------------------------|----------------|-----------|------------|----------------|-----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2006 | | | | | | | |
| Mean MDA coverage per year: | | 39.5 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 304 | 100 | — | 686 | 100 | — | 899 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 75 | 24.6 | — | 60 | 8.7 | — | 9 | 1.0 | — |
| Mf-positive (age 5+) | 75 | 24.5 | — | 60 | 8.7 | — | 9 | 1.0 | — |
| Worm infected | 100 | 32.9 | — | 119 | 17.3 | — | 53 | 5.9 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 12 | 3.9 | <0.5 | 7 | 1.0 | <0.5 | 2 | 0.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 9 | 3.1 | 2 | 4 | 0.6 | 1 | <0.5 | 0.1 | <0.5 |
| Reactive skin disease | 6 | 2.1 | <0.5 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 16 | 5.1 | 2 | 6 | 0.9 | 1 | 1 | 0.1 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.8 | <0.5 | 3 | 0.5 | <0.5 | 2 | 0.3 | <0.5 |
| Severe depigmentation | 2 | 0.7 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 1.5 | <0.5 | 6 | 0.8 | <0.5 | 4 | 0.4 | <0.5 |
| Total skin disease (OSD) | 32 | 10.5 | 2 | 19 | 2.7 | 1 | 6 | 0.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 4 | 1.4 | <0.5 | 5 | 0.8 | <0.5 | 4 | 0.4 | <0.5 |
| Blindness | 1 | 0.4 | 9 | 1 | 0.2 | 8 | 1 | 0.1 | 4 |
| Eye disease (OED) | 6 | 1.8 | 10 | 6 | 0.9 | 8 | 4 | 0.5 | 4 |
| Total all manifestations | 38 | 12.4 | 12 | 25 | 3.7 | 9 | 10 | 1.2 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Upper Nile, South Sudan




| Project, country: | | West Bahr El Ghazal, South Sudan | | | | | | | |
|-----------------------------------|------------|---|------------|------------|------------|------------|------------|------------|-----------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2006 | | | | | | | |
| Mean MDA coverage per year: | | 44.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 1,758 | 100 | — | 3,968 | 100 | — | 5,205 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 525 | 29.8 | — | 509 | 12.8 | — | 137 | 2.6 | — |
| Mf-positive (age 5+) | 524 | 29.8 | — | 509 | 12.8 | — | 137 | 2.6 | — |
| Worm infected | 687 | 39.1 | — | 978 | 24.7 | — | 429 | 8.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 137 | 7.8 | 1 | 141 | 3.5 | 1 | 53 | 1.0 | 1 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 76 | 4.3 | 14 | 46 | 1.2 | 8 | 9 | 0.2 | 2 |
| Reactive skin disease | 56 | 3.2 | 3 | 17 | 0.4 | 1 | 2 | <0.05 | <0.5 |
| Reversible skin disease | 132 | 7.5 | 16 | 63 | 1.6 | 9 | 11 | 0.2 | 2 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 18 | 1.0 | <0.5 | 25 | 0.6 | <0.5 | 20 | 0.4 | <0.5 |
| Severe depigmentation | 18 | 1.0 | 1 | 24 | 0.6 | 2 | 18 | 0.3 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | 1 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 36 | 2.1 | 2 | 51 | 1.3 | 2 | 38 | 0.7 | 1 |
| Total skin disease (OSD) | 305 | 17.4 | 19 | 255 | 6.4 | 13 | 101 | 1.9 | 4 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 32 | 1.8 | 1 | 46 | 1.2 | 1 | 35 | 0.7 | 1 |
| Blindness | 15 | 0.9 | 119 | 16 | 0.4 | 131 | 9 | 0.2 | 74 |
| Eye disease (OED) | 47 | 2.7 | 120 | 63 | 1.6 | 133 | 44 | 0.8 | 75 |
| Total all manifestations | 353 | 20.1 | 139 | 317 | 8.0 | 145 | 145 | 2.8 | 79 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in West Bahr El Ghazal, South Sudan




| Project, country: | | West Equatoria, South Sudan | | | | | | | |
|-----------------------------------|-----------|------------------------------------|----------------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 62.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 415 | 100 | — | 936 | 100 | — | 1,228 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 141 | 33.9 | — | 26 | 2.7 | — | 1 | <0.05 | — |
| Mf-positive (age 5+) | 140 | 33.9 | — | 26 | 2.7 | — | 1 | <0.05 | — |
| Worm infected | 182 | 43.9 | — | 121 | 13.0 | — | 12 | 1.0 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 38 | 9.2 | <0.5 | 7 | 0.8 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 19 | 4.6 | 3 | 2 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 13 | 3.2 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 33 | 7.8 | 4 | 2 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 1.1 | <0.5 | 5 | 0.6 | <0.5 | 4 | 0.3 | <0.5 |
| Severe depigmentation | 4 | 1.0 | <0.5 | 4 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 2.2 | <0.5 | 10 | 1.0 | <0.5 | 6 | 0.5 | <0.5 |
| Total skin disease (OSD) | 80 | 19.2 | 5 | 19 | 2.0 | 1 | 7 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 8 | 2.0 | <0.5 | 9 | 1.0 | <0.5 | 6 | 0.5 | <0.5 |
| Blindness | 3 | 0.7 | 22 | 2 | 0.2 | 14 | 1 | 0.1 | 7 |
| Eye disease (OED) | 11 | 2.7 | 22 | 11 | 1.2 | 14 | 7 | 0.6 | 7 |
| Total all manifestations | 91 | 21.9 | 27 | 30 | 3.2 | 15 | 14 | 1.1 | 7 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in West Equatoria, South Sudan




| Project, country: | | P5Sudan, Sudan | | | | | | | |
|-----------------------------------|-----------|-----------------------|----------------|-----------|-------------|----------------|-----------|------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 2025 | | | | | | | |
| Mean MDA coverage per year: | | 65.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 127 | 100 | — | 286 | 100 | — | 375 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 29 | 22.6 | — | 61 | 21.2 | — | 48 | 12.9 | — |
| Mf-positive (age 5+) | 29 | 22.6 | — | 61 | 21.2 | — | 48 | 12.9 | — |
| Worm infected | 38 | 30.3 | — | 82 | 28.8 | — | 88 | 23.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 2.9 | <0.5 | 8 | 2.7 | <0.5 | 7 | 1.8 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 2.8 | 1 | 8 | 2.7 | 1 | 4 | 1.1 | 1 |
| Reactive skin disease | 2 | 1.9 | <0.5 | 5 | 1.7 | <0.5 | 1 | 0.3 | <0.5 |
| Reversible skin disease | 6 | 4.7 | 1 | 13 | 4.4 | 2 | 5 | 1.4 | 1 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.8 | <0.5 | 2 | 0.7 | <0.5 | 2 | 0.5 | <0.5 |
| Severe depigmentation | 1 | 0.6 | <0.5 | 2 | 0.6 | <0.5 | 2 | 0.4 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.4 | <0.5 | 4 | 1.3 | <0.5 | 4 | 1.0 | <0.5 |
| Total skin disease (OSD) | 11 | 8.9 | 1 | 24 | 8.4 | 2 | 15 | 4.1 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 2 | 1.3 | <0.5 | 3 | 1.2 | <0.5 | 4 | 0.9 | <0.5 |
| Blindness | <0.5 | 0.4 | 3 | 1 | 0.4 | 7 | 1 | 0.2 | 6 |
| Eye disease (OED) | 2 | 1.7 | 3 | 5 | 1.6 | 8 | 4 | 1.2 | 6 |
| Total all manifestations | 13 | 10.6 | 4 | 28 | 10.0 | 9 | 20 | 5.3 | 7 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Sudan, Sudan




| Project, country: | | Sudan, Sudan | | | | | | | | |
|-----------------------------------|--|---------------------|------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | | |
| MDA start year: | | 2008 | | | | | | | | |
| Mean MDA coverage per year: | | 78.0 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 120 | 100 | — | 270 | 100 | — | 354 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 25 | 21.1 | — | 2 | 0.7 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | | 25 | 21.1 | — | 2 | 0.7 | — | <0.5 | <0.05 | — |
| Worm infected | | 34 | 28.6 | — | 17 | 6.4 | — | 1 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | 3 | 2.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | 3 | 2.5 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | | 2 | 1.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 5 | 4.2 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | 1 | 0.7 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | | 1 | 0.6 | <0.5 | 1 | 0.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | 1 | 1.2 | <0.5 | 2 | 0.6 | <0.5 | 1 | 0.3 | <0.5 |
| Total skin disease (OSD) | | 9 | 7.6 | 1 | 2 | 0.8 | <0.5 | 1 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | 1 | 1.2 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Blindness | | <0.5 | 0.3 | 3 | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | | 2 | 1.5 | 3 | 2 | 0.6 | 2 | 1 | 0.3 | 1 |
| Total all manifestations | | 11 | 9.1 | 4 | 4 | 1.4 | 2 | 2 | 0.6 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Sudan, Sudan




| Project, country: | | Sudan Abu Hamed, Sudan | | | | | | | | |
|-----------------------------------|--|-------------------------------|------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | | |
| MDA start year: | | 2008 | | | | | | | | |
| Mean MDA coverage per year: | | 78.0 | | | | | | | | |
| | | 1990 | | | 2020 | | | 2030 | | |
| | | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | | 120 | 100 | — | 270 | 100 | — | 354 | 100 | — |
| Infection: | | | | | | | | | | |
| Mf-positive | | 25 | 21.1 | — | 2 | 0.7 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | | 25 | 21.1 | — | 2 | 0.7 | — | <0.5 | <0.05 | — |
| Worm infected | | 34 | 28.6 | — | 17 | 6.4 | — | 1 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | | |
| Palpable nodules | | 3 | 2.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | | |
| Severe itch | | 3 | 2.5 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | | 2 | 1.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | | 5 | 4.2 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | | |
| Mild depigmentation | | 1 | 0.7 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | | 1 | 0.6 | <0.5 | 1 | 0.3 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | | 1 | 1.2 | <0.5 | 2 | 0.6 | <0.5 | 1 | 0.3 | <0.5 |
| Total skin disease (OSD) | | 9 | 7.6 | 1 | 2 | 0.8 | <0.5 | 1 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | | |
| Visual impairment | | 1 | 1.2 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Blindness | | <0.5 | 0.3 | 3 | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | | 2 | 1.5 | 3 | 2 | 0.6 | 2 | 1 | 0.3 | 1 |
| Total all manifestations | | 11 | 9.1 | 4 | 4 | 1.4 | 2 | 2 | 0.6 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Sudan Abu Hamed, Sudan




| Project, country: | | Kilosa, Tanzania | | | | | | | |
|-----------------------------------|----------------|-------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2002 | | | | | | | | |
| Mean MDA coverage per year: | 74.6 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 287 | 100 | — | 647 | 100 | — | 849 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 80 | 27.8 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 80 | 27.8 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 102 | 35.6 | — | 16 | 2.5 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 14 | 4.8 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 11 | 3.8 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 8 | 2.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 19 | 6.5 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.0 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Severe depigmentation | 3 | 0.9 | <0.5 | 2 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 5 | 1.9 | <0.5 | 5 | 0.7 | <0.5 | 3 | 0.3 | <0.5 |
| Total skin disease (OSD) | 38 | 13.2 | 3 | 5 | 0.8 | <0.5 | 3 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 38 | 13.2 | 3 | 5 | 0.8 | <0.5 | 3 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Kilosa, Tanzania




| Project, country: | | Mahenge, Tanzania | | | | | | | |
|-----------------------------------|-----------|--------------------------|----------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1998 | | | | | | | |
| Mean MDA coverage per year: | | 68.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 287 | 100 | — | 647 | 100 | — | 849 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 127 | 44.2 | — | 8 | 1.3 | — | 1 | 0.1 | — |
| Mf-positive (age 5+) | 126 | 44.1 | — | 8 | 1.3 | — | 1 | 0.1 | — |
| Worm infected | 154 | 53.8 | — | 42 | 6.5 | — | 6 | 0.7 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 48 | 16.8 | 1 | 3 | 0.5 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 22 | 7.7 | 4 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 17 | 6.0 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 39 | 13.7 | 5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 1.6 | <0.5 | 4 | 0.6 | <0.5 | 3 | 0.3 | <0.5 |
| Severe depigmentation | 6 | 2.1 | <0.5 | 4 | 0.7 | <0.5 | 3 | 0.3 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 11 | 3.8 | 1 | 8 | 1.3 | <0.5 | 5 | 0.6 | <0.5 |
| Total skin disease (OSD) | 99 | 34.4 | 6 | 12 | 1.9 | <0.5 | 6 | 0.7 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.2 | 3 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | 1 | 0.3 | 3 | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 99 | 34.6 | 9 | 13 | 1.9 | 1 | 6 | 0.7 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Mahenge, Tanzania




| Project, country: | | Morogoro, Tanzania | | | | | | | |
|-----------------------------------|----------------|---------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Mesoendemic | | | | | | | | |
| MDA start year: | 2004 | | | | | | | | |
| Mean MDA coverage per year: | 73.1 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 205 | 100 | — | 463 | 100 | — | 608 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 58 | 28.1 | — | 2 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 58 | 28.1 | — | 2 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 75 | 36.8 | — | 22 | 4.7 | — | 1 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 11 | 5.6 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 3.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 5 | 2.5 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 13 | 6.2 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.9 | <0.5 | 2 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 2 | 0.8 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 1.8 | <0.5 | 3 | 0.7 | <0.5 | 2 | 0.4 | <0.5 |
| Total skin disease (OSD) | 28 | 13.5 | 2 | 4 | 0.9 | <0.5 | 2 | 0.4 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 28 | 13.5 | 2 | 4 | 0.9 | <0.5 | 2 | 0.4 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Morogoro, Tanzania




| | | | | | | | | | |
|-----------------------------------|-----------------------------|-----------------|----------------|----------------|-----------------|-----------|----------------|-----------------|----------------|
| Project, country: | P5Tanzania, Tanzania | | | | | | | | |
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | Hypoendemic | | | | | | | | |
| MDA start year: | 2023 | | | | | | | | |
| Mean MDA coverage per year: | 65.0 | | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 520 | 100 | — | 1,174 | 100 | — | 1,540 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 135 | 25.9 | — | 296 | 25.2 | — | 182 | 11.8 | — |
| Mf-positive (age 5+) | 135 | 25.9 | — | 296 | 25.2 | — | 182 | 11.8 | — |
| Worm infected | 176 | 33.7 | — | 389 | 33.1 | — | 371 | 24.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 23 | 4.4 | <0.5 | 50 | 4.3 | 1 | 33 | 2.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 18 | 3.4 | 3 | 39 | 3.3 | 7 | 15 | 1.0 | 3 |
| Reactive skin disease | 12 | 2.3 | 1 | 27 | 2.3 | 1 | 3 | 0.2 | <0.5 |
| Reversible skin disease | 30 | 5.7 | 4 | 66 | 5.6 | 8 | 19 | 1.2 | 3 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 5 | 0.9 | <0.5 | 10 | 0.9 | <0.5 | 10 | 0.7 | <0.5 |
| Severe depigmentation | 4 | 0.8 | <0.5 | 9 | 0.8 | 1 | 9 | 0.6 | 1 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 9 | 1.7 | <0.5 | 19 | 1.7 | 1 | 19 | 1.2 | 1 |
| Total skin disease (OSD) | 61 | 11.7 | 4 | 136 | 11.6 | 10 | 71 | 4.6 | 4 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | 1 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 61 | 11.8 | 5 | 136 | 11.6 | 10 | 71 | 4.6 | 4 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Tanzania, Tanzania




| Project, country: | | Ruvuma, Tanzania | | | | | | | |
|-----------------------------------|------------|-------------------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 68.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 227 | 100 | — | 511 | 100 | — | 671 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 127 | 56.2 | — | 28 | 5.4 | — | 3 | 0.5 | — |
| Mf-positive (age 5+) | 127 | 56.0 | — | 28 | 5.4 | — | 3 | 0.5 | — |
| Worm infected | 146 | 64.6 | — | 93 | 18.2 | — | 23 | 3.4 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 64 | 28.3 | 1 | 12 | 2.4 | <0.5 | 1 | 0.2 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 28 | 12.5 | 5 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 24 | 10.5 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 52 | 23.0 | 6 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 6 | 2.4 | <0.5 | 5 | 1.0 | <0.5 | 4 | 0.6 | <0.5 |
| Severe depigmentation | 8 | 3.7 | 1 | 7 | 1.4 | <0.5 | 5 | 0.7 | <0.5 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 15 | 6.5 | 1 | 13 | 2.5 | 1 | 9 | 1.3 | <0.5 |
| Total skin disease (OSD) | 131 | 57.8 | 8 | 26 | 5.2 | 1 | 10 | 1.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.3 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 1 | 0.4 | 7 | <0.5 | 0.1 | 2 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 2 | 0.7 | 7 | 1 | 0.2 | 3 | <0.5 | 0.1 | 1 |
| Total all manifestations | 133 | 58.5 | 15 | 27 | 5.3 | 4 | 10 | 1.5 | 1 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Ruvuma, Tanzania




| Project, country: | | Tanga, Tanzania | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2001 | | | | | | | |
| Mean MDA coverage per year: | | 73.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 178 | 100 | — | 401 | 100 | — | 526 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 47 | 26.3 | — | <0.5 | 0.1 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 47 | 26.3 | — | <0.5 | 0.1 | — | <0.5 | <0.05 | — |
| Worm infected | 62 | 34.9 | — | 8 | 2.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 8 | 4.5 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 6 | 3.4 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 2.3 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 10 | 5.7 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 0.9 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.2 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 1.6 | <0.5 | 2 | 0.6 | <0.5 | 1 | 0.3 | <0.5 |
| Total skin disease (OSD) | 21 | 11.8 | 1 | 2 | 0.6 | <0.5 | 1 | 0.3 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 21 | 11.8 | 2 | 2 | 0.6 | <0.5 | 1 | 0.3 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Tanga, Tanzania




| Project, country: | | Tukuyu, Tanzania | | | | | | | |
|-----------------------------------|----------------|-------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Mesoendemic | | | | | | | |
| MDA start year: | | 2001 | | | | | | | |
| Mean MDA coverage per year: | | 75.0 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 65 | 100 | — | 147 | 100 | — | 193 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 25 | 38.9 | — | <0.5 | 0.3 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 25 | 38.8 | — | <0.5 | 0.3 | — | <0.5 | <0.05 | — |
| Worm infected | 31 | 48.0 | — | 5 | 3.7 | — | <0.5 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 8 | 13.0 | <0.5 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 6.3 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 4.7 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 7 | 11.0 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.4 | <0.5 | 1 | 0.5 | <0.5 | 1 | 0.3 | <0.5 |
| Severe depigmentation | 1 | 1.6 | <0.5 | 1 | 0.5 | <0.5 | <0.5 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 3.0 | <0.5 | 2 | 1.1 | <0.5 | 1 | 0.5 | <0.5 |
| Total skin disease (OSD) | 18 | 27.1 | 1 | 2 | 1.2 | <0.5 | 1 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 18 | 27.2 | 1 | 2 | 1.2 | <0.5 | 1 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Tukuyu, Tanzania




| Project, country: | | Tunduru, Tanzania | | | | | | | |
|-----------------------------------|----------------|--------------------------|----------------|----------------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2005 | | | | | | | |
| Mean MDA coverage per year: | | 77.3 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 71 | 100 | — | 159 | 100 | — | 209 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 33 | 46.7 | — | 3 | 1.9 | — | <0.5 | 0.1 | — |
| Mf-positive (age 5+) | 33 | 46.6 | — | 3 | 1.9 | — | <0.5 | 0.1 | — |
| Worm infected | 40 | 56.4 | — | 19 | 11.7 | — | 2 | 0.8 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 13 | 18.0 | <0.5 | 1 | 0.9 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 6 | 8.1 | 1 | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 4 | 6.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 10 | 14.3 | 1 | <0.5 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 1.7 | <0.5 | 1 | 0.8 | <0.5 | 1 | 0.4 | <0.5 |
| Severe depigmentation | 1 | 2.1 | <0.5 | 1 | 0.9 | <0.5 | 1 | 0.5 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 3 | 3.9 | <0.5 | 3 | 1.7 | <0.5 | 2 | 0.9 | <0.5 |
| Total skin disease (OSD) | 25 | 36.1 | 1 | 4 | 2.8 | <0.5 | 2 | 0.9 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | 0.1 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.2 | 1 | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 26 | 36.4 | 2 | 5 | 2.9 | <0.5 | 2 | 1.0 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Tunduru, Tanzania




| Project, country: | | P5Uganda, Uganda | | | | | | | |
|-----------------------------------|----------------|-------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 1997 | | | | | | | |
| Mean MDA coverage per year: | | 72.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 131 | 100 | — | 295 | 100 | — | 387 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 31 | 23.4 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 31 | 23.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 41 | 31.3 | — | <0.5 | 0.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 4 | 3.2 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 4 | 3.0 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 3 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 6 | 4.9 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 1 | 0.8 | <0.5 | 1 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Severe depigmentation | 1 | 0.7 | <0.5 | <0.5 | 0.2 | <0.5 | <0.5 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 2 | 1.5 | <0.5 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 13 | 9.6 | 1 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 13 | 9.6 | 1 | 1 | 0.4 | <0.5 | 1 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in P5Uganda, Uganda




| Project, country: | | Phase 1, Uganda | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 73.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 205 | 100 | — | 463 | 100 | — | 607 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 58 | 28.3 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 58 | 28.2 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 75 | 36.5 | — | 1 | 0.3 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 12 | 5.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 8 | 3.9 | 1 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 5 | 2.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 13 | 6.5 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 2 | 1.0 | <0.5 | 1 | 0.3 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 2 | 0.9 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 4 | 1.9 | <0.5 | 2 | 0.5 | <0.5 | 1 | 0.2 | <0.5 |
| Total skin disease (OSD) | 29 | 14.0 | 2 | 2 | 0.5 | <0.5 | 1 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 29 | 14.0 | 2 | 2 | 0.5 | <0.5 | 1 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Phase 1, Uganda




| Project, country: | | Phase 2, Uganda | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hypoendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 72.4 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 399 | 100 | — | 900 | 100 | — | 1,181 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 90 | 22.6 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 90 | 22.6 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 119 | 29.8 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 10 | 2.4 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 11 | 2.9 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 8 | 1.9 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 19 | 4.8 | 2 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 0.8 | <0.5 | 2 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Severe depigmentation | 3 | 0.7 | <0.5 | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 1.5 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Total skin disease (OSD) | 35 | 8.7 | 3 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 35 | 8.7 | 3 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Phase 2, Uganda




Note: We assume no ivermectin MDA for Phase 2 and Phase 4 as the foci in these APOC-projects are currently under post-treatment surveillance (PTS), or completed the PTS successfully [5-10][‡], page 354.

| Project, country: | | Phase 3, Uganda | | | | | | | |
|-----------------------------------|------------|------------------------|-----------|-----------|------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 63.8 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 736 | 100 | — | 1,660 | 100 | — | 2,178 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 336 | 45.7 | — | 3 | 0.2 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 335 | 45.5 | — | 3 | 0.2 | — | <0.5 | <0.05 | — |
| Worm infected | 397 | 54.0 | — | 67 | 4.0 | — | 3 | 0.1 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 145 | 19.7 | 2 | 4 | 0.2 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 67 | 9.2 | 12 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 55 | 7.5 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 123 | 16.7 | 15 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 14 | 1.9 | <0.5 | 11 | 0.7 | <0.5 | 8 | 0.3 | <0.5 |
| Severe depigmentation | 20 | 2.7 | 1 | 14 | 0.8 | 1 | 9 | 0.4 | 1 |
| Atrophy | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 35 | 4.7 | 2 | 25 | 1.5 | 1 | 16 | 0.7 | 1 |
| Total skin disease (OSD) | 302 | 41.1 | 18 | 30 | 1.8 | 1 | 16 | 0.8 | 1 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | 1 | 0.2 | <0.5 | 1 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | 2 | 0.3 | 14 | <0.5 | <0.05 | 3 | <0.5 | <0.05 | 1 |
| Eye disease (OED) | 3 | 0.5 | 14 | 1 | 0.1 | 3 | 1 | <0.05 | 1 |
| Total all manifestations | 306 | 41.6 | 32 | 31 | 1.9 | 5 | 17 | 0.8 | 2 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Phase 3, Uganda




| Project, country: | | Phase 4, Uganda | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 1999 | | | | | | | |
| Mean MDA coverage per year: | | 77.2 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 416 | 100 | — | 940 | 100 | — | 1,233 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 114 | 27.4 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 114 | 27.4 | — | <0.5 | <0.05 | — | <0.5 | <0.05 | — |
| Worm infected | 148 | 35.5 | — | 1 | 0.1 | — | <0.5 | <0.05 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 21 | 5.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 15 | 3.7 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 11 | 2.6 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 26 | 6.2 | 3 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 4 | 0.9 | <0.5 | 2 | 0.3 | <0.5 | 2 | 0.1 | <0.5 |
| Severe depigmentation | 4 | 0.8 | <0.5 | 2 | 0.2 | <0.5 | 1 | 0.1 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 7 | 1.8 | <0.5 | 4 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |
| Total skin disease (OSD) | 54 | 13.1 | 4 | 4 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 55 | 13.1 | 4 | 4 | 0.5 | <0.5 | 3 | 0.2 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Phase 4, Uganda




Note: We assume no ivermectin MDA for Phase 2 and Phase 4 as the foci in these APOC-projects are currently under post-treatment surveillance (PTS), or completed the PTS successfully [5-10]‡, page 354.

| Project, country: | | Phase 5, Uganda | | | | | | | |
|-----------------------------------|----------------|------------------------|----------------|----------------|-----------------|----------------|----------------|-----------------|----------------|
| Bioclimate: | | | | | | | | | |
| Endemicity level(s): | | Hyperendemic | | | | | | | |
| MDA start year: | | 2012 | | | | | | | |
| Mean MDA coverage per year: | | 71.1 | | | | | | | |
| | 1990 | | | 2020 | | | 2030 | | |
| | N | % | DALYs | N | % | DALYs | N | % | DALYs |
| Total populaton at risk | 268 | 100 | — | 605 | 100 | — | 794 | 100 | — |
| Infection: | | | | | | | | | |
| Mf-positive | 79 | 29.6 | — | 5 | 0.8 | — | <0.5 | <0.05 | — |
| Mf-positive (age 5+) | 79 | 29.6 | — | 5 | 0.8 | — | <0.5 | <0.05 | — |
| Worm infected | 101 | 37.6 | — | 79 | 13.1 | — | 2 | 0.2 | — |
| Clinical manifestations: | | | | | | | | | |
| Palpable nodules | 18 | 6.8 | <0.5 | 6 | 1.0 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease: | | | | | | | | | |
| Severe itch | 12 | 4.3 | 2 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reactive skin disease | 8 | 3.0 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Reversible skin disease | 20 | 7.3 | 2 | 2 | 0.3 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease: | | | | | | | | | |
| Mild depigmentation | 3 | 1.1 | <0.5 | 3 | 0.5 | <0.5 | 2 | 0.2 | <0.5 |
| Severe depigmentation | 3 | 1.0 | <0.5 | 3 | 0.4 | <0.5 | 2 | 0.2 | <0.5 |
| Atrophy | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Hanging groin | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Irreversible skin disease | 6 | 2.1 | <0.5 | 5 | 0.9 | <0.5 | 4 | 0.5 | <0.5 |
| Total skin disease (OSD) | 43 | 16.2 | 3 | 13 | 2.2 | 1 | 4 | 0.5 | <0.5 |
| Eye disease (OED): | | | | | | | | | |
| Visual impairment | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Blindness | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Eye disease (OED) | <0.5 | 0.1 | <0.5 | <0.5 | <0.05 | <0.5 | <0.5 | <0.05 | <0.5 |
| Total all manifestations | 44 | 16.2 | 3 | 14 | 2.2 | 1 | 4 | 0.5 | <0.5 |

Note 1: Population at risk, number of cases (N) and DALYs are presented in thousands.

Note 2: Total skin disease is defined as the sum of the number of cases with palpable nodules, reversible and irreversible skin disease.

MDA coverage in Phase 5, Uganda



‡ References:

1. ESPEN Portal. Onchocerciasis maps. Expand Spec Proj Eliminate Neglected Trop Dis (ESPEN) World Health Organization Regional Office for Africa. Available at: <http://espen.afro.who.int/diseases/onchocerciasis>. Accessed on: 10 May 2021.
2. Herrador Z, Garcia B, Ncogo P, Perteguer MJ, Rubio JM, Rivas E, et al. Interruption of onchocerciasis transmission in Bioko Island: Accelerating the movement from control to elimination in Equatorial Guinea. Wanji S. *PLoS Negl Trop Dis*. Public Library of Science; 2018;12: e0006471.
3. Traoré S, Wilson MD, Sima A, Barro T, Diallo A, Ak? A, et al. The elimination of the onchocerciasis vector from the island of Bioko as a result of larviciding by the WHO African Programme for Onchocerciasis Control. *Acta Trop*. 2009;111: 211-218.
4. Richards FO, Eigege A, Umaru J, Kahansim B, Adalamo S, et al. (2020) The interruption of transmission of human onchocerciasis by an annual mass drug administration program in Plateau and Nasarawa States, Nigeria. *Am J Trop Med Hyg* 102: 582–592.
5. Katarwa MN, Lakwo T, Habomugisha P, Unnasch TR, Garms R, et al. (2018) After 70 years of fighting an age-old scourge, onchocerciasis in Uganda, the end is in sight. *Int Health*10: i79–i88.
6. Katarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, et al. (2014) Transmission of *Onchocerca volvulus* by *Simulium neavei* in Mount Elgon focus of eastern Uganda has been interrupted. *Am J Trop Med Hyg* 90: 1159–1166.
7. Lakwo TL, Garms R, Rubaale T, Katarwa M, Walsh F, et al. (2013) The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector *Simulium neavei* and 19 years of annual ivermectin treatments. *Acta Trop* 126: 218–221.
8. Katarwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, et al. (2012) Transmission of onchocerciasis in Wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. *J Parasitol Res* 2012.
9. Katarwa MN, Katamanywa J, Lakwo T, Habomugisha P, Byamukama E, et al. (2016) The imaramagambo onchocerciasis focus in southwestern Uganda: Interruption of transmission after disappearance of the vector *simulium neavei* and its associated freshwater crabs. *Am J Trop Med Hyg* 95: 417–425.
10. Katarwa MN, Habomugisha P, Khainza A, Oguttu DW, Byamukama E, et al. (2020) Historical elimination of onchocerciasis from victoria Nile focus in Central Uganda verified using WHO criteria. *Am J Trop Med Hyg* 102: 1411–1416.